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3 Abbreviations 
aa amino acid 
ADP adenosine diphosphate 
AGM aorta-gonad-mesonephros 
AIDS acquired immunodeficiency 
syndrome 
APC antigen-presenting cell 
APL altered peptide ligand 
ATP adenosine triphosphate 
BBB blood brain barrier 
BCR B cell receptor 
BDNF brain derived neurotrophic factor 
CCL CC-chemokine ligand 
CCR CC-chemokine receptor 
CFA complete Freund´s adjuvant 
CLA cutaneous lymphocyte antigen 
CNS central nervous system 
c/pSMAC central/peripheral supra-
molecular activation cluster 
CS-1 connecting segment-1 
DC dendritic cell 
DNA deoxyribonucleic acid 
EAE experimental autoimmune 
encephalomyelitis 
EBV Epstein-Barr virus 
ECM extracellular matrix 
EDSS Expanded Disability Status 
Scale 
ES embryonic stem 
E embryonic day 
FAK focal adhesion kinase 
FDA Food and Drug Adminstration 
FucT fucosyltransferase 
GAP GTPase-activating protein 
GDI guanine nucleotide dissociation 
inhibitor 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange 
factor 
GSK3β glycogen-synthase kinase-3β 
GTP guanosine triphosphate 
GM-CSF granulocyte-macrophage 
colony-stimulating factor 
HEV high endothelial venule 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HSC hematopoietic stem cell 
IBD inflammatory bowel disease 
ICAM intercellular adhesion molecule 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
ILK integrin-linked kinase 
IPP ILK-PINCH-parvin 
JCV JC virus 
LAD leukocyte adhesion deficiency 
LAT linker for activation of T cells 
LDV leucine-aspartic acid-valine 
LFA lymphocyte function-associated 
antigen 
LPAM lymphocyte Peyer's patch 
adhesion molecule 
LPS lipopolysaccharide 
mAb monoclonal Ab 
Mac macrophage adhesion molecule 
MAdCAM mucosal addressin cell adhesion 
molecule 
MAPK mitogen-activated protein kinase 
MBP myelin basic protein 
MHC major histocompatibility complex 
MOG myelin oligodendrocyte 
glycoprotein 
MMP matrix metalloproteinase 
MRI magnetic resonance imaging 
MS multiple sclerosis 
NF-κB nuclear factor-κB 
PAS para-aortic splanchnopleura 
PINCH particularly interesting new 
cystidine-histidine-rich protein 
PIP2 phosphatidylinositol (4,5) 
bisphosphate 
PIPKIγ phosphatidylinositol phosphate 
kinase type Iγ 
PKB/AKT protein kinase B 
PKD1 protein kinase D1 
PLP proteolipid protein 
PML progressive multifocal 
leukoencephalopathy 
PNAD peripheral node addressin 
PPMS primary progressive MS 
PSGL P-selectin glycoprotein ligand 
RAPL regulator of cell polarization and 
adhesion enriched in lymphoid 
tissues 
RGD arginine-glycine-aspartic acid 
RIAM Rap1 GTP-interacting adapter 
molecule 
RRMS relapsing-remitting MS 
RTK receptor tyrosine kinase 
SCF stem cell factor 
SPMS secondary progressive MS 
STAT signal transducer and activator 
of transcription 
TCR T cell receptor 
TNBS 2, 4, 6-trinitrobenzene sulfonic 
acid 
TNF tumor necrosis factor 
Treg regulatory T cell 
TH1 cell CD4+ T helper type 1 cell 
TH2 cell CD4+ T helper type 2 cell 
VCAM vascular-cell adhesion molecule 
VLA very late antigen 
 Summary 
IV 
4 Summary 
Members of the integrin family of adhesion molecules are transmembrane 
proteins that provide a link between the cytoskeleton and the extracellular matrix 
(ECM) or neighboring cells. Thereby they control the shape, proliferation and survival 
of cells and modulate various intracellular signaling pathways. They are heterodimers, 
consisting of α and β subunits. Integrins and intracellular effector molecules of integrin 
signaling, such as small Rho GTPases that regulate the actin cytoskeleton, play 
important roles during hematopoiesis and immune responses.  
Firstly, we examined the role of α4 integrins in adult murine hematopoiesis 
(Paper II), since previous experiments investigating the function of the integrin α4 
subunit and its two association partners β1 and β7 provided controversial results for 
hematopoietic development. We analyzed the hematopoietic system of bone marrow 
chimeric mice with an inducible knockout of the β1 subunit and a constitutive deletion 
of the β7 gene. We found only subtle or transient alterations in the number and 
distribution of progenitor cells, while the maintenance and retention of hematopoietic 
stem cells (HSC) was not altered. The development of T and B lymphocytes and their 
adhesion molecule expression profiles were normal. Furthermore, the development of 
myeloid and erythroid cells was unchanged. In summary, both α4β1 and α4β7 integrins 
are dispensable for adult hematopoiesis indicating that previously observed severe 
hematopoietic defects in somatic chimeric α4-/- mice are likely due to the loss of α4 
expression on non-hematopoietic cells. 
Secondly, we analyzed the role of the small GTPase RhoH in the hematopoietic 
system (Paper III). Previous publications implicated RhoH in the development of B cell 
lymphomas, proliferation and survival of HSCs as well as migration and adhesion of 
lymphocytes and HSCs. Since RhoH is expressed only in hematopoietic cells we 
introduced a constitutive RhoH gene disruption in the germline of mice and analyzed 
their hematopoietic development. RhoH-null mice had no remarkable changes in 
myeloid, erythroid or B lymphocyte populations. In contrast T cell development was 
impaired at two distinct steps: (i) during late stages of development of CD4-CD8- 
double negative cells, and (ii) during the transition of double positive CD4+CD8+ T cells 
to CD4+ or CD8+ single positive cells. These defects could be attributed to: (i) defective 
pre-TCR signaling to T cells that generated functional TCR β-chains during β-selection, 
and (ii) compromised positive selection. Both defects resulted from impaired pre-TCR 
and TCR signaling to the scaffold protein linker for activation of T cells (LAT) and its 
associated molecules downstream of the tyrosine kinase ZAP70. In conclusion, RhoH 
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deficient mice have no defect in the maintenance of HSCs, but the differentiation of T 
lymphocytes is severely disturbed due to reduced pre-TCR and TCR signaling. 
Finally, we examined the functions of β1 integrins during the development of 
autoimmunity (Paper IV). Previous investigations pointed to a crucial role of α4 
integrins in the development of multiple sclerosis (MS) in man and experimental 
autoimmune encephalomyelitis (EAE) in rodents. Antibodies that block the α4 subunit 
became an efficient new medication for the treatment of MS and other inflammatory 
diseases, such as inflammatory bowel disease (IBD). Although these antibodies are 
already approved for the treatment of MS, their exact working mechanism, their target 
cells and their precise target integrin (α4β1 and/or α4β7) are not clear.  Mice with 
hematopoietic cells that lack integrin β1 expression provided the opportunity to analyze 
particularly the role of α4β1 during activation, proliferation and extravasation of 
encephalitogenic T cells. Furthermore, we examined whether β1 integrins play a role 
on other immune cells during the pathogenesis of EAE. We found that 
encephalitogenic T cells rely on β1 integrins to accumulate in the CNS, a defect that 
could not be rescued by the presence of α4β7. This implies that α4β1 is the main target 
of anti-inflammatory therapies directed against the α4 integrin subunit.  The antigen-
specific proliferation and cytokine response of β1-/- T cells in vivo was not significantly 
altered. In contrast, the firm adhesion of β1 integrin deficient T lymphoblasts to 
postcapillary venules of the spinal cord white matter was greatly reduced in vivo; 
indicating that the failure of β1-/- T cells to enter the CNS and the main effect of the 
antibody therapy is due to impaired extravasation. Furthermore, we could demonstrate 
that active EAE development is significantly delayed in mice lacking β1 expression 
specifically on T lymphocytes. This result, together with the observation that lack of β1 
expression on granulocytes and macrophages does not alter active EAE development, 
indicates that the main targets of the antibody therapy are the α4β1 integrins on T 
lymphocytes. 
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5 Introduction 
5.1 The integrin family of adhesion and signal transduction 
receptors 
5.1.1 Integrins in general 
Integrins are heterodimeric, type I single-span transmembrane glycoproteins 
consisting of non-covalently associated α and β subunits. The extracellular domain of 
each subunit is large and contains around 1000 amino acids (aa) or 750 aa for α or β 
subunits, respectively, whereas the short intracellular parts consist of only 20 to 50 aa1. 
The genome of mouse and man contains 18 α and 8 β subunits, which form together at 
least 24 heterodimers with different binding and signaling properties (Figure 5.1)2. The 
extracellular domains of integrins bind to a wide variety of extracellular matrix (ECM) 
molecules, soluble proteins or to counter receptors on other cells. The N-termini of α 
subunits are folded into 7-bladed β propellers and the distal ends of the β subunits are 
folded into I/A domains. Together these globular head domains form the ligand-binding 
domain that is separated from the plasma membrane in both subunits by a long stalk1,3. 
Accordingly the ligand binding specificity of a heterodimer is dependent on both 
subunits. The cytoplasmic tails are connected by adaptor proteins to the actin 
cytoskeleton and to various signal transduction pathways. An exception is the β4 
subunit, which has an unusually long 1072 aa cytoplasmic domain, which recruits 
intermediate filaments3. Therefore integrins bridge the gap between the cytoskeleton 
and the ECM or other cell adhesion molecules. Apart from mediating mere adhesion to 
substrates and cells integrins have important functions as signaling molecules and 
thereby regulate processes as diverse as proliferation, cell survival, immune responses 
and cell shape leading to cell polarity and motility4. Although the integrin family is huge 
several studies indicate that they have overlapping as well as specific functions. 
Genetic inactivation of single integrin subunits5-9, for example leads to distinct 
phenotypes (ranging from early and severe peri-implantation lethality in β1 integrin-
deficient mice lacking 12 different integrins (Figure 5.1)10 to subtle effects in other 
knockouts), while compound mutants uncovered novel functions5. 
5.1.2 The four classes of integrin ligands 
Extracellularly most integrins bind to several different ligands and most integrin 
ligands are recognized by several members of the integrin family. Nevertheless the 
different integrins can be grouped into four main classes, based on their ligand-binding 
specificity. 
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Figure 5.1: The family of integrin heterodimers. Shown are all known combinations of 
integrin subunits in mammalian cells. The color code of the connecting lines between the 
subunits indicates the major ligand binding specificity of the respective heterodimer. 
Black: RGD-binding integrins, green: collagen-binding integrins, red: laminin-binding 
integrins, grey: integrins binding the LDV motif and related or structurally similar 
sequences. Note that these are only the main ligands, and that most integrins bind to 
additional molecules2. The subunits that are depicted in orange are expressed 
exclusively on leukocytes. 
The first group (connected by black lines in Figure 5.1) contains all αv integrins, 
the platelet integrin αIIbβ3 and some β1 heterodimers and binds RGD-containing 
ligands. RGD (arginine-glycine-aspartic acid) is a tripeptide binding motif that is present 
in soluble and ECM molecules, for example fibronectin, vitronectin, fibrinogen, 
thrombospondin, osteopontin, and laminins11. The α1, α2, α10 and α11 chains dimerize 
exclusively with the β1 subunit (connected by green lines) and form the collagen-
binding integrins. The heterodimers that are connected by red lines are laminin-binding 
integrins. While the α6 subunit-containing integrins bind only laminin, the α3β1 integrin 
also binds a large number of additional ligands. The fourth subclass of integrin 
receptors include the leukocyte-specific subunits (orange subunits connected by grey 
lines) and recognize the LDV or structurally related motifs. LDV (leucine-aspartic acid-
valine) is an acidic tripeptide that can be found for example, in the alternatively spliced 
connecting segment-1 (CS-1) fragment of fibronectin. Other typical ligands of this 
integrin subfamily including vascular-cell adhesion molecule-1 (VCAM-1), mucosal 
addressin cell adhesion molecule-1 (MAdCAM-1) and intercellular adhesion molecule-1 
(ICAM-1), contain binding motifs that have a different aa sequence but are structurally 
related to the LDV motif2. 
5.1.3 Inside-out and outside-in signaling of integrins 
Binding of integrins to their ligands depends on the composition of the 
heterodimer and on its activation state. A striking example is the platelet integrin αIIbβ3 
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that is amongst other integrins present on all circulating thrombocytes. In its active 
state, αIIbβ3 binds ligands such as fibrinogen, fibrin, von Willebrand factor and 
fibronectin, resulting in platelet adhesion to subendothelial cells, plug formation and 
sealing of injured vessels12. If αIIbβ3 integrins are constitutively active they trigger 
pathologic thrombus formation causing strokes, myocardial infarction and other embolic 
events. Therefore, αIIbβ3 is in a low-affinity state on all circulating platelets but can be 
activated instantly if plug formation is required. Activation of αIIbβ3 is achieved via 
agonists such as thrombin, collagen, adenosine diphosphate (ADP), and adenosine 
triphosphate (ATP) that signal through different types of receptors12. The various signal 
transduction pathways converge as a final step in the activation and recruitment of 
several molecules including kindlins and talins to the cytoplasmic tail of integrin β 
subunits13. Recruitment of kindlin and talin is followed by the separation of the 
membrane-proximal α-helical regions of the two short cytoplasmic tails that are in close 
proximity in the inactive conformation and interact via hydrophobic and electrostatic 
interactions. Tail separation leads to conformational changes characterized by a 
switchblade-like opening of the bended, inactive into an extended, highly active integrin 
(Figure 5.2)4. Thus, the cytoplasmic domains alter the activation state of the 
extracellular domains and consequently, this process was named inside-out signaling. 
Integrins are therefore unique as they act as classical signal transduction receptors 
transferring signals from the extracellular space to the cytoplasm (outside-in signaling) 
and at the same time regulate their activation state by inside-out signaling. Notably, it 
has also been shown that signaling by one integrin heterodimer can alter the activation 
state of other integrins on the same cell. A good example for such an integrin crosstalk 
is the activation of β2 integrins on leukocytes upon engagement of α4β114. It has also 
been shown that the avidity of integrin binding is regulated. Binding of extracellular 
ligands leads to clustering of integrins and to the recruitment of signaling and adapter 
proteins to the intracellular tails resulting in increased binding strength or avidity. These 
integrin clusters are called focal complexes when they are developing, and focal 
adhesions when they have matured to their final size4.  
Since integrins do not have enzymatic activity themselves the focal complex 
proteins are needed to connect them with signal transduction pathways and the actin 
cytoskeleton. Talin for example,  mediates integrin activation by inside-out signaling13 
and participates in integrin clustering and linkage to the actin cytoskeleton. 
Furthermore, talin recruits proteins that are involved in outside-in signaling such as the 
non receptor tyrosine kinase focal adhesion kinase (FAK) and phosphatidylinositol 
phosphate kinase type Iγ (PIPKIγ), which is producing the second messenger 
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phosphatidylinositol (4,5) bisphosphate (PIP2)4. An essential role of talin in outside-in 
signaling was corroborated in talin1-deficient platelets. In platelets, integrin ligand-
binding leads via activation of Src family kinases to cell spreading, a process that is 
completely abolished in platelets lacking talin-1.13  
 
Figure 5.2: Adaptor proteins binding directly and indirectly to the cytoplasmic tail of 
integrin heterodimers and linking them to the actin cytoskeleton and to signal 
transduction processes. Note the two conformations of the heterodimers: the bent, 
inactive form and the extended, active form with separated cytoplasmic tails. The ILK-
PINCH-parvin complex represents a large multiprotein complex at the cytoplasmic tail of 
activated β1 and perhaps β3 integrins that links integrins to the actin cytoskeleton and to 
signal transduction pathways. RTK, receptor tyrosine kinase. The cartoon is taken from 
Grashoff et al.15. 
The proteins binding intracellularly to integrins are organized in several 
multiprotein complexes. One example for such a protein complex is the ILK-PINCH-
parvin (IPP) complex consisting of integrin-linked kinase (ILK) and different isoforms of 
the adaptor proteins particularly interesting new cystidine-histidine-rich protein (PINCH) 
and parvin (Figure 5.2). ILK is binding to the β1 subunit of integrins16, and it has also 
been shown to interact with β3 subunits17 but the recruitment of the IPP complex to 
focal adhesions requires an interaction with other adaptor molecules, including paxillin 
(Figure 5.2)18. The resulting multiprotein complex mediates binding to F-actin, actin 
polymerization and turnover, and modulates signals of a wide variety of signaling 
pathways4,15. Despite of its name there are doubts, whether ILK acts as a kinase in 
vivo. ILK possesses a domain that has a high homology to serine/threonine kinases but 
it lacks several residues thought to be essential for kinase activity18. It has been 
demonstrated that ILK is phosphorylating the protein kinase B (PKB/AKT) and 
glycogen-synthase kinase-3β (GSK3β) in vitro, but in vivo current data support as well 
as object an ILK kinase activity18-20. There is consensus in the community that a major 
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function of ILK in vivo is linking integrins to the actin cytoskeleton and modulating actin 
reorganization4. 
5.1.4 The Rho family of small GTPases 
Rho GTPases represent an important class of signaling machines downstream of 
integrins. The >20 mammalian Rho GTPases are small signaling molecules that exist 
in two conformational states, the active, guanosine triphosphate (GTP) bound state, 
and the inactive guanosine diphosphate (GDP) bound state. The switch between these 
two conformations is carefully regulated positively by guanine nucleotide exchange 
factors (GEFs) and negatively by GTPase-activating proteins (GAPs). The C-terminus 
of most Rho GTPases is prenylated, and can therefore target the proteins to plasma 
membranes. Another level of regulation occurs through guanine nucleotide dissociation 
inhibitors (GDIs) that bind inactive GDP bound GTPases and extract them from the 
plasma membrane (Figure 5.3)21,22. 
 
Figure 5.3: GEFs mediate the exchange from the GDP to the GTP bound state and thus 
activate Rho GTPases. GAPs enhance the hydrolysis of GTP that is catalyzed by the 
GTPases themselves, and thereby inactivate Rho GTPases. GDIs bind inactive Rho 
GTPases and sequester them from the cell membrane and block the nucleotide 
exchange. The cartoon is taken from Etienne-Manneville et al.21. 
The three best studied members of the family of Rho GTPases RhoA, Rac1 and 
Cdc42 exemplify that - despite structural and functional similarities - each GTPase 
performs distinct functions. At the leading edge of cells both Rac1 and Cdc42 promote 
actin polymerization resulting in the formation of lamellipodia and filopodia, 
respectively. At the rear end of a migrating cell RhoA regulates contraction of the cell 
body by inducing the assembly and contraction of actomyosin filaments23. 
Another member of the Rho GTPase family is RhoH, which is expressed 
exclusively in hematopoietic cells including HSCs, differentiated myeloid cells and B 
and T lymphocytes, particularly T cells with a TH1 phenotype24-27. RhoH inhibits 
activation of the mitogen-activated protein kinase (MAPK) p38 and the transcription 
factor nuclear factor-κB (NFκB), which are both activated by GTPases such as RhoA, 
Rac1 and Cdc4224. In HSCs RhoH negatively regulates proliferation and survival25. 
Furthermore, RhoH is an atypical GTPase since it is GTPase deficient and exists only 
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in the active, GTP-bound state24, and is kept in check through interaction with all three 
classical GDIs24. Besides it was proposed that RhoH is regulated on the transcriptional 
level. In T cells it was demonstrated that RhoH transcription is rapidly downregulated 
upon T cell activation24. In B cell lymphomas RhoH is affected by mutations in non-
coding regions of the gene and by chromosomal translocations26,28,29. Both types of 
mutations likely result in deregulated expression of RhoH. Moreover, RhoH was 
implicated in lymphocyte adhesion and migration since downregulation of RhoH 
expression increases integrin αLβ2-mediated adhesion of a Jurkat T cell clone30. 
Finally, overexpression of RhoH leads to defective assembly and polarization of F-actin 
and thereby impairs the migration of HSCs towards a chemokine25. In order to assess 
the function of RhoH in vivo we analyzed the hematopoietic system of RhoH-/- mice 
(Paper III). 
5.1.5 The α4 subfamily of integrin receptors 
The α4 integrins are mainly expressed on cells of the hematopoietic system. The 
α4 integrin subunit can dimerize with two β chains: β1 and β731. In the hematopoietic 
compartment, α4 is expressed by lymphocytes32, HSCs33, monocytes34, eosinophils, 
basophils35 and natural killer cells36. Neutrophils express little or no α435, although the 
expression is upregulated under chronic inflammatory conditions37. Integrin α4 is also 
expressed on HSCs of the adreno-gonad-mesonephros (AGM) region (Figure 5.5), the 
fetal liver and the adult bone marrow38. There is evidence that the α4β1 heterodimer on 
those cells is in a high affinity state triggered by the stem cell factor (SCF) through c-kit 
binding39. 
α4β1 was first described as an activation-dependent receptor on hematopoietic 
cells and is therefore also called very late antigen 4 (VLA-4) whereas α4β7 is also 
called lymphocyte Peyer`s patch adhesion molecule-1 (LPAM-1) due to its ability to 
home lymphocytes to high endothelial venules of Peyer`s patches. Both heterodimers 
belong to the family of LDV motif binding integrins. The main ligand for α4β1 is VCAM-
1 whereas the main ligand for α4β7 is MAdCAM-1. Both receptors bind to the 
alternatively spliced CS-1 fragment of fibronectin (Table 5.1). Interestingly the α4 chain 
has the unique property to exist in two different forms: either as single molecule with a 
molecular weight of 150 kDa or as cleaved molecule consisting of two non covalently 
linked fragments of 70 and 80 kDa40. The cleavage is thought to increase upon T cell 
activation but is neither altering the adhesion to VCAM-1 nor to fibronectin41. In addition 
to the classical ligands VCAM-1 and MAdCAM-1 many other interaction partners for α4 
integrins have been described. 
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Table 5.1: The α4 integrins and some of their described interaction partners. 
integrin ligand properties α4β1 (VLA-4; 
CD49d/CD29) 
α4β7 (LPAM-
1; CD49d/β7 ) 
VCAM-1 Ig superfamily protein expressed on 
vascular endothelial cells of inflamed 
tissues 
main ligand42,43 binding44 
MAdCAM-1 Ig superfamily protein expressed in HEVs 
of gut-associated lymphatic tissues and 
endothelial cells of the lamina propria 
binding2 main ligand42,45 
fibronectin protein of the ECM, isoform containing 
the alternatively spliced CS-1 region 
binding44 binding44 
osteopontin phosphorylated acidic matrix glycoprotein 
that is secreted by osteoblasts, 
monocytes and macrophages; contains 
an RGD-sequence and hence is bound 
by several different integrins 
binding2,46 binding2 
thrombospondin ECM protein secreted by platelets and 
endothelial cells in damaged and 
inflamed tissue 
weak binding; 
α4β1 has to be 
activated44,47 
no interaction2 
HEV, high endothelial venule; Ig, immunoglobulin 
 
The activation state of both α4 heterodimers is tightly regulated and can vary 
considerably. During leukocyte extravasation into inflamed tissues (Chapter 5.3.1) 
leukocyte integrins are activated in milliseconds to ensure their adhesion to the vessel 
wall under high shear. Other processes in the hematopoietic system where integrins 
possess high affinity include antigen recognition by T and B cell receptors.  
The final step of integrin activation is mediated by talin as described in chapter 
5.1.3. Upstream of talin are members of the Rap family of small GTPases like Rap1 
that mediate talin activation in hematopoietic cells upon stimulation by chemokines, 
growth factors or activation of the T cell receptor (Figure 5.4)48. Rap1 enhances the 
adhesion of T cells to fibronectin via α4β1 by activation of β1 integrins. Interestingly, 
Rap1 increases the binding of β2 integrins by increasing their avidity through integrin 
clustering rather than integrin activation49. One important effector molecule of Rap1 
during these processes is regulator of cell polarization and adhesion enriched in 
lymphoid tissues (RAPL). In RAPL-deficient mice the chemokine CCL21 is unable to 
stimulate adhesion of T cells to VCAM-1 via α4β1 and the homing of T and B 
lymphocytes and dendritic cells to their target organs is impaired, indicating that RAPL 
is involved in activation of α4β1 and other integrins50. Protein kinase D1 (PKD1) and 
Rap1 GTP-interacting adapter molecule (RIAM) are other recently identified effector 
proteins of Rap1 that are mediating inside-out activation of β1, β2 and β3 integrins 
through the activation of talin51. Similar mechanisms of integrin activation take place 
after B cell receptor stimulation52. 
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Figure 5.4: The small GTPase Rap and its effector RAPL mediate the rapid activation and 
clustering of integrins. Upon stimulation of e.g. chemokines or engagement of the T cell 
receptor Rap1 is activated by the GEF-mediated GDP/GTP exchange, translocates to the 
cell membrane and binds RAPL. RAPL then mediates integrin activation via talin by an as 
yet unknown mechanism that might involve the serine-threonine kinase Mst153. The 
cartoon is taken from Price and Bos54. 
Apart from the control of affinity and avidity, the expression level of VLA-4 on 
lymphocytes is tightly regulated. Memory T cells that have encountered their specific 
antigen express much more α4β1 and α4β7 than naïve T cells and therefore show also 
enhanced ligand binding55,56. 
5.1.6 The role of α4 integrins in embryonic and adult hematopoiesis 
The two α4 integrins have many important roles during development and in 
physiology. Ablation of the α4 integrin gene leads to two waves of embryonic lethality, 
first around embryonic day (E)10 due to disturbed fusion of the allantois with the 
chorion and then again between E11.5 and E14 due to severe cardiac hemorrhage57. 
These defects are very similar to those found in mice lacking VCAM-1, indicating that 
the observed defects are due to an abrogated interaction between α4 integrins and 
VCAM-158,59.  
Apart from the early developmental defects in mice lacking the α4 subunit other 
studies implicated α4 integrins in the development and homing of hematopoietic cells 
and in inflammation. The interactions between α4β1 and CS-1 of fibronectin or VCAM-
1, and between α5β1 and fibronectin, are important for HSC binding to stroma cells of 
the bone marrow60, and for lymphopoiesis33,61-64. Furthermore, the attachment of HSCs 
to fibronectin via integrins depends on the cytokine regulated activation state of 
integrins65. Binding of α4β7 to MAdCAM-1 is important for lymphocyte homing to 
Peyer`s patches and the lamina propria of the intestine45,66. Finally, the interaction 
between α4β1 and VCAM-1 is important for the homing of leukocytes to the inflamed 
CNS during EAE67. Due to the early embryonic lethality of the α4 knockout mice the 
role of α4 integrins in the hematopoietic system in vivo was subsequently studied in 
somatic α4 chimeras and conditional mutants. Somatic chimeras are generated by 
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injecting gene deficient embryonic stem (ES) cells into wild-type blastocysts. In this 
system cells derived from the injected stem cells as well as from the blastocysts will 
contribute to the development of all tissues of the adult mouse. This often circumvents 
the problem of early embryonic lethality. Moreover, the absence of mutant cells in a 
certain tissue indicates a failure or disadvantage for the mutant cells to contribute to its 
formation. 
 
Figure 5.5: Hematopoiesis during murine embryogenesis. Hematopoietic cells are first 
generated in the extra-embryonic yolk sac (around E7) and the intra-embryonic 
splanchnopleura that first develops into the para-aortic splanchnopleura (PAS) and then 
into the AGM region. HSCs from the AGM region are colonizing the fetal liver and thymus 
and from the fetal liver the HSCs migrate subsequently to the spleen and the bone 
marrow, the place of adult self-renewing HSCs. Around E8 the fetal circulation starts, 
allowing an exchange of cells between the yolk sac and the splanchnopleura/AGM 
region68. 
In order to analyze the role of α4 integrins for hematopoiesis, wild-type 
blastocysts or blastocysts deficient for RAG-1 or RAG-2 (RAG-1 or RAG-2 knockouts 
lack mature lymphocytes) were injected with α4-deficient ES cells. These experiments 
showed that α4 is important for the continuous input of T cell precursors from the bone 
marrow into the thymus after birth, is crucial for the formation of Peyer`s patches and 
for the development of B cells in the bone marrow after birth69. Fetal liver erythropoiesis 
is diminished in the chimeric animals although α4 deficient cells are able to differentiate 
into mature erythrocytes in vitro, indicating that those defects are likely due to the α4 
deficient microenvironment of the fetal liver (see Figure 5.5 for a description of fetal 
hematopoiesis). Similar results were obtained with myeloid and B lymphoid progenitors 
from fetal livers. In vivo the α4 deficient progenitors contribute less to the development 
of mature cells than wild-type progenitors, but in in vitro colony formation assays their 
differentiation potential is not altered, indicating that the reduced differentiation in vivo 
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occurs in a non cell autonomous mode. Post-natally the development of α4 deficient 
erythrocytes, myeloid cells and B lymphocytes in bone marrow and spleen is almost 
completely abolished although α4-/- erythroid burst forming colonies develop. In vitro it 
was shown that erythroid cells and B cells have a diminished ability to interact with 
cultures of bone marrow stromal cells and proliferate less than wild-type cells70. The 
latter result is in accordance with observations that α4 antibodies inhibit the 
development of B cells and erythroid cells on a stroma cell layer in vitro 61,71.  
To distinguish cell autonomous phenotypes from defects caused by an α4 
deficient microenvironment studies were performed with mice in which the α4 gene was 
ablated in a conditional manner. Using the inducible Mx1-Cre system all cells of the 
hematopoietic system lose the α4 gene (Paper V). This circumvents embryonic lethality 
and excludes side-effects of a knockout in non-hematopoietic cells such as bone 
marrow stromal cells, for example. The deletion of α4 on HSCs results in a persisting 
increase of lymphocytes and hematopoietic progenitor cells in peripheral blood and a 
continuously increasing number of progenitor cells in the spleen, but the steady-state 
hematopoiesis and erythropoiesis are still normal. To study the role of α4 integrins 
during erythropoiesis after anemia an acute hemolysis was induced by treating the 
mutant mice with phenylhydrazine. α4 knockout animals show a delayed regeneration 
of erythroid cells. Furthermore, the colony forming units in the bone marrow recover 
with a delay from 5-fluorouracil induced killing of hematopoietic cells. The self-renewal 
of α4 deficient HSCs and their homing to the bone marrow of lethally irradiated 
recipient mice is impaired. Accordingly the number of HSCs in the spleen of such 
animals is slightly higher than in control mice72,73. These results are in accordance with 
experiments showing that the administration of antibodies specific for the α4 chain or 
VCAM-1 reduces the homing of HSCs to the bone marrow of irradiated recipient mice 
and leads to an accumulation of HSCs in the spleen. Administration of these antibodies 
to non-irradiated mice results in an increase of HSC numbers in peripheral blood74. The 
injection of fibronectin fragments also impairs the repopulation of irradiated mice with 
stem cells and in addition causes their mobilization into the blood75. The authors of 
another study proposed that α4 integrins might be of crucial importance during the fetal 
development of HSCs. To test this hypothesis they transplanted control or α4 deficient 
embryonic HSCs isolated from E12.5 AGM regions into irradiated adult wildtype mice. 
This experimental design bypasses fetal development of HSCs and leads to a 
comparable reconstitution of recipient mice with control and α4-/- cells. The α4 deficient 
HSCs contribute stably to hematopoiesis and are able to engraft irradiated recipient 
mice in secondary transplantations. Only in Peyer`s patches and the peritoneal cavity a 
relative reduction of α4 deficient myeloid and lymphoid cells could be observed38. The 
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failure to develop Peyer`s patches is in line with observations made in mice that lack 
the β7 subunit, indicating that Peyer`s patch development is a specific function of the 
α4β7 subunit. Interestingly, lymphocyte development is not disturbed in β7 deficient 
animals, which suggests that mainly α4β1 regulates lymphopoesis76. In Mx1-Cre 
induced conditional knockout mice lacking VCAM-1, the counter receptor for α4β1, the 
retention of B cells in the bone marrow is disturbed while the remaining aspects of 
hematopoiesis are unaffected77. 
Although the β1 subfamily of integrins and their role in the hematopoietic system 
are described in detail in Paper I it is important to mention in this context that β1 
deficient somatic cell chimeric mice lack β1 deficient cells in liver and spleen10. In ES 
cell chimeric β1 deficient mice hematopoietic stem and progenitor cells develop in the 
yolk sac and the PAS. These cells are able to differentiate into erythroid, myeloid and 
lymphoid cells in vitro. However, in vivo the colonization of the fetal liver, thymus and 
spleen by HSCs does not occur in the absence of β1 integrins and HSCs accumulate in 
the fetal circulation78,79. In conditional β1 knockout mice HSCs were isolated from the 
bone marrow and the β1 gene was deleted by retroviral Cre-recombinase expression. 
The β1-deficient HSCs are unable to home to the bone marrow and the spleen of 
irradiated recipient wild-type mice and hence accumulate in their blood79. In summary, 
β1 integrins are crucial for HSC homing, but they are neither required for the retention 
and survival nor for the differentiation of HSCs into the different blood cell lineages. In 
addition, the homing of the different blood cell lineages to spleen, lymph nodes and 
Peyer`s patches is β1 integrin-independent80. Interestingly, mice with a β1 deficient 
hematopoietic system show a unique phenotype in the T cell mediated immune 
response. After immunization with a T cell dependent antigen they secrete highly 
reduced levels of IgM, whereas the IgG production is increased. After immunization 
with a T cell independent antigen both IgM and IgG responses are decreased80. Since 
this effect could not be rescued by β1 expressing T or B lymphocytes it might be 
caused by an impaired function of dendritic cells. Notably, mice lacking VCAM-1, one 
counter receptor of β1 integrins, in the hematopoietic system also show an impaired 
humoral immune response after immunization with a T cell dependent antigen77. 
An apparent explanation for the different results regarding the hematopoietic 
development in α4, β7 and β1 deficient mice would be that α4β1 and α4β7 functions 
compensate each other. Furthermore it is possible that α4 integrins are important for 
HSCs during fetal hematopoiesis which would at least partially explain the differences 
observed between the α4-deficient ES cell chimeras69,70 and α4-deficient bone marrow 
chimeras38,73. To unravel a possible compensation between α4β1 and α4β7 we 
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analyzed hematopoietic development in adult mice lacking the β1 and the β7 subunits 
(Paper II). 
5.1.7 The role of α4 integrins in the adult immune system 
In addition to the important functions in the developing hematopoietic system and 
the homing to mucosal lymphoid organs and the inflamed CNS, many functions have 
been attributed to α4 integrins in the adult immune system. The role of α4β1 in 
leukocyte extravasation is discussed in detail in chapter 5.3. α4 integrins also regulate 
the correct positioning of immune cells in different organs: together with αLβ2, α4β1 is 
important for retaining B cells in the marginal zone of the spleen81, and for the adhesion 
of B cells to follicular dendritic cells in germinal centers, which is critical for the 
maturation of the immune response82,83 and the prevention of B cell apoptosis84. 
It has already been discussed that the activation state of integrins is highly 
regulated, and that T cell integrins are rapidly activated upon chemokine stimulation 
during extravasation. Furthermore the activation state of integrins on T lymphocytes is 
dependent on the activation state of the T cells themselves. Stimulation of the CD3-T 
cell receptor (TCR) complex results in signaling to integrins – probably via the tyrosine 
kinases Lck, Fyn, ZAP-70 and Itk – and subsequently activates β1 integrins85 ensuring 
the interaction of T cells with antigen presenting cells and the extracellular matrix. The 
generation of a stable contact between T lymphocytes and antigen presenting cells is a 
key event during the generation of an adaptive immune response. β2 integrins mediate 
adhesive interactions in the immunological synapse that develops between T and 
antigen presenting cells (Figure 5.6). Recently α4β1 has also been localized to the 
immunological synapse86, which is in line with data showing that α4β1 has a 
costimulatory potential in T lymphocytes. 
 
Figure 5.6: Schematic view of the immunological synapse. (a) Top view of the interaction 
zone. The central supramolecular activation cluster (cSMAC) is surrounded by the ring-
like peripheral supramolecular activation cluster (pSMAC). (b) The cSMAC consists of the 
T cell receptor and associated coreceptors binding to the antigen presented by 
molecules of the major histocompatibility complex (MHC). The cSMAC is surrounded by 
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the pSMAC which consists mainly of adhesion molecules. The integrins in the pSMAC 
are linked by adaptor proteins to F-actin, ensuring proper formation of the pSMAC87. 
The B cell receptor (BCR) on B cells binds soluble antigens and cell-bound 
antigens such as antigens bound by Fc or complement receptors. The recognition of 
membrane antigens is also facilitated by interactions between αLβ2/ICAM-1 and 
α4β1/VCAM-1 that organize into an immunological synapse with the BCR-antigen 
complexes in the cSMAC and the four adhesion molecules in the pSMAC and enhance 
BCR signaling88,89. 
5.2 Multiple sclerosis and experimental autoimmune 
encephalomyelitis 
5.2.1 Multiple sclerosis in general 
MS is an inflammatory autoimmune disease of the central nervous system (CNS) 
that can lead to severe disability. With its early onset during the second and third 
decade of life MS is the most common cause of non-traumatic disability in young 
adults90. In Germany MS has an estimated prevalence of 83 per 100.00091 and 
worldwide approximately 2,5 million people are affected92,93. Based on the different 
disease courses three different forms of MS are distinguished clinically. Around 85% of 
the patients present with relapsing-remitting MS (RRMS) at the beginning. RRMS is 
characterized by attacks of clinical symptoms followed by periods of complete or partial 
improvement. After around 10 years RRMS changes into secondary progressive MS 
(SPMS) in most of the patients93. The repeated inflammatory episodes lead to 
irreversible damage of the CNS and the neurological condition is slowly but 
continuously worsening over the course of many years.  Approximately 15% of the 
patients suffer from primary progressive MS (PPMS) where the clinical course is 
progressive with the onset of disease and no periods of relapses can be observed94. 
Since MS is causing many different symptoms and impairments systems like the 
Expanded Disability Status Scale (EDSS) have been developed to record the disease 
course of patients, provide a basis for prognosis and validate the efficacy of new 
treatments. The EDSS is ranging from 0 to 10 in 0,5 intervals with 0 standing for a 
complete lack of symptoms and 10 being death due to MS95. MS is causing 
characteristic lesions in the patients CNS that can be detected by magnetic resonance 
imaging (MRI). The two most useful types of imaging are normal T2-weighted MRI that 
detects lesions in the white matter and gadolinium-enhanced MRI that detects areas 
with an increased permeability of the blood-brain-barrier in T1-weighted scans. These 
areas of enhancement are often the first detectable change during the development of 
a new lesion93. 
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Up to now, there is no cure for MS, and patients need a lifelong treatment with 
disease damping drugs. Therefore, MS is severely impairing the quality of life of 
affected patients and is also causing high social costs. 
5.2.2 The etiology of multiple sclerosis 
The wide variety of symptoms characteristic for MS such as numbness, 
weakness, paresis, visual problems, severe fatigue and depression and also 
intellectual and cognitive impairments are caused by demyelinating lesions in the 
various myelinated regions of the CNS. This demyelination leads to the loss of saltatory 
conduction and therefore nerve impulses are not transmitted properly anymore. 
Furthermore also the axons themselves can be damaged or lost. It is widely accepted 
that MS lesions are caused by an autoimmune reaction, although the triggers of this 
inflammatory process remain unclear and complex96. Despite the lack of clarity about 
the etiology of MS several factors show a correlation to increased MS susceptibility. 
Genetically there is a clear association with certain human leukocyte antigen 
(HLA) class II region alleles, particularly HLA-DRB1 and HLA-DQB197. Susceptibility as 
well as protective alleles have been identified in both regions. In recently published 
large screens, it could be shown that additional, earlier discovered susceptibility loci for 
MS are explained by linkage disequilibrium with certain HLA class II haplotypes that 
seem to have the only valid association with MS risk98. 
In addition to the genetic factors, environmental factors such as the geographic 
location in which individuals grew up, have been demonstrated to play a role. 
Furthermore, MS is diagnosed more frequently in individuals that grew up in a 
temperate climate than in people originating from tropical or subtropical areas99. This 
might be partially explained by the influence of sunlight and UV light-induced formation 
of vitamin D96. There is a clear inverse correlation between vitamin D levels and the 
risk to develop MS100. 
Furthermore, different infectious agents have been discussed as risk factors for 
MS. Parasitic infections decrease the risk of developing MS and other autoimmune 
diseases, supposedly due to a TH2 deviation of the T helper cell response101. On the 
contrary, strong evidence supports an increased MS risk for individuals with Epstein-
Barr virus (EBV) infection102. The relation between infections and MS can be explained 
by several mechanisms. In a process called molecular mimicry potentially self-reactive 
T cells are activated by foreign antigens that share similarities with self-antigens. 
Epitope spreading is a process where epitopes other than the initial dominant epitope 
are recognized by the immune system. Upon the first inflammatory process the 
ongoing inflammation leads to tissue destruction which in turn releases new epitopes 
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which can be different peptides from the initial protein (intramolecular epitope 
spreading) or dominant epitopes of neighboring proteins (intermolecular epitope 
spreading). Therefore, an inflammatory response to viruses present in the CNS could 
lead to immune reactions against CNS antigens. Moreover, autoreactive T cells can be 
activated by the pro-inflammatory milieu during an ongoing infection, a process called 
bystander activation. 
Another - albeit moderate - environmental risk factor is smoking. There is no 
conclusive explanation for this association, although many hypotheses are discussed. 
Substances like nicotine can increase leakiness of the blood brain barrier (BBB), other 
cigarette smoke components like cyanide are directly toxic for the CNS and smoke 
components might also interfere with antigen-dependent signaling in T lymphocytes103. 
Finally, there is a clear sex discrepancy in MS development: females have a risk 
more than twice as high as males104, an observation that holds also true for other 
autoimmune diseases like rheumatoid arthritis and is ascribed to different hormone 
status and immune responses between men and women105. 
In summary, although many risk factors for MS have been identified the complex 
interplay between them and the exact mechanisms that lead to the development of MS 
are not clear and need to be better understood in order to develop specific treatments 
and perhaps preventive measures for MS. 
5.2.3 The pathology of multiple sclerosis 
Although the disease pathology of MS is better understood than the etiology the 
involved processes are complex as well. An acute MS lesion is a region in the white 
matter of the brain or spinal cord where myelin is focally lost. These lesions contain 
many CD4+ and CD8+ T cells, macrophages, activated microglial cells and some B 
cells and plasma cells, which are the key players of the autoimmune process106,107. 
The presence of T cells that are reactive to self-antigens is a prerequisite for all 
autoimmune diseases and is caused by the escape of some autoreactive T cells from 
negative selection in the thymus108. Self-reactive T cells are present in all individuals 
and are normally kept in check by several additional mechanisms that maintain self-
tolerance109. Firstly, antigens have to be presented by MHC molecules and recognized 
in the context of costimulation to excite T cell activation. Secondly, antigens can be 
separated by their target cells via anatomical barriers such as the BBB in the CNS. In 
the meantime, however, it has been shown that also the CNS undergoes constant 
immunosurveillance110. Finally, the autoreactive T cells present in healthy individuals 
are tightly controlled by regulatory T cells108. This has been impressively demonstrated 
in mice carrying TCR transgenic T cells specific for myelin antigens that escape 
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spontaneous EAE111,112. It is not clear, why these safety mechanisms fail in MS patients 
and autoreactive T cells are induced, persist and proliferate in the CNS. The 
association between MS and certain infectious agents such as EBV suggests that 
molecular mimicry for example, might break the self-tolerance, possibly in the context 
of certain HLA alleles and other predisposing factors. 
Autoreactive CD4+ T cells that enter the CNS mediate the first steps of the 
disease process. It has been shown by gadolinium-enhanced MRI that early MS 
lesions are associated with a breakdown of the BBB that most likely facilitates entry of 
T cells into the CNS. Furthermore the expression of VCAM-1 on endothelial cells is 
upregulated under inflammatory conditions which allows increased binding of activated 
T cells to endothelial cells via integrins113. After firm adhesion and crossing of the 
endothelial cell layer T cells have to penetrate the basement membrane of the BBB 
that is composed of type IV collagen. T cells use the matrix metalloproteinases-2 
(MMP-2) and 9 for penetrating through basement membranes114,115. 
After extravasation T cells are reactivated upon recognizing their antigen on 
perivascular antigen-presenting cells in the CNS. It is well established that the 
extravasation of activated T lymphocytes into the brain and spinal cord occurs 
independent of their antigen-specificity. Nevertheless only T cells that recognize their 
target antigen in the perivascular area can persist and proliferate in the CNS116. In vitro 
studies revealed that astrocytes and microglia are capable of efficiently presenting 
antigen upon stimulation with cytokines like granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interferon-γ (IFN-γ). In vivo microglia cells are 
required as well for the development of EAE117. In addition blood-borne CD11c+ 
dendritic cells (DCs) are required and sufficient to present antigen to invading 
encephalitogenic T lymphocytes107. Furthermore, it has been shown in mouse models 
of MS that epitope spreading takes place in the CNS rather than in the periphery and is 
mediated by local antigen-presenting cells, possibly DCs118. This process most likely 
plays an important role in the chronic progression of MS118,119.  
It is not resolved which antigens are the targets for MS-inducing CD4+ T cells but 
there is evidence that the classic myelin proteins that are also used to elicit EAE in 
model animals such as myelin basic protein (MBP), myelin proteolipid protein and 
myelin oligodendrocyte glycoprotein (MOG), are also targets in human MS. This is 
underscored by the fact, that most of these proteins are restricted by the HLA class II 
molecules associated with MS120.  In addition the small heat-shock protein αB-
crystallin, that is upregulated in MS lesions has been identified as a major target 
antigen in MS121. αB-crystallin has neuroprotective and anti-inflammatory properties, 
which makes its loss especially fatal122. Beside CD4+ T cell mediated damage a 
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humoral immune response by autoantibodies can lead to demyelination in EAE and 
MS. In the murine EAE model the myelin protein MOG is the only known protein that 
elicits a demyelinating autoantibody response. Although it is unlikely that MOG is the 
only protein evoking such responses in humans, it is likely that proteins recognized by 
demyelinating autoantibodies are membrane proteins which expose their epitopes in 
the extracellular space123,124. 
Until recently it has been thought that CD4+ T cells initiating MS have a TH1 
phenotype, characterized by the production of IFN-γ, interleukin-2 (IL-2), tumor 
necrosis factor-α (TNF-α) and lymphotoxin and mediating cellular immunity125. Now 
there is increasing evidence, mainly from the EAE model, but also from studies in MS 
patients that these CD4+ T cells represent a subset distinct from the classical TH1 
biased cells. Instead they are expressing IL-17 which gave this new subset the name 
TH-17. They are dependent on IL-23 for their development120,126 (Figure 5.7). TH17 cells 
migrate easier through a layer of human brain-derived microvascular endothelial cells 
than TH1 cells in vitro, and IL-17 together with IL-22 were shown to contribute to the 
breakdown of the BBB by binding to their respective receptors on brain microvessel 
endothelium in MS lesions and disrupting tight junctions. Furthermore, stimulation with 
IL-17 and IL-22 induces expression of the chemokine CCL2 in endothelial cells, which 
promotes the recruitment of further CD4+ T cells127. 
 
Figure 5.7: Naïve, CD4+ T helper cells can differentiate into three different classes of 
effector T cells that are characterized by the expression of distinct cytokines. TH1 cells 
are induced by the cytokine IL-12 which activates the transcription factors signal 
transducer and activator of transcription 1 (STAT1), STAT4 and T-bet. IL-4 leads to the 
activation of STAT6 and GATA-3 and induces TH2 cells. IL-23 promotes via other 
unknown transcription factors the development of TH17 cells that express high levels of 
IL-17. TH1 and TH2 cells antagonize each other via the expression of IL-4 and IFN-γ, which 
at the same time both inhibit the differentiation of TH17 cells. The cartoon is modified 
from Iwakura and Ishigame126. 
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Antigen-specific stimulation of the infiltrated CD4+ T cells results in the production 
of various pro-inflammatory molecules. They increase the permeability of the BBB, lead 
to upregulation of adhesion molecules on vascular endothelial cells and the recruitment 
of more lymphocytes into the CNS. Pro-inflammatory cytokines that amplify CNS 
inflammation include IFN-γ, TNF-α, TNF-β, lymphotoxin, IL-1α, IL-2, IL-6 and IL-12125. 
Although CD4+ T cells mediate the early events during the establishment of a 
new MS lesion the actual damage to the myelin sheath, oligodendrocytes and axons is 
mediated by multiple mechanisms and cell types. The main target of the autoimmune 
process is the myelin sheath, which can principally be repaired by remyelination. The 
alternating destruction and repair processes lead to the clinical picture of RRMS. 
During long-term disease the myelin sheath is destroyed and in addition, more and 
more axons are damaged. The transection of an axon within a demyelinating lesion 
causes the subsequent loss of the whole distal axon by Wallerian degeneration.  Since 
axonal loss is irreversible this leads to persisting disability and neurological symptoms 
after a threshold of axonal damage is reached128,129. 
It has been demonstrated for MS patients that the mechanisms of tissue destruction 
are very heterogeneous between different patients and that at least four different types 
of MS lesions (called type I to type IV patterns) can be distinguished histologically128. 
The mechanisms of tissue destruction are summarized in Figure 5.8. Tissue 
destruction by activated macrophages is found in type I lesions. The pro-inflammatory 
cytokines released by the infiltrated CD4+ T cells lead to macrophage recruitment and 
activation of macrophages and microglia cells. The activated macrophages and 
microglia produce many factors leading to demyelination and axon damage including 
TNF-α, reactive oxygen species, matrix metalloproteinases and other proteases. 
Another event that leads to both neuron and oligodendrocyte destruction is excessive 
glutamate production by activated lymphocytes and microglia (Figure 5.8). This causes 
excitotoxicity mediated by a massive Ca2+ influx130. Type II lesions also contain T cells 
and macrophages but tissue destruction is mediated by a humoral immune response. 
Myelin-specific antibodies bind to and damage myelin through opsonization and 
complement activation. In most MS patients immunoglobulins can be detected in the 
cerebrospinal fluid. Since there is no concomitant increase of antibody levels in the 
serum they are likely produced in the CNS by plasma cells derived from infiltrating B 
cells131. An observation that underscores the significance of destruction by humoral 
immunity is the fact that patients unresponsive to glucocorticoid treatment during a 
relapse often benefit from plasma exchange and have type II lesions132. 
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Figure 5.8: Mechanisms of myelin and axonal destruction in MS. CD4+ T cells cross the 
blood brain barrier and become reactivated in the perivascular space by cells presenting 
myelin antigens. Activated, IL-17 expressing T cells recruit macrophages (MΦ) from the 
circulation that lead to tissue destruction by the production of proinflammatory factors 
and activation of microglial cells. In some cases B cells cause a humoral immune 
response and deposits of complement and antibodies. Furthermore CD8+ T cells can 
damage oligodendrocytes directly. The cartoon is taken from McFarland and Martin120. 
Lesion patterns III and IV are characterized by apoptotic or non-apoptotic loss of 
oligodendrocytes, respectively. The loss of oligodendrocytes leads to destruction of the 
myelin sheath and secondary axonal loss due to the missing trophic support. Another 
cell type mediating tissue destruction in active MS lesions are CD8+ T cells which 
outnumber CD4+ T cells133. CD8+ T cells induce cell death, aided by the upregulation of 
MHC I molecules on target cells under inflammatory conditions134.  
Up to now, no clear correlation between the different histological and clinical 
manifestations of MS has been shown. Great efforts are made to identify the types of 
tissue destruction in patients since this knowledge has important implications for 
prognosis and therapy128. 
Surprisingly at first glance, immune cells also play a role during neuroprotective 
processes such as remyelination. CD4+ T cells can produce neurotrophins including 
brain derived neurotrophic factor (BDNF) that promote remyelination. Furthermore it 
has been shown in EAE that CD4+CD25+Foxp3+ regulatory T cells (Treg) can inhibit the 
inflammatory processes135. 
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5.2.4 Treatment and treatment trials of multiple sclerosis 
The most frequently prescribed treatments for RRMS are corticosteroids, IFN-β 
and glatiramer acetate. Corticosteroids are administered during an acute attack of MS 
to treat the symptoms like weakness, visual and gait impairments. IFN-β and glatiramer 
acetate are used as long-term disease modifying drugs to prevent relapses. 
Corticosteroids like methylprednisolone act anti-inflammatory and 
immunosuppressive. They act by inhibiting transcription factors including NF-κB and 
AP-1 which mediate the expression of many pro-inflammatory cytokines including IL-1, 
IL-2 and IL-6 and also adhesion molecules such as ICAM-1. Glucocorticoids interfere 
also with T cell proliferation by inhibiting IL-2 synthesis136. 
The type-1 interferons, IFN β1-b (trade name: Betaferon) and IFN β1-a (trade 
name: Avonex, Rebif) used for the treatment of RRMS are cytokines that are normally 
produced by fibroblasts to combat viral infections. Interferons bind to a dimer of 
interferon receptor 1 and interferon receptor 2 which leads to phosphorylation of 
tyrosine kinases including Jak-1. The tyrosine kinases subsequently activate 
transcription factors like STAT, which trigger an anti-inflammatory response by inducing 
expression of the anti-inflammatory TH2 cytokine IL-10 and IL-1 receptor antagonist. 
Furthermore they suppress IL-1β and TNF-α expression and antagonize IFN-γ induced 
MHC II upregulation on antigen presenting cells (APCs). IFN-β reduces T cell 
proliferation and extravasation into the CNS137, increases the amount of soluble 
vascular cell-adhesion molecules138, and reduces the VLA-4 expression on T cells in 
peripheral blood139. Furthermore IFN-β reduces expression of the MMPs 2 and 9, that 
are crucial for disintegrating collagen type IV and increases the expression of MMP 
inhibitors. Unfortunately interferons evoke a variety of adverse side effects such as 
systemic flu-like symptoms with fever, chills and headache that last for 24 hours140 and 
they can be neutralized by antibodies impairing or decreasing efficacy of this 
therapy141. 
Glatiramer acetate (trade name: Copaxone) is a mixture of synthetic random 
copolymers of four basic amino acids (alanine, glutamic acid, lysine and tyrosine) that 
were initially designed to mimic MBP. Glatiramer acetate is thought to antagonize the 
binding of MBP to the TCR and MHC class II antigens and to induce suppressor T 
cells142. A recent study showed that glatiramer acetate is not effective in treating 
PPMS143. Another problem of both glatiramer acetate and IFN-β treatment is that the 
administration route of subcutaneous or intramuscular injection is cumbersome for 
many patients.  
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In patients that fail to respond to IFN-β or glatiramer acetate treatment or that 
suffer from progressive MS, administration of the chemotherapeutic mitoxantrone is a 
novel treatment option. Mitoxantrone was primarily used to treat malignancies, 
especially leukemias. It interferes with deoxyribonucleic acid (DNA) synthesis by 
intercalating into DNA and inhibiting the topoisomerase II136. These unspecific cytotoxic 
effects lead to a general immunosuppression. Furthermore, mitoxantrone induces 
apoptosis in APCs144. Common side effects are myelosuppression and potentially 
severe cardiotoxicity. Therefore, the lifetime cumulative dose for mitoxantrone is 
reached after only two to three years136,145. Currently about 10% of all MS patients are 
treated either with mitoxantrone or with immunosuppressants such as 
cyclophosphamide, azathioprine and methotrexate although all of these drugs show 
considerable toxicity and have a high long-term risk145. Further treatments based on 
immunosuppression include total lymphoid radiation, infusion of intravenous γ-globulins 
and treatment with cytotoxic drugs combined with autologous bone marrow 
transplantation. 
The severe side effects and limited effectiveness of the commonly prescribed 
drugs underscore the need for new treatments of MS. Some of these attempts are 
described below. Alemtuzumab is a humanized monoclonal antibody (mAb) against the 
leukocyte surface molecule CD52. The proposed action is the removal of 
lymphomononuclear cells. It showed considerable success in the treatment of patients 
with progressive MS but in early studies 30% of them developed Grave´s disease, an 
autoimmune disorder of the thyroid gland. Other possible monoclonal antibody 
therapies are rituximab, which is approved for the treatment of non-Hodgkin 
lymphomas. Rituximab is an anti-CD20 mAb that depletes B lymphocytes by binding 
complement and mediating B cell lysis. Another mAb is the anti-CD25 Ab daclizumab 
that has shown promising results in phase II clinical trials146,147, although the 
mechanism of action is unclear. 
A very interesting new substance that is currently tested in phase III clinical trials 
and can be administered orally is FTY720 or fingolimod. Fingolimod is a chemical 
derivative of the fungal product myriocin. It is an agonist of the sphingosine 1-
phosphate receptor on lymphocytes and thymocytes, which is crucial for the egress of 
T and B lymphocytes from secondary lymphoid tissues148. Upon fingolimod binding the 
receptor is internalized trapping lymphocytes in secondary lymphoid organs and 
preventing their migration to peripheral target tissues149.  
Statins were initially developed as drugs that lower serum cholesterol levels136, 
but they also have immunomodulatory effects150. Statins inhibit the proliferation of 
lymphocytes, reduce the expression of adhesion molecules on activated T lymphocytes 
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and shift their cytokine expression profile towards a TH2 phenotype151. They also 
downregulate the expression of MMP-9 and chemokine receptors on T and B 
lymphocytes150. Statins are interesting drugs for MS therapy since they can be taken 
orally, show promising results and are well tolerated152. 
5.2.5 Experimental autoimmune encephalomyelitis: an animal model 
for MS 
EAE is a very well characterized animal model that resembles many aspects of 
MS. The phenomenon of EAE was discovered already in 1933, when it was observed 
that injections of brain tissue emulsions, and even more so mixtures of brain emulsions 
with killed Mycobacterium tuberculosis and paraffin oil induce a paralyzing disease in 
rhesus macaques and rabbits153,154. The mixture of heat-inactivated M. tuberculosis and 
mineral oil was termed complete Freund´s adjuvant (CFA) after its inventor and is used 
until today to induce so-called active EAE155. Subsequently it was found that myelin 
components, especially myelin basic protein were even more potent in inducing EAE, 
and that EAE can be induced in many different species including guinea pigs, rabbits, 
goats, mice, rats, hamsters, dogs, sheep, marmosets, and chickens153. Later it was 
shown, that EAE could not only be induced by immunization with various myelin 
peptides in CFA but also by adoptive transfer of encephalitogenic lymphocytes, a 
strategy that was named passive or adoptive transfer EAE156,157. Initially the induction 
of EAE was more robust and reproducible in guinea pigs and rats compared to mice. 
However it was discovered that EAE induction in mice can be facilitated by the injection 
of pertussis toxin, an effect that is mediated by several mechanisms. Pertussis toxin 
activates APCs158 and steers them to promote a TH1-biased immune response159. It 
also promotes P-selectin upregulation on brain endothelial cells in a toll-like receptor 4 
dependent way and increases thereby T cell recruitment. Interestingly it could also be 
shown that the increased permeability of the BBB that is discussed since a long time as 
an effect of pertussis toxin treatment is a result of the rolling and adhesion of T 
lymphocytes and not vice versa160. 
Since the use of pertussis toxin, mice became an invaluable tool for investigating 
disease mechanisms in EAE, largely due to the many possibilities of genetic 
manipulation and the abundant immunological agents available. The clinical course 
and the susceptibility to EAE vary considerably between different mouse strains and 
the genetic background of the mice also requires the use of different peptides to induce 
the disease. For instance EAE induction in C57BL/6 mice is done with the MOG35-55 
peptide and induces chronic-progressive disease, whereas EAE in SJL mice can best 
be induced by immunizing with a proteolipid protein peptide (PLP139-151) and the 
disease course is relapsing123,161. 
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With the help of EAE models many mechanisms regarding human autoimmune 
disease have been unraveled. The role of T lymphocytes for MS pathology was 
confirmed157, although most mouse EAE models underestimate the role of CD8+ T 
cells, which are more important in MS than in EAE. The importance of a TH1 or TH17-
biased cytokine profile of T lymphocytes and secondary macrophage recruitment for 
the development of autoimmune diseases has been demonstrated in the EAE model as 
well162. The need for a humoral immune response for the development of demyelinating 
lesions in MS patients was also deduced from EAE. Finally, three of the currently 
approved treatments for MS have been developed in the EAE model: glatiramer 
acetate, mitoxantrone and natalizumab67,163,164. 
5.2.6 Limitations of experimental autoimmune encephalomyelitis 
 Although many insights were gained from EAE models, they have limitations. 
Firstly, EAE is not a spontaneous disease but requires induction by adjuvants like heat-
inactivated mycobacteria and pertussis toxin. Secondly, many EAE models exist that 
reflect specific aspects of MS, but no model shows all the hallmarks of human MS. For 
instance, MOG35-55 induced EAE in C57BL/6 mice reflects the T cell mediated 
inflammation and the subsequent recruitment of deleterious macrophages but shows 
no demyelination mediated by a humoral immune response. Furthermore, no EAE 
model with a primary progressive disease course exists123. Thirdly, treatment trials in 
EAE have sometimes a poor predictive value for MS. Although the above mentioned 
therapies were developed in EAE, other EAE-based therapeutic strategies showed 
disappointing results in man. For example, altered peptide ligands (APL) with contact 
residues to the TCR specific for encephalitogenic peptides have been examined in 
human trials165. APLs are thought to interfere with TCR signaling by acting as partial 
agonists or antagonists, to induce anergy or a TH2 shift in T cells and to activate 
regulatory T cells. Indeed, APLs ameliorated MS in some patients, but in other patients 
they led to an exacerbation of MS and evoked allergic-type hypersensitivity reactions. 
Therefore, the trials were abandoned166. Similarly, interference with several cytokines 
worked well in the mouse model but not in humans. The blockade of TNF-α for 
example, ameliorated mouse EAE167,168 but neither mAbs against TNF-α169 nor 
treatment with a recombinant p55 TNF receptor immunoglobulin fusion protein170 
alleviated human MS. Nevertheless, blockade of TNF-α represents an effective 
treatment of other autoimmune diseases such as rheumatoid and psoriatic arthritis and 
Crohn´s disease171. Similar complications halted the treatment trials of IFN-γ for MS 
patients. Recombinant IFN-γ administration led to a significant increase in immune-
mediated disease exacerbations in MS patients172, although increased IFN-γ 
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production is correlated with EAE suppression in mice173. It is still unclear how these 
contrasting results can be explained. 
5.3 Leukocyte extravasation in EAE and MS 
Progress in understanding the paradigm of leukocyte extravasation promoted the 
development of drugs that interfere with integrin function. 
5.3.1 The extravasation cascade 
The general concept of leukocyte extravasation from the circulation into tissues is 
an extensively studied and well described multistep process42 (Figure 5.9). First, the 
cells slow down their movement within the blood stream by short, transient contacts 
between selectins on leukocytes and carbohydrate ligands on the blood vessel 
endothelium. The so-called tethering decreases the speed of leukocyte movement and 
permits selectin-mediated rolling on the vessel wall. Rolling can also be mediated by α4 
integrin binding to VCAM-1 or MadCAM174. The reduced speed of rolling leukocytes 
facilitates the interaction of G-protein coupled chemokine receptors on hematopoietic 
cells with chemokines presented on the luminal surface of endothelial cells. 
Chemokine-triggered signals induce integrin inside-out signaling which leads to the 
activation of leukocyte integrins. This step is mediated by Gαi proteins and hence can 
be inhibited with pertussis toxin. The activated integrins bind counter-receptors on 
endothelial cells resulting in firm adhesion, cell arrest and spreading followed by 
transmigration through the endothelium. 
 
Figure 5.9: Crucial steps during leukocyte extravasation. Leukocytes are captured or 
tethered by transient interactions and start to roll on the endothelium. Integrins become 
activated by chemokine receptor signaling which leads to their firm arrest. Upon 
adhesion strengthening and spreading cells crawl on the vessel wall, supposedly 
seeking an appropriate spot for transmigration. The subsequent transmigration through 
the endothelium and the underlying basement membrane occurs either directly through 
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an endothelial cell in a process called emperipolesis or between two adjacent endothelial 
cells. For each step the main molecular players are shown in the blue boxes. The cartoon 
is taken from Ley et al.175. 
Although this general concept holds true for a wide variety of tissues the three 
receptor events – selectins and carbohydrate ligands, chemokines and chemokine 
receptors and integrins and their counter-receptors – vary in different extravasation 
processes and for different leukocyte subtypes to grant specificity116. The tissue 
specific mechanisms of extravasation have been compared with zip codes allowing the 
highly organized and tightly restricted extravasation of certain cell types into certain 
organs (Paper I)42. Table 5.2 summarizes some typical extravasation processes and 
the involved adhesion molecules and chemokines. Interestingly, the different 
extravasation processes also require different time frames. Whereas the extravasation 
of lymphocytes to peripheral lymphoid tissues via HEVs takes place within minutes the 
extravasation of lymphocytes into the CNS requires hours176. 
Table 5.2: List of adhesion molecules, chemokines and chemokine receptors executing 
extravasation processes. The table is modified from Ransohoff et al. and 
Engelhardt116,177. 
Process Endothelium Tethering/ 
Rolling/ 
Capture 
Activation Adhesion 
recruitment of naïve 
lymphocytes to 
peripheral lymphoid 
tissues178 
HEVs of secondary 
lymphoid organs 
L-selectin – 
PNAD 
CCR7 – 
CCL21 
αLβ2 – 
ICAM-1 (and 
ICAM-2) 
TH1 cell recruitment to 
inflamed skin179,180 
dermal blood vessels CLA and 
PSGL-1 – E- 
and P-
selectin 
CCR4 – 
CCL17 
αLβ2 – 
ICAM-1 
lymphocyte 
recruitment to the 
mesenteric lymph 
nodes and Peyer´s 
patches178 
HEVs of mesenteric 
lymph nodes and 
Peyer´s patches 
α4β7 – 
MAdCAM-1 
CCR7 – 
CCL21 
αLβ2 – 
ICAM-1 
T lymphocyte 
recruitment to the 
CNS176,181 
postcapillary venules 
of the spinal cord 
white matter 
α4β1 - 
VCAM-1 
CCR7 – 
CCL19 and 
CCL21 
α4β1 - 
VCAM-1 
CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; CLA, cutaneous lymphocyte 
antigen; PNAD, peripheral node addressin; PSGL-1, P-selectin glycoprotein ligand 1 
 
5.3.2 Extravasation of leukocytes into the CNS 
Apart from the longer time that lymphocytes require to extravasate into the CNS 
the process is unique in several additional aspects. Firstly, the extravasation of 
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leukocytes into normal, non-inflamed CNS is carefully controlled by the BBB. The 
extravasation of autoreactive T cells into the CNS parenchyma mainly takes place at 
postcapillary venules where the BBB consists of endothelial cells tightly associated with 
each other through tight junctions, and their basement membrane. Secondly, 
transmigrating leukocytes have to penetrate a thin layer of leptomeningeal cells 
originating from invaginations of the arachnoid and the pial membranes. Finally, the 
leukocytes have to overcome the so-called glia limitans that covers the CNS 
vasculature and consists of the endfeet of astrocytes and their basement membrane182. 
Although previous views of leukocytes being unable to enter the CNS have been 
dismissed, the CNS is an immunoprivileged site with a low influx of immune cells110. 
The very low expression of adhesion receptors on brain endothelial cells seems key to 
the low leukocyte influx. 
Already the first transient interactions during the extravasation process seem to 
be different from the classical extravasation cascade. In vivo imaging of the 
microcirculation of the white matter of the cervical spinal cord of healthy SJL/N mice 
revealed that freshly stimulated encephalitogenic T cells did not roll at the capillary 
endothelium but instead were instantly captured 176. The abrupt capture was almost 
abrogated by pretreatment with antibodies either against α4 or VCAM-1 but not with 
pertussis toxin. VCAM-1 is upregulated during EAE on vessels of the CNS white 
matter183, and blockade of VCAM-1 ameliorates the course of EAE184. The results 
suggest that encephalitogenic T cell blasts are captured in the microvasculature of the 
CNS white matter without prior rolling and that the T cell capture is mediated by an 
interaction between α4 integrins and VCAM-1 without the requirement of G-protein 
mediated activation of the integrins. The reduced permanent firm adhesion of T 
lymphocytes to the endothelial vessel wall in pertussis toxin treated mice, however, 
indicates that firm adhesion critically depends on G-protein mediated signaling and 
integrin activation. T lymphoblast recruitment to the uninflamed BBB endothelium 
without prior rolling is probably important during the initiation of the inflammatory 
autoimmune process. During later stages of the disease the recruited leukocytes cause 
a proinflammatory milieu by producing various cytokines. Under these conditions 
lymphocytes roll on the endothelium which is also mediated by α4 integrins174,185. 
Therefore α4 integrins can mediate both the immediate capture without prior rolling and 
capture after rolling during lymphocyte extravasation into the inflamed CNS. 
Although ICAM-1 and ICAM-2 are detectable on uninflamed microvessels of the 
CNS and become further upregulated upon inflammation181,183 there is accumulating 
evidence that the interaction between ICAM-1 and αLβ2 does not contribute to the 
capture and firm adhesion of activated lymphocytes to the inflamed endothelium of the 
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healthy uninflamed spinal cord white matter. In accordance with a role of ICAM-1/αLβ2 
interaction during diapedesis the stable firm adhesion of the T lymphocytes to the 
endothelial cells after two hours and the transendothelial migration of T cells was 
slightly reduced after anti-αL antibody treatment181. 
5.3.3 The role of selectins during leukocyte extravasation into the 
CNS 
Although it has been shown that lymphocytes can be captured by the CNS 
microvasculature without prior rolling176 there is a controversy about the involvement of 
selectins in tethering and rolling of encephalitogenic T cells. The selectin family 
contains three members, of which P- and E-selectin are highly expressed on inflamed 
endothelial cells and L-selectin on circulating leukocytes42.  
In vitro E- and P-selectin expression is upregulated in cultured cortical endothelial 
cells after IL-1β and TNF-α treatment186. In vivo, one study failed to detect E- and P-
selectin in brain vessels of healthy and EAE mice187, whereas others detected them in 
CNS vessels of EAE mice188,189.  
Interestingly, ligands for both selectins were found  on a subset of  
encephalitogenic T cells187. PSGL-1, the main ligand for P-selectin is expressed on 
encephalitogenic T lymphocytes. However, antibodies directed against PSGL-1 do not 
influence the course of passive EAE in SJL mice. Furthermore, active EAE in PSGL-1 
knockout mice is indistinguishable from control mice.190 CLA, another selectin ligand, is 
derived from PSGL-1 by a fucosyltransferase-VII (FucT-VII)-mediated carbohydrate 
modification. Rolling and adhesion of FucT-VII-/- T cells is reduced, indicating that 
under inflammatory conditions CLA is important for both rolling and adhesion of T 
lymphocytes in the CNS grey matter191.  
All these findings, however, are in contrast to intravital microscopy studies that 
analyzed the interaction between encephalitogenic lymphocytes and endothelial cells. 
Superficial cerebral vessels were observed through the intact skull of young mice191. 
Rolling or firm adhesion of activated T cells to the endothelium was only observed in 
recipient mice that were treated either with lipopolysaccharide (LPS) or with TNF-α. 
The rolling interactions were dramatically reduced by preincubation of the T cells with 
antibodies to PSGL-1, P- and E-selectin. Notably, antibodies against α4, integrin αLβ2, 
VCAM-1 or ICAM-1 reduce the rolling only by about 50%. The firm arrest of 
encephalitogenic T cells was blocked almost completely with antibodies to PSGL-1 and 
P-selectin and considerably  reduced by antibodies to αLβ2, ICAM-1 and E-selectin.188 
In another intravital microscopy study, Kerfoot and Kubes imaged rolling of all 
endogenous leukocytes in superficial vessels of the brain during active EAE in 
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C57BL/6 mice. The rolling interactions were reduced with antibodies to α4, and the 
remaining rolling interactions were abrogated by additional administration of antibodies 
to P-selectin.189 Antibodies to P-selectin alone reduce rolling completely160,192.  
Importantly, neither genetic deficiency of P-selectin or PSGL-1 in C57BL/6 mice 
or P-selectin and/or E-selectin antibody treatment of SJL/J mice change the clinical 
course of active EAE187. Furthermore the development of active EAE in both C57BL/6 
and SJL mice that are deficient for E- and P-selectin is indistinguishable from control 
mice193.  
One explanation for these conflicting results might be that the described intravital 
microscopy studies analyzed superficial CNS vessels of the grey matter, where the 
mechanisms of lymphocyte recruitment might differ when compared with those in the 
white matter. Furthermore, Kerfoot and Kubes189,192 did not distinguish between distinct 
cell types in their analyses. Finally, it was shown that the efficacy of antibody blockade 
of α4 and/or P-selectin differs between C57BL/6 and SJL mice and depends also on 
how EAE was induced192. 
Regarding the recruitment of T cell blasts to the CNS the role of L-selectin is 
clear. Activated T cells do not express L-selectin194, and treatment of mice with 
antibodies directed against L-selectin does not influence lymphocyte rolling on CNS 
vessels188 or EAE development194. Notably L-selectin-deficient mice are protected from 
EAE, which is explained by an impaired effector function of macrophages195. 
5.3.4 The role of β2 integrins for EAE development 
In addition to the α4 integrin family and selectins, leukocyte-specific integrins of 
the β2 family of adhesion molecules and their interaction partners have been reported 
to influence the course of EAE and possibly MS.  The β2 integrins consist of four 
different members: αLβ2 or lymphocyte function-associated antigen-1 (LFA-1), αMβ2 or 
macrophage adhesion molecule-1 (Mac-1), αXβ2 and αDβ2. The β2 integrins are 
expressed on a wide variety of hematopoietic cells. LFA-1 is expressed on B cells, 
macrophages and T cells, Mac-1 on macrophages, neutrophils and natural killer cells, 
αXβ2 on dendritic cells, macrophages, monocytes, natural killer cells and activated T 
cells and αDβ2 on macrophages and neutrophils196-198. The β2 integrins play a vital role 
for the recruitment of neutrophils and other leukocytes (for example TH1 cells that home 
to the inflamed dermis) into inflamed tissues and genetic dysfunction of the β2 subunit 
causes leukocyte adhesion deficiency (LAD) characterized by severe, recurrent 
bacterial infections197. As described already above, β2 integrins are important during 
formation of the immunological synapse199,200. 
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Treatment of passive EAE in rats and mice with antibodies against the αL or the 
αM subunit ameliorates disease severity194,201,202. In another independent study, active 
EAE in rats could only be inhibited by treatment with antibodies against both LFA-1 and 
its counterreceptor ICAM-1203. Treatment of murine EAE with antibodies directed 
against LFA-1 produces opposing results ranging from no effect to severe 
exacerbation204,205. Mice lacking the αL gene develop delayed and less severe active 
EAE. This effect is most likely due to the impaired migration of lymphocytes to the 
draining lymph nodes as well as disturbed lymphocyte proliferation206. Blockade of 
ICAM-1, the main counterreceptor of LFA-1, interferes mainly with antigen-induced T 
cell proliferation; antibody blockade of ICAM-1 ameliorates active EAE but fails to 
prevent the passive transfer of EAE with T cells that are already activated203,204,207,208. T 
cells that lack all ICAM-1 isoforms have an impaired antigen-specific proliferation 
capacity and cannot transfer EAE in wild-type recipients209. Interestingly, one group 
found that passive transfer EAE in rats could be delayed profoundly with an anti-ICAM-
1 antibody184. The reason for the contrasting results is not clear. 
Genetic deletion of αM results in delayed and ameliorated active EAE and 
reduces leukocyte infiltration and demyelination of the spinal cord. When wild-type T 
cells are passively transferred into Mac-1-/- mice the onset of EAE is delayed and when 
Mac-1-/- T cells are transferred into wild-type mice, they do not develop signs of EAE. 
Mac-1-/- T cells have no significant reduction of antigen-specific proliferation in vitro but 
draining lymph nodes of Mac-1-/- mice contain fewer blasts, indicating a disturbed 
proliferative response in vivo. Mac-1-/- T cells have a TH2 shifted cytokine response. 
Taken together these results suggest that during EAE αM plays a role on T cells and 
also on other cell types, presumably macrophages210. Mac-1 is the main macrophage 
receptor for the recognition and uptake of myelin, therefore it has been suggested that 
blockade of Mac-1 interferes mainly with macrophage-mediated tissue destruction 
during the effector phase of EAE211,212. 
A genetic deficiency of the αx subunit results in milder active EAE and both the 
passive transfer of αx-deficient T cells into wild-type mice as well as vice versa results 
in an ameliorated disease course indicating a role for αx on both T cells and other 
inflammatory cells213. Genetic deletion of the fourth β2 heterodimer αDβ2 does not 
influence the development of active EAE, leukocyte infiltration of the CNS and the 
cytokine response and proliferation of T cells214. 
5.3.5 Blockade of the α4 subunit in EAE and MS 
Natalizumab (brand name: Tysabri) is a humanized monoclonal IgG4 antibody 
directed against the α4 subunit of the integrin heterodimers α4β1 and α4β7. IgG4 
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antibodies fail to activate complement and have a longer serum half-life than other 
isotypes215. Natalizumab is an effective treatment of MS and significantly reduces the 
number and severity of clinical relapses. Natalizumab was approved by the U.S. Food 
and Drug Administration (FDA) and the European Medicines Agency as a 
monotherapeutic treatment for relapsing MS. 
The development of natalizumab began in 1992 when it was noted, that 
antibodies directed against the α4 integrin subunit prevent leukocyte accumulation in 
the CNS and impair the development of passive EAE in Lewis rats. Since antibodies 
against other β1 or β2 integrin subunits showed little or no influence on lymphocyte and 
monocyte binding to inflamed blood vessels, it was concluded that α4β1 and/or α4β7 
are the key adhesion molecules for leukocyte homing to the inflamed CNS67. This was 
further supported by the observation that the expression level of α4 integrin on T cells 
correlates with their encephalitogenic potential184,216.  
α4β1 and α4β7 can bind VCAM-1 and the CS-1 fragment of fibronectin43,55 (Table 
5.1). Since only antibodies against α4 or β1 that interfere with VCAM-1 adhesion 
blocked the adhesion of T cells to inflamed vessels, VCAM-1 is the most likely counter-
receptor for α4 integrins during leukocyte adhesion67. In line with this finding, VCAM-1 
is upregulated on the endothelium of microvessels in MS lesions113,217 and venules of 
mice suffering from EAE218. Furthermore, α4 integrins and VCAM-1 are important for 
the adhesion but not the diapedesis of encephalitogenic T cells through brain 
endothelial cells218. 
Since then many publications demonstrated a positive effect of anti-α4 antibodies 
in vivo in both active and passive rodent models of EAE. In a murine passive EAE 
model the development of transfer EAE was dependent on the expression of high 
levels of α4 on the encephalitogenic T cells and could be inhibited by an antibody 
versus the α4 integrin subunit184. Although another study could not find this clear 
correlation between α4 expression and encephalitogenicity they also found α4 
expression on all encephalitogenic T cell lines that they tested, and prophylactic 
administration of antibodies to α4 prevented passive EAE elicited by those 
encephalitogenic cells194. In active guinea pig EAE treatment with an anti-α4 antibody 
before the onset of clinical symptoms results in a delayed onset of disease. The delay 
can be maintained as long as blocking antibodies are still present in the circulation. 
Furthermore treatment after development of clinical symptoms ameliorates them 
significantly. Under both treatment regimens the antibody reduces the number of 
infiltrated T lymphocytes and monocytes in the CNS and prevents demyelination219. 
Similar results were obtained by treatment of PLP-induced EAE in CSJLF1 mice with 
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an antisense nucleotide specific for the integrin α4 subunit. Antisense nucleotide 
treatment led to a significant reduction of α4 mRNA and expression in cell lines and 
primary lymphoid cells, alleviated EAE when administered before and reduced the 
severity when given after disease onset. Like with the antibody treatment the antisense 
oligonucleotides reduced the numbers of infiltrated CD4+ T cells and macrophages in 
the CNS220. Treatment with an anti-α4 antibody or  a small molecule antagonist to α4 in 
PLP-induced active relapsing EAE in SJL mice resulted in delay and amelioration of 
the disease. Surprisingly, treatment after onset of clinical symptoms led to increased T 
cell accumulation in the CNS, increased relapse rates, augmented TH1 responses to 
the priming peptide and supported epitope spreading221,222. It is possible that the 
observed exacerbation is specific for this disease model, since it was neither observed 
in other EAE models nor during clinical trials in humans. 
5.3.6 Blockade of integrin α4β7 by natalizumab 
A role for α4 integrins in the recruitment of inflammatory cells has been shown for 
various additional disease models including rheumatoid arthritis, contact 
hypersensitivity, type I diabetes mellitus, nephritis223 and allergic airway responses44,224. 
α4 integrins also play a crucial role for lymphocyte recruitment in the gut associated 
lymphoid tissue. During IBD the recruitment of lymphocytes is mediated by the 
interaction of α4β7 with MAdCAM-1225,226, whose expression is restricted to venules in 
the gut and high endothelial venules of the gut-associated lymphatic tissues (Peyer´s 
patches, mesenteric lymph nodes, and the appendix). Therefore, blockade of integrin 
α4β7 with natalizumab is also effective for the treatment of ulcerative colitis and 
Crohn´s disease227-229. Interestingly, the effect of natalizumab on IBD is not as 
pronounced as the efficacy in MS suggesting that additional adhesion molecules are 
required for the development of IBD. The predominant leukocytes in Crohn´s disease 
are indeed neutrophils, which extravasate mainly with the help of β2 integrins. 
Therefore, it is assumed that natalizumab interferes with the recruitment of T cells in 
IBD like in MS, and indirectly diminishes the secondary recruitment of neutrophils230. 
Although the role of a4β7 in the recruitment of lymphocytes to the gut is well 
established, its role in EAE is controversial. Theoretically natalizumab could block both 
a4β1 and α4β7 and both integrins are expressed on encephalitogenic T cells56. In 
SJL/N mice blockade of α4β7 via antibodies directed to β7 or α4β7 does not influence 
the development of passive EAE56. Furthermore, a small molecule inhibitor that is 
specific for the α4β1 heterodimer is sufficient to inhibit active EAE in Lewis rats which 
suggests that α4β7 plays no important role in this model231. On the contrary, it was 
shown in passive EAE in C57BL/6 mice that the administration of anti-β7 antibodies at 
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the peak of disease caused a partial disease remission and reduced the clinical score. 
β7 gene-deficient T cells are less encephalitogenic when transferred into wild-type 
mice and surprisingly also β7 gene-deficient mice show delayed and reduced clinical 
symptoms upon transfer of wild-type T cells232. Subsequently, the authors showed that 
an anti-MAdCAM-1 antibody prevented the development of MOG35-55-induced EAE in 
C57BL/6 mice or, administered during ongoing chronic disease, supported remission of 
the disease233. It could be that these different findings are due to differences of disease 
models such as relapsing EAE in SJL mice or chronic, non-remitting EAE in C57BL/6 
mice. 
5.4 α4-integrin blockade for the treatment of MS 
5.4.1 Clinical trials for Natalizumab 
After the promising results from the animal studies and several small clinical 
trials234-236 two randomized, double-blind, placebo-controlled, parallel-group, multicenter 
study phase III trials of natalizumab for the treatment for relapsing-remitting MS either 
alone (AFFIRM; Safety and Efficacy of Natalizumab in the Treatment of Multiple 
Sclerosis) or in combination with IFN-β (SENTINEL; Safety and Efficacy of 
Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis) were 
initiated237,238. Already the natalizumab monotherapy proved to be extremely effective 
as it reduced the rate of clinical relapses per year by 68% and the accumulation of new 
or enlarging T2-weighted lesions over two years by 83%. The mean number of 
gadolinium-enhancing lesions after both one and two years was reduced by 92%. The 
risk of a sustained progression of disability, which was defined as an increase of the 
EDSS of 1.0 or more that lasted at least for 12 weeks, was decreased by 42%. 
Importantly, no rebound effects were observed after discontinuation of natalizumab 
treatment238. In comparison, the current standard treatment with glatiramer acetate or 
IFN-β is reducing the rate of clinical relapses per year by about 30%239,240. In patients 
that were already treated with IFN β-1a additional therapy with natalizumab decreased 
the risk of a sustained progression of disability by 24% and the annualized rate of 
relapses by 55%. Very similar to the natalizumab monotherapy over two years the 
number of new or enlarging T2-weighted lesions was reduced by 83% and the mean 
number of gadolinium-enhancing lesions by 89%237. 
Three patients participating in natalizumab trials developed progressive multifocal 
leukoencephalopathy (PML). This serious side effect is discussed in detail below. 
Besides PML only a few additional side effects were observed during the clinical trials. 
Neither of the two studies showed a significantly different incidence of opportunistic 
infections between the natalizumab and the control group indicating that natalizumab 
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specifically acts on CNS inflammation and displays no classic immunosuppressive 
action. Apart from that, natalizumab probably does not impair neutrophils, the bodies 
mainstay in the immune response against bacterial and fungal infections42. Neutrophils 
rely under normal conditions or during an acute inflammation mainly on β2 integrins for 
their extravasation37. A persistent presence of antibodies that occurred in 6% of the 
treated patients correlated with a loss of clinical efficacy237,238,241. 
Apart from MS, the efficacy of natalizumab was also shown for Crohn´s disease 
in phase III clinical trials227,228,242. The results of a completed phase II clinical trial of 
natalizumab for rheumatoid arthritis are not available to the public 
(http://clinicaltrials.gov/show/NCT00083759) but it has been shown in murine and rat 
models for arthritis that blockade of α4β1 is beneficial243,244. 
Currently alternative ways of blocking α4 by small molecule inhibitors are 
explored245. Small molecule inhibitors were effective in the treatment of rodent EAE231. 
These small molecule inhibitors offer the advantages that they can be orally 
administered whereas antibodies are always administered intravenously. Furthermore 
small molecule inhibitors are less likely to elicit binding antibodies in the patients that 
render the antibody treatment ineffective230. And their affinity, specificity and 
pharmacokinetics can be optimized easier than those of antibodies. Phase II clinical 
studies with orally available VLA-4 antagonists are currently ongoing 
(http://clinicaltrials.gov/ct2/show/NCT00484536). 
5.4.2 Progressive multifocal leukoencephalopathy 
Based on the positive clinical trials natalizumab was approved by the American 
FDA in November 2004 for treatment of relapsing-remitting MS246. Only three months 
later, in February 2005, natalizumab was voluntarily withdrawn from the market after 
two patients developed PML under combined treatment with IFN β-1a and 
natalizumab247,248. One of those patients died from PML and another patient in the 
clinical trial for Crohn´s disease also developed fatal PML249. Out of approximately 
3000 patients treated on average for 18 month with natalizumab three developed 
PML250. Before the clinical trials with natalizumab, PML was only known to occur in 
immunocompromised patients, for example organ transplant recipients receiving 
immunosuppressants, patients with hematologic cancers or patients suffering from 
acquired immunodeficiency syndrome (AIDS). PML has never been described to be 
connected with MS. PML is caused by an infection with JC virus (JCV), a polyomavirus. 
The primary, asymptomatic infection with JCV is usually acquired during childhood. A 
seroprevalence of 86% was shown in healthy adults 251. If the latent virus is reactivated 
oligodendrocytes are infected leading to viral lysis, which in turn causes an irreversible 
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demyelination of nerve fibers and persisting, severe neurologic deficits. PML has a very 
high mortality rate and there exists no specific treatment252.  
Under normal conditions JCV is kept in check, mainly by CD8+ T cells. Therefore 
it is possible that the prevention of normal lymphocyte trafficking by natalizumab 
causes the reactivation of JCV, especially under conditions with an additional 
immunomodulation by IFN-β or other medications253. It is also possible, that 
natalizumab has a direct effect on the JCV reactivation itself. JCV is known to remain 
latent in the kidney, in lymphoid organs and the bone marrow where JCV is associated 
with B cells252. Therefore, it is possible hat natalizumab might release JCV-infected 
cells from the bone marrow thereby promoting virus replication, distribution to the 
whole body and entry into the CNS254-256. It is also possible that the interplay of both 
mechanisms is aiding the development of PML in the natalizumab-treated patients257. 
After a careful reexamination of all treated cases and a safety analysis250 the 
FDA reapproved natalizumab for the monotherapeutic treatment of relapsing-remitting 
MS in June 2006 under a special distribution program (TOUCH; Tysabri Risk 
Minimization Action Plan). According to current consensus natalizumab is not regarded 
as a first-line treatment but is only considered after treatment with drugs such as 
glatiramer acetate, IFN-β, cyclophosphamide or mitoxantrone is not successful or 
poorly tolerated. Natalizumab is used in patients with relapsing-remitting MS and 
requires intensive monitoring for the occurrence of PML, exclusion of factors that 
interfere with cell-mediated immunity and normal leukocyte counts before natalizumab 
therapy258. 
5.4.3 Effects of natalizumab on the immune system 
In all phase III clinical trials it was noted that natalizumab is increasing the 
number of circulating lymphocytes, monocytes, eosinophils and basophils, and 
sometimes nucleated red cells227,237,238. In addition, natalizumab treatment leads to the 
release and therefore to elevated levels of CD34+ HSCs in the circulation259,260. 
Peripheral blood mononuclear cells from natalizumab-treated patients show a reduced 
migratory potential across a fibronectin layer in Boyden chamber experiments261. T 
lymphocytes have a reduced surface expression of the α4 subunit261,262, and 
leukocytes, particularly CD4+ and CD8+ T cells, CD19+ B cells and CD138+ plasma 
cells in the CSF are dramatically reduced, even 6 months after cessation of 
treatment263. Natalizumab treatment also significantly decreases the ratio of CD4+ to 
CD8+ T cells in the CSF, but only slightly in peripheral blood. It is possible that CD8+ T 
cells are less affected by natalizumab because they express more α4 integrin and are 
thus inhibited less efficiently. Interestingly, the CD4+/CD8+ ratio in the CSF of 
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natalizumab recipients is reduced to the same extent as in HIV-positive patients, which 
have a high risk to develop PML262. 
5.4.4 Open questions regarding the natalizumab treatment 
Although 15 years passed since the first report describing integrin α4-blockade 
for the treatment of MS appeared, several questions remain still unanswered.  
Firstly, it is not clear which cell types are affected by the natalizumab treatment 
and thus mediate the main clinical benefit. Interestingly, it has been shown that B cells 
and monocytes express more α4 than T cells, and CD8+ T cells have a higher α4 
expression than CD4+ T cells261. In contrast, neutrophils express little or no α4β1. 
Nevertheless it has been discussed that neutrophils might also utilize α4 integrins for 
extravasation under chronic inflammatory conditions37. One group demonstrated that 
anti-α4 antibody treated rats suffering from active EAE loose T cell infiltrates whereas 
macrophages were still detected in the CNS, indicating that the macrophages were not 
affected by the antibody treatment264.  
Secondly, it is not clear whether both α4β1 and α4β7 integrins have a function 
during EAE development. Some reports suggest that the β7 subunit has no role for 
EAE development56,231, whereas others identified a beneficial influence of α4β7 
blockade on the EAE course232,233 (Chapter 5.3.6). 
Thirdly, it is not known whether blockade of the α4β1-VCAM-1 interaction disturbs 
several immune functions, such as extravasation and/or T cell priming. Transfer EAE in 
SJL mice is less efficiently ameliorated with antibodies against VCAM-1 than with 
antibodies against α4 suggesting that α4 blockade either inhibits the interaction with a 
second ligand such as CS-1 fibronectin, that the α4 blockade interferes not only with 
lymphocyte adhesion or that anti-VCAM-1 blockade is incomplete. In vivo the anti-α4 
antibody R1.2 in contrast to the PS/2 antibody is a poor inhibitor of lymphocyte homing 
to Peyer´s patches226, but both antibodies have the same clinical potency in 
ameliorating EAE56. This suggests that R1.2 interferes with EAE development by 
mechanisms different from a mere adhesion blockade. This is in line with the fact that 
binding of immobilized CS-1 fibronectin, VCAM-1 or antibodies to α4β1 has a 
costimulatory effect during antigen-dependent activation and proliferation of T 
lymphocytes265-268. Both R1.2 and PS/2 interfere in vitro with antigen-specific 
proliferation of encephalitogenic T cell lines56. Antibodies against α4β1 that bind the 
same epitopes which mediate the binding to fibronectin and VCAM-1 have the highest 
costimulatory potential269. As described above, α4β1 is localized in the pSMAC of the 
immunological synapse between T lymphocytes and antigen presenting cells86. For B 
lymphocytes it has been shown that α4β1/VCAM-1 binding enhances cell-cell 
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adhesion, which in turn increases BCR signaling by indirectly strengthening the 
interaction of the BCR with membrane-associated antigens. The outcome is to facilitate 
the activation of B cells, especially for antigens that have a low affinity to the BCR88. 
In vitro myelin-specific T cells induce the production of proinflammatory cytokines 
such as TNF-α and IL-1β in microglia cells. This effect is contact-dependent and can be 
significantly reduced by treatment with blocking antibodies against integrin α4270. It was 
also shown that the expression of the α4 subunit on an encephalitogenic T cell clone 
induced MMP-2 and thereby facilitated transmigration through the blood brain 
barrier271. Finally, it was reported that α4 is important for the retention of autoreactive T 
cells in the parenchyma of the CNS114. Another interaction that might be inhibited by 
natalizumab is the binding of α4β1 to osteopontin46, an ECM protein that promotes 
proliferation and differentiation of T cells into the TH1 lineage. Osteopontin is 
upregulated in EAE and in CNS lesions of MS patients272, and mice that lack 
osteopontin seem to have a decreased EAE severity272,273.  
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6 Aim of the thesis 
Firstly, we wanted to analyze the role of the two α4 integrins, α4β1 and α4β7, in 
adult murine hematopoiesis (Paper II). Previous studies with somatic α4 chimeras 
suggested an important role for α4 integrins in hematopoiesis, especially during 
retention and maintenance of HSCs in the bone marrow, while deletion of α4 in HSCs 
caused only mild hematopoietic defects and hematopoiesis of β1 deficient bone 
marrow chimeras and β7 knockout mice is normal. The following hypotheses were 
brought forward to explain the conflicting results: (i) α4β1 and α4β7 compensate each 
other, (ii) a lack of α4 expression in non-hematopoietic cells such as bone marrow 
stroma cells causes the severe phenotype in α4-/- somatic chimeric mice, and (iii) fetal 
hematopoiesis depends more on α4 integrins than adult hematopoiesis. In order to test 
these hypotheses we analyzed adult hematopoiesis in mice deficient for the β7 gene 
and lacking the β1 gene in the hematopoietic system in an inducible fashion. 
Secondly, we wanted to assess the role of RhoH, a downstream effector of 
integrin signaling, during hematopoiesis (Paper III). The small Rho GTPase RhoH is 
expressed exclusively in cells of the hematopoietic lineage and it has been implicated 
in several processes including the maintenance of HSCs, leukocyte adhesion and 
migration and the development of B cell lymphomas. In order to assess these roles of 
RhoH in vivo, we generated and analyzed mice that are genetically deficient for RhoH. 
Finally, we examined the function of integrin β1 in the autoimmune disease model 
EAE, which resembles in many aspects MS in man (Paper IV). The monoclonal 
antibody natalizumab directed against the α4 subunit is currently used to treat MS but 
its exact working mechanism is not clear. The main mechanism seems to be 
interference with the interaction of extravasating leukocytes with endothelial cells of the 
blood brain barrier. However, several observations suggest that the antibody is also 
interfering with additional processes such as T cell proliferation, the production of 
inflammatory cytokines by activated microglia cells or other, yet unknown functions of 
the α4 subunit. Furthermore it is unknown, whether the beneficial effects of the 
antibody treatment rely on the inhibition of α4β1 and/or α4β7 and which cell type is 
mainly inhibited. Our main goals were to find out: (i) which events are inhibited by the 
antibody, (ii) which α4 heterodimer is the main target of the antibody, and (iii) which cell 
types are affected by the treatment. Therefore, we examined the development of EAE 
in mice lacking the β1 subunit in the hematopoietic system or specifically in T cells. 
Furthermore, we analyzed the proliferation, cytokine response and adhesion of β1 
deficient T lymphocytes. 
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7 Brief summaries of the publications 
7.1 Paper I: β1 integrins: zip codes and signaling relay for 
blood cells 
The functions of β2 integrins - which are specifically expressed on blood cells – in 
the hematopoietic and immune system have been described in great detail. However, 
many members of the large family of β1 integrins are expressed on blood cells as well, 
and fulfill a variety of important functions. In this review we describe the functions of β1 
integrins on hematopoietic cells during the various steps of an immune response. The 
basis of an adaptive immune response is the antigen-specific activation and 
proliferation of lymphocytes. Upon activation, lymphocytes have to extravasate from 
blood vessels and subsequently migrate through the endothelium, the underlying 
basement membrane and the connective tissue. When they finally reach the site of an 
ongoing inflammation they have to be correctly positioned and retained in the tissue. A 
role of integrins of the β1 family has been shown for all these steps. Therefore β1 
integrins gain more and more importance as targets of anti-inflammatory drugs, which 
is discussed in the last part of the article. 
7.2 Paper II: Adult murine hematopoiesis can proceed without 
β1 and β7 integrins 
We intended to clarify the role of α4 integrins in adult murine hematopoiesis, 
since previous experiments examining the importance of the α4 subunit and its two 
association partners, β1 and β7 for hematopoietic development produced controversial 
results. Therefore, we analyzed the hematopoietic system of bone marrow chimeric 
mice with an inducible knockout of the β1 subunit and a deletion of the β7 gene. 
To compensate each other, both β1 and β7 have to be expressed on the same 
cell type. Therefore, we assessed the expression of the β7 subunit on hematopoietic 
cells and found that β7 is indeed expressed together with β1 on HSCs and on many 
other cells of the lymphoid and myeloid lineage. Analysis of hematopoiesis in bone 
marrow chimeras with β1/β7 double-deficient HSCs showed that the maintenance of 
HSCs was not impaired. Furthermore, neither the development of T nor of B 
lymphocytes was disturbed. To check whether the upregulation of other adhesion 
molecules compensates the loss of β1 and β7 in B and T lymphocytes, we compared 
the expression profiles of control and knockout lymphocyte populations with the help of 
affymetrix microarrays. No compensatory changes in molecules such as other 
integrins, selectins, VCAM-1 and MAdCAM-1 could be detected. Likewise, myeloid and 
erythroid cells developed normally in the double knockouts. Hematopoietic progenitor 
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cells in bone marrow and peripheral blood were slightly and transiently increased. We 
could show that the dramatic increase of those cells in non-bone marrow chimeric α4 
Mx1-Cre mice results most likely from a loss of α4 expression on bone marrow stromal 
cells. After challenge of erythropoiesis by phenylhydrazine induced lysis of 
erythrocytes, the number of erythropoietic progenitor cells in the spleen was 
significantly reduced in β1/β7 double knockouts, suggesting a role for β1 and β7 
integrins during recovery of erythropoietic progenitor cells.  
In summary, we found that there were only subtle or transient alterations in the 
number and distribution of progenitor cells, while the maintenance and retention of 
HSCs was not severely altered in the absence of β1 and β7 integrins. Furthermore 
lymphoid, myeloid and erythroid cell development were normal. These results indicate 
that adult hematopoiesis is indeed independent of α4 integrins, and thus imply that 
there is no need for a compensation between α4β1 and α4β7. This result hence 
indicates that the observed severe defects in the somatic chimeric α4-/- mice are likely 
attributed to a loss of α4 expression on non-hematopoietic cells.  
7.3 Paper III: RhoH is important for positive thymocyte 
selection and T-cell receptor signaling 
The small Rho GTPase RhoH has been implicated in the development of B cell 
lymphomas, for the proliferation and survival of HSCs and for the migration and 
adhesion of lymphocytes and HSCs. In order to elucidate the role of RhoH in vivo we 
analyzed the hematopoietic system of RhoH deficient mice. 
First, we generated mice carrying a disrupted RhoH gene. Animals with a 
homozygous disruption of the RhoH gene were born at Mendelian ratios. Both two and 
six months after birth mutant mice developed no remarkable changes in myeloid, 
erythroid or B lymphocyte populations in peripheral lymphoid organs and the bone 
marrow. In contrast, at both points of time the number of T lymphocytes was 
dramatically decreased in bone marrow, spleen and lymph nodes. Analysis of 
thymocytes in vivo and in vitro revealed that the generation of T lymphocytes was 
severely affected during the development of late CD4-CD8- double negative 
thymocytes. Accordingly during the late stages of double negative thymocyte 
development, apoptosis was increased and proliferation decreased. At this stage T 
cells that generated functional β-chains receive signals from the pre-TCR and continue 
their development (β-selection). In addition the transition of double positive cells into 
single positive cells was impaired in vivo, suggesting that also positive selection of T 
cells that recognize self-MHC molecules was compromised. Therefore we analyzed 
mice carrying an ovalbumin-specific TCR in addition to the RhoH deficiency. In those 
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animals we observed an impaired positive selection of thymocytes from double positive 
into CD4+ single positive cells, a process that requires weak signaling of the TCR. In 
vitro analysis of TCR signaling revealed that signaling downstream of the tyrosine 
kinase ZAP70 to the scaffolding protein LAT and molecules associated with LAT was 
diminished in RhoH deficient thymocytes and splenocytes. Since it was proposed that 
RhoH negatively regulates the adhesive properties of integrin αLβ2 we also tested the 
adhesion of RhoH-/- thymocytes to ICAM-1, VCAM-1 or endothelial cells. The adhesion 
of control and RhoH-null thymocytes was indistinguishable. In line with these findings 
the defective T cell development could not be rescued in RhoH/β2 double knockout 
mice. 
In conclusion, RhoH deficient mice have no defect in the maintenance of HSCs, 
but the differentiation of T lymphocytes is severely disturbed due to reduced pre-TCR 
and TCR signaling. 
7.4 Paper IV: Extravasation of autoreactive T cells into the 
central nervous system is controlled by β1 integrins 
The aim of this work was to elucidate the role of β1 integrins during the 
development of an autoimmune disease. Previous investigations had implicated the α4 
integrins α4β1 and/or α4β7 in the development of the human disease MS and the 
animal model EAE. The blockade of the integrin α4 subunit with antibodies is an 
approved treatment of MS, nevertheless it is not known, which integrin heterodimer and 
which cell types are mainly targeted and what is the main mechanism of action of the 
therapy.  
To elucidate the role of integrin α4β1 during EAE pathogenesis, particularly 
during proliferation and extravasation of encephalitogenic T cells, we analyzed EAE 
development in mice missing β1 expression in all hematopoietic cells or specifically in 
T lymphocytes. We found that the ability of β1 deficient T cells to accumulate in the 
CNS of mice during active EAE is severely impaired. This result supports the current 
opinion that the main α4 integrin implicated in EAE pathogenesis is α4β1 since the 
presence of α4β7 could not rescue the defective T lymphocyte accumulation. To clarify, 
whether the reduced accumulation is due to diminished activation and proliferation 
and/or extravasation of the T cells we first analyzed T cell proliferation. In vivo 
proliferation of β1-/- T cells was not significantly altered; furthermore, β1 deficient T 
lymphoblasts showed a normal cytokine response upon antigen-specific stimulation in 
vivo. Second, we examined the adhesion of T cell blasts to the spinal cord 
microvasculature by means of IVM. We found that the adhesion of β1 integrin deficient 
T lymphoblasts to postcapillary venules was greatly reduced indicating that the failure 
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of β1 knockout T cells to enter the CNS during EAE is mainly caused by their impaired 
extravasation. Furthermore we could demonstrate that active EAE development is 
significantly delayed in mice lacking β1 expression specifically on most T lymphocytes 
whereas the EAE course was not changed in mice with a complete absence of β1 on 
myeloid cells. These results indicate that the main targets of the antibody therapy are 
the T lymphocytes. 
In summary, we could show in this study that encephalitogenic T cells critically 
rely on members of the β1 integrin family during the pathogenesis of the autoimmune 
disease EAE, identifying α4β1 as major target of anti-inflammatory therapies directed 
against the α4 integrin subunit. Furthermore, we could show that the main effect of the 
antibody therapy is the blockade of T cell extravasation, whereas the antigen-
dependent proliferation of T lymphocytes was not impaired. Finally, we demonstrate 
that T lymphocytes are the major target cell hit by the treatments with blocking anti-α4 
antibodies. 
7.5 Paper V: Analysis of integrin functions in blood 
This paper was published as part of a review on the “Analysis of integrin 
functions in peri-implantation embryos, hematopoietic system, and skin”, and focuses 
on methods permitting to analyze the functions of integrins in the hematopoietic and 
the immune system in gene targeted mice. The availability of Cre lines that induce a 
deletion of loxP-site flanked genes facilitates the analysis of integrin functions in 
basically all branches and cell types of the hematopoietic system. In addition, 
hematopoietic system-restricted integrin knockouts can be generated with the help of 
bone marrow chimeric mice. Subsequently flow cytometric methods that are essential 
for the examination of the hematopoietic system are discussed. Another interesting 
feature of hematopoietic cells is the fact that most of them can be readily isolated, 
cultivated and analyzed in detail in vitro. Therefore, we describe the generation of 
dendritic cells and methods to analyze the proliferation of T lymphocytes. In the end, 
we explain the induction of EAE in mice, since this is an elegant system to test the 
properties of integrin deficient hematopoietic cells in an autoimmune disease model. 
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11 Supplements 
In the following, papers I to V are reprinted. On the enclosed CD the 
supplementary figure for paper II, the supplementary methods and figures for paper III 
and the supplementary movies for paper IV can be found. The supplementary movies 
are provided in QuickTime Movie format. 
 
Paper I
b1 integrins: zip codes and signaling relay for blood cells
Michael Sixt, Martina Bauer, Tim La¨mmermann and Reinhard Fa¨ssler
At least eight of the twelve known members of the b1 integrin
family are expressed on hematopoietic cells. Among these, the
VCAM-1 receptor a4b1 has received most attention as a main
factor mediating ﬁrm adhesion to the endothelium during blood
cell extravasation. Therapeutic trials are ongoing into the use of
antibodies and small molecule inhibitors to target this
interaction and hence obtain anti-inﬂammatory effects.
However, extravasation is only one possible process that is
mediated by b1 integrins and there is evidence that they also
mediate leukocyte retention and positioning in the tissue,
lymphocyte activation and possibly migration within the
interstitium. Genetic mouse models where integrins are
selectively deleted on blood cells have been used to investigate
these functions and further studies will be invaluable to critically
evaluate therapeutic trials.
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Introduction
To fulﬁll their surveillance function immune cells con-
tinuously patrol the organism, shuttling back and forth
between the blood stream, the lymphatic ﬂuid, secondary
lymphatic organs and peripheral tissues [1]. This mobile
life style requires ﬂexible switching between passive
transport and various cell-to-cell and cell-to-extracellular
matrix (ECM) interactions to arrest, migrate and become
activated.
The current paradigm of cell locomotion within tissues
and along cell surfaces involves integrin-mediated adhe-
sion to ECM or cellular counter-receptors, which gener-
ates traction forces necessary for translocation of the cell
body [2]. Integrins are perfectly suited to this task since
they link the cytoskeleton with the extracellular environ-
ment. Integrins are heterodimeric cell surface receptors
made up of a and b subunits. The combination of 18
known a and 8 b subunits in mammals can give rise to 24
different receptors [3]. Antibody blocking studies, gene
targeting approaches in mice and investigation of human
diseases have unambiguously revealed that integrins are
essential for intact hematopoietic development, home-
ostasis and inﬂammation. However, integrin ligand bind-
ing can affect several cellular events in addition to
adhesion and migration, including cell differentiation,
polarization, activation and survival [3]. A drawback of
most studies manipulating integrin functions on blood
cells in vivo is that the cell-biological process affected by
the manipulation is not exactly deﬁned. This is especially
evident when complex inﬂammatory models (for example
for autoimmune diseases) are studied and clinical symp-
toms or histological parameters are used as readout. A
further critical issue is that within recent years an increas-
ing number of mouse knockout studies have been pub-
lished that address the in vivo function of cytoplasmic
proteins involved in integrin signaling without explicitly
investigating which integrins are affected.
In this review we focus on the largest integrin family
which contains the b1 chain. The blood-cell-speciﬁc b2
integrin subfamily has been extensively reviewed by
others [4]. We will try to dissect the different cell-biolo-
gical functions that b1 integrins mediate when leukocytes
emerge from the blood vessels, locate within tissues,
become activated and re-enter the blood circulation.
Extravasation from the blood circulation
One of the best-established concepts in leukocyte biology
is the extravasation paradigm. When hematopoietic cells
leave the blood stream they go through a sequential
adhesion cascade to overcome both the high shear forces
within the blood vessel and the tight seal of the endothe-
lial cells (see Figure 1). Transient selectin–carbohydrate
interactions cause hematopoietic cells to begin to roll
along an activated endothelium. While rolling, the cells
sense chemokines that are immobilized on heparan sul-
fate residues on the luminal side of the endothelial cells.
The ligated chemokine receptors then transmit signals
into the leukocyte that lead to the rapid activation of
integrins (inside-out signaling — see Box 1), which
results in the integrins adhering ﬁrmly to their counter
receptors on the endothelial cell. Although adhesion
during extravasation is an essential step during leukocyte
trafﬁcking, it has little in common with cell migration in
the true sense. It is rather a cell adhesion event of the
hematopoietic cell to the two-dimensional surface of the
endothelial lumen.
The crucial b1 integrin family member involved in extra-
vasation is a4b1, which binds to the endothelial Ig
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superfamily cell surface receptor VCAM-1 (vascular cell
adhesion molecule 1). This interaction is conserved in
many different physiological settings where extravasation
occurs. In the steady state, lymphocyte recirculation via
high endothelial venules [5], T cell precursor entry into
the thymus [6] and T cell and stem cell homing into the
bone marrow [7–9] are regulated via this pathway. During
inﬂammation, lymphocytes and monocytes use a4b1 to
immigrate into the skin, lung, peritoneum and liver
[10,11,12]. For several cell types it has also been shown
that VCAM-1-a4b1 binding can mediate not only ﬁrm
adhesion but also rolling along the endothelium [12]. In a
somewhat controversial deviation from the paradigm,
there is evidence that extravasation of lymphocytes into
the central nervous system during autoimmune inﬂam-
mation is possible in the absence of previous rolling
[13,14]. Here the cells can be rather abruptly captured
by VCAM-1 exposed on the endothelial lumen.
In most cases the function of a4b1 is partially redundant
with that of b2 integrins and a4b7, which bind the
endothelial counter-receptors intercellular adhesion
molecule (ICAM-1) and mucosal addressin cell adhesion
molecule-1 (MAdCAM-1), respectively. An impressive
example of this redundancy is lymphocyte recirculation
into lymph nodes, which is only partially affected by b2
and b7 elimination [5] and unimpaired in the absence of
b1 integrin [15]. Combined blockade, however, results in
almost 100% reduction of lymphocyte recirculation [5].
Many details concerning the overlapping functions of
these integrins remain to be clariﬁed using genetic mod-
els in which the separate families are targeted
simultaneously.
Important exceptions to this redundancy are T cell traf-
ﬁcking into the CNS, which is largely inhibitable by a4b1
blockade [16], stem cell homing into the bone marrow,
which is completely defective in the absence of b1
integrin [7], and the migration of hematopoietic progeni-
tor cells from the fetal blood into the fetal liver during
early development. In early hematopoietic development,
we could show that genetic deletion of the b1 integrin
gene in progenitor cells leads to their accumulation in the
fetal blood and hence the inability to populate hemato-
poietic tissues [7,17]. Although it is likely that a4 is of
major importance in this setting, other a chains may be
involved. A possible candidate is the largely neglected
integrin a9b1, which is highly expressed on granulocytes
and binds to VCAM-1 and the ECM proteins tenascin,
osteopontin and ﬁbronectin. a9b1 has been shown to
mediate transendothelial migration in vitro via interaction
with VCAM-1 [18]. Interestingly, a4 and a9 chain are
closely related and together form a sub-family that binds
to the cytoplasmic adaptor paxillin [19].
Migration through the endothelium
Tight adhesion to the endothelium is followed by a
cascade of migration events that probably successively
trigger each other. First the cells have to pass through the
endothelial monolayer. There is no in vivo evidence that
this process — called ‘diapedesis’ — is directly depen-
dent on b1 integrins. It is rather mediated by cell adhe-
sion molecules of the JAM family, CD99 and PECAM-1
[1]. Nevertheless, ligation of endothelial VCAM-1 via
a4b1 seems to be a prerequisite for diapedesis, as it
triggers a signal within the endothelial cell that is trans-
mitted via the cytoplasmic tail of VCAM [20]. The
endothelial cell then reacts by actively extending protru-
sions to capture and guide the extravasating cell through
intercellular junctions or by transcytosing it directly
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Box 1 Regulation of b1 integrin activation
On circulating leukocytes, integrins are locked in the low-affinity
state. Only upon ‘inside out’ signaling (triggered, for example, by
chemokines, growth factors or T cell receptor activation) integrins
adopt a high-affinity conformation (termed integrin activation)
facilitating ligand binding and subsequent cell adhesion. Ligand
binding in turn induces integrin ‘outside in’ signaling that (among
many other effects) further consolidates cell binding by clustering
the integrins and thereby increasing binding avidity. Cytoplasmic
key players mediating ‘inside-out’ signaling are the small GTPases
of the Rap family and talin.
Rap1: Several recent in vitro studies have proven that Rap1, the
best-characterized member of the five Rap proteins, is essential for
b1 integrin activation on leukocytes. Studies with cell lines revealed
that activated Rap1 increases b1 integrin-mediated adhesion and
migration on VCAM-1 via a4b1 and on fibronectin via a4b1 and
a5b1 [57,58]. The same was shown for primary thymocytes of
transgenic mice expressing the constitutively active Rap1-mutant
Rap1V12 [59], whereas T and B cells derived from Rap1-deficient
mice show impaired adhesion on fibronectin [60]. Rap1 is recruited
to the plasma membrane by PKD1, where it is activated upon
integration into a complex containing the b1 integrin cytoplasmic tail
[61,62]. For Rap1-mediated inside-out signaling, the two Rap1
binding effectors RIAM and RAPL are essential. Accordingly, T cells
and dendritic cells from RAPL-deficient mice show impaired
adhesion to b1 integrin ligands and reduced transmigration through
endothelial monolayers [63]. Overexpression of RIAM enhances
Rap1-mediated T cell adhesion to fibronectin. Through its interac-
tion with profilin and ENA/Vasp proteins, RIAM probably links
Rap1–GTP to the actin cytoskeleton [64].
Talin: Talin is a large rod-like molecule that binds via its globular
head domain to the membrane proximal NPXY motif of b integrins
in a phosphorylation-regulated manner. Talin acts as a physical
link between integrins and the actin cytoskeleton and its binding to
integrin b chains is regarded as the final common step in integrin
activation [65]. Two recent studies assessed the in vivo role of the
b1 integrin NPXY motifs by employing mouse genetic models.
They revealed that the intact conformation of the NPXY motifs are
essential, as substitution of the tyrosines by alanine abolishes b1
integrin function and leads to a b1 integrin-null phenotype [66,67].
Accordingly, chimeric mice with alanine substitutions, similar to a
b1 integrin-null chimera, fail to develop hematopoietic cells,
probably as a result of impaired talin binding [67]. Both studies,
however, challenged the former view that tyrosine phosphorylation
is essential for affinity regulation of b1 integrins, as replacement of
both cytoplasmic tyrosines with phenylalanine did not result in an
obvious phenotype, indicating that tyrosine phosphorylation is
dispensable for the physiological b1 integrin function in vivo.
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Figure 1
Roles of b1 integrins during extravasation, interstitial migration and lymphocyte activation. (a) During selectin-mediated rolling, the extravasating
cell senses chemokines that are immobilized on the surface of the endothelium, leading to the inside-out activation of integrin a4b1. (b) The
a4b1–VCAM-1 interaction mediates firm adhesion and triggers a reverse signal via VCAM-1 that induces the extension of endothelial protrusions,
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through the endothelial cell body— called emperipolesis
[20,21].
Transmigration through the basement
membrane
All the events following diapedesis are far less character-
ized, which is mainly due to their experimental inacces-
sibility and the lack of established in vitromodels to study
molecular interactions. Directly after passing through the
endothelium, the transmigrating cells face a seemingly
impermeable barrier of ECM: the endothelial basement
membrane (BM). BMs are tightly interconnected and
thin (50–100 nm) sheets of specialized ECM compo-
nents of the laminin and collagen IV family [22]. It is
possible that b1 integrins play an active role during this
passage and in vitro studies have demonstrated that
leukocytes can actively bind BM components [23]. If
BM transmigration is selectively blocked in vivo one
would expect that extravasating leukocytes become
trapped between the endothelial cell layer and the under-
lying BM. Indeed this phenomenon was observed when
extravasation of granulocytes triggered by interleukin
(IL)-1 was studied in mice in which platelet endothelial
cell adhesion molecule-1 (PECAM-1) was functionally
inactivated by blocking antibodies or genetic deletion
[24]. The homophilic interaction between PECAM-1 on
granulocyte and endothelium induced the up-regulation
of the laminin binding a6b1 integrin on the granulocyte
surface, which in turn was necessary for BM transmigra-
tion [25]. Although this sequence of events was well
demonstrated in this speciﬁc experimental setting, it is
not a general phenomenon, as granulocyte extravasation
in response to tumor necrosis factor (TNF)a occurred
independently of PECAM-1 and a6b1 [26]. Another
recently reported example of the possible involvement
of a BM binding integrin during extravasation is the
reduced homing of hematopoietic stem cells into the
bone marrow after antibody blockade of a6b1 [27].
A physiologically distinct situation where leukocytes
cross a BM occurs during the emigration of Langerhans
cells from the epidermis. Their penetration through the
epidermal BM (which is biochemically distinct from
blood vessel BMs [28]) can also be inhibited by antibody
blockade of a6 integrin [29]. Although in this case it
remains to be shown which b chain (b1 or b4) pairs with
a6, laminin is the likely ligand.
Apart from these fragmentary data about molecular
players, the progression of physiological events that leads
to BM transmigration is completely enigmatic.
Proteolytic digestion via proteases, especially by the
matrix metalloproteinase (MMP) family, has been sug-
gested in several ex vivo models [30,31]. In this context it
is interesting that ligation of integrins can lead to the
induction of MMPs on leukocytes [31,32]. It remains to
be shown if integrins merely signal the presence of a BM
to induce proteolytic cascades or other events leading to
the BM’s local disassembly, or if integrin-mediated adhe-
sion is also a physical requirement for the translocation of
the cell body through the BM.
Migration through the interstitium
The diverse extracellular environments that leukocytes
face upon passaging through the BM range from the
loosely packed and ﬁbrillar-collagen-dominated connec-
tive tissue of the mesenchymal interstitium to the
cell-rich environment of secondary lymphatic organs.
At this stage, true directed migration takes over and it
is assumed that leukocytes navigate along gradients of
chemotactic agents towards their destinations. Despite
numerous in vitro studies using artiﬁcial settings such as
transwell ﬁlters coated with ECM components, it is still
controversial if this directed migration depends on integ-
rins at all in vivo. The most direct experimental evidence
for integrin involvement is provided by a series of intra-
vital microscopy studies revealing that migration of gran-
ulocytes through the mesenteric interstitium can be
partially inhibited by blocking antibodies against the
collagen-binding b1 and a2 integrin chains [33–35].
However, measured reductions in speed of only 30%
raise the question of whether the remaining migratory
activity is mediated by compensating (b2 or av) integrins
or whether it is completely integrin-independent. In vitro
experimental approaches using three-dimensional gels of
the ﬁbrillar collagens I and III, which mimic the inter-
stitial ECM, can be utilized as migration matrices and
studied by video microscopy. Even in this artiﬁcial and
very deﬁned setting, the results obtained with integrin-
blocking antibodies are controversial. By combined anti-
body blockade of av, b2 and b1 integrins, it was shown
that random T cell migration in the gel can occur in an
‘ameboid’ fashion in the complete absence of integrin-
mediated binding [36] and proteolytic activity [37]. How-
ever, others demonstrated that in the presence of che-
motactic agents, T cells utilize b1 (a1, a2, a6) integrins
for locomotion within collagen gels [38]. Although the
issue of interstitial migration remains to be clariﬁed using
genetic approaches in combination with intravital micro-
scopy, it is evident that it is essential to deﬁne not only the
nature of the ECM ligand but also the spatial conﬁgura-
tion of the extracellular environment in order to establish
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(Figure Legend 1 continued) establishing a ‘docking structure’. (c) Diapedesis is mediated via PECAM-1, JAMs, CD99 and b2 integrins
(not shown). Signals from the endothelium induce surface expression of a6b1 and proteases on the transmigrating cell. (d,e) In some cases the
laminin-binding integrin a6b1 and cell surface proteases mediate passage of the basement membrane. (f) a4b1 localizes to synapses between
follicular dendritic cells and B cells and dendritic cells and T cells where it promotes lymphocyte activation. (g) Interstitial migration along
chemotactic gradients is possibly mediated by the collagen-binding a2b1 integrin.
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integrin dependency. In an elegant study, Malawista et al.
[39] showed that in the spatially constrained environment
of a narrow space between two closely adjacent glass
surfaces, granulocytes can switch to biophysical mechan-
isms of translocation (squeezing or ‘chimneying’) that are
independent of integrin binding. By contrast, on two
dimensional surfaces granulocytes are completely depen-
dent on integrins to generate traction forces [39]. These
ﬁndings impressively demonstrate the importance of
using 3-dimensional model systems to study interstitial
blood cell migration.
In the light of these diverse and partially controversial
data, it seems possible that within the 3-dimensional
environment of the interstitium the quickly migrating
blood cells employ adhesive mechanisms that are funda-
mentally different from the integrin-dependent migra-
tion strategies used by mesenchymal cells.
Retention and positioning within the tissue
While it still remains to be clariﬁed to what extent
integrins are involved in interstitial leukocyte migration,
there is solid evidence that integrin-mediated binding can
deﬁne the position of hematopoietic cells by immobiliz-
ing and retaining them in their niches. Owing to the poor
knowledge about the spatial conﬁguration and molecular
composition of these niches, it is not known if retention
simply reﬂects integrin-mediated cell binding or if more
complex processes are triggered via integrin signaling that
ultimately lead to retention. Two prominent examples of
integrin-mediated retention are illustrated by studies
involving marginal zone B cells and hematopoietic pro-
genitor cells.
Several studies revealed that different precursors can be
released from the bone marrow by antibody blockade or
genetic inactivation of the a4 integrin [40,41]. Similar
results were obtained with mice lacking the a4b1 ligand
VCAM-1 [42]. It has been proposed that in the bone
marrow the stroma-derived chemokine CXCL12 triggers
a sustained signal that keeps the integrin in the active
state and therefore immobilizes the cells to VCAM-1 and
ﬁbronectin on stroma cells [43].
Marginal zone B cells are part of the ﬁrst line defense
system against circulating soluble antigens. As such, they
are located in a deﬁned ring area around the white pulp
follicles of the spleen, where they capture blood-borne
antigens. Only upon activation by microbial stimuli or
antigen do they downregulate integrin avidity, detach
from the marginal zone and follow a chemotactic gradient
of the chemokine CXCL13 that guides them into the
follicle, where they produce immunoglobulins. The
retention of marginal zone B cells is redundantly
mediated by a4b1 and aLb2 integrin, and blockade or
genetic ablation of these integrins causes the cells to
dislocate from the marginal zone [44]. In marginal zone
B cells, integrin afﬁnity was shown to be regulated via the
GTPase RhoA and the exchange factor lsc, as in the
absence of lsc these cells are unable to leave their niche
following stimulation owing to an insufﬁcient down-mod-
ulation of integrin avidity [45].
An interesting series of studies that suggests a role for
integrin-mediated retention during pathological pro-
cesses has been performed by de Fougerolles and
co-workers. Using antibody blockade and genetic inactiva-
tion, they demonstrated that the collagen receptors a1b1
and a2b1 are critically involved in the course of cutaneous
hypersensitivity, experimental arthritis and colitis by
localizing T cells within the interstitium [46–48]. Further-
more, in twomodels of murine virus infection, the number
of virus-speciﬁc CD8 memory T cells in the lung of
infected animals could be reduced by anti-a1b1 adminis-
trationwithout affectingT cell recruitment during primary
infection [49,50]. Therefore it is likely that a1b1
is needed for the long term retention of CD8 memory
T cells in the lung.
Cell–cell interactions and activation of
lymphocytes
The initiating step in all T-cell-dependent immune
responses is the formation of an immunological synapse
— the contact between an antigen-presenting cell (B
cell or dendritic cell) and a T cell. A main functional
constituent of the synapse is a sealing zone (the periph-
eral supramolecular activation cluster or pSMAC), which
is deﬁned and maintained by the interaction of LFA1
on the T cell with ICAM 1 on the antigen presenting
cell.
Although early in vitro studies already suggested that b1
integrins have potent co-stimulatory functions, condi-
tional knockout mice lacking b1 integrins on hemato-
poietic cells showed a relatively weak immunological
phenotype: T-cell-dependent immune responses were
grossly unaffected with the surprising exception that
IgM production was severely decreased [15]. However,
recent data suggest that members of the b1 integrin
family might play a more subtle regulatory role during
immune synapse formation. Mittelbrunn et al. showed
that a4b1, like aLb2, localizes within the pSMAC of
synapses between T cells and dendritic cells/B cells.
Furthermore, they could demonstrate that this interaction
is important for shifting of the T cells towards a Th1-type
cellular immune response [51]. Another recent study
showed that B cells utilize a4b1 to bind VCAM-1 co-
expressed with antigen on the surface of ﬁbroblasts in
vitro, which might reﬂect B cell interaction with follicular
dendritic cells in the lymph node [52,53]. Moreover, it
could be shown that this interaction synergizes with the B
cell receptor signal and triggers B cell activation. It will be
important to test if integrins assist T/B cell receptor
signaling only indirectly, by establishing and maintaining
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the cell–cell contact, or if active cross talk occurs between
the signaling pathways triggered by both receptors.
Members of the b1 integrin subfamily as
anti-inﬂammatory drug targets
Pharmacological interference with leukocyte extravasa-
tion is an attractive strategy for anti-inﬂammatory thera-
pies that was sparked off by the discovery of the
extravasation paradigm in the late 1980s. Table 1 lists
some selected diseases where blockade of b1 integrins
showed beneﬁcial effects, together with a proposed
mechanism of action. Although the intended therapeutic
effect ofmost of these therapeutic approaches involves the
inhibition of ﬁrm adhesion to the endothelium, it is not
clear whether other processes, for example lymphocyte
activation, could be affected as well. A prominent example
of this uncertainty is autoimmune inﬂammation of the
central nervous system. It is well established that the
binding of lymphocytes to inﬂamed brain blood vessels
during experimental autoimmune encephalomyelitis in
rodents is inhibited by antibodies against a4b1 and that
these antibodies prevent the development of the disease
[16]. This therapeutic principle was used in a clinical trial
to treat patients suffering from the equivalent human
disease, multiple sclerosis [54]. Despite very promising
results, approximately one out of thousand patients
acquired a deadly opportunistic viral infection of the
CNS during chronic treatment [55]. These could have
been caused either by impaired trafﬁcking of non-patho-
genic lymphocytes that are essential for normal CNS
immunosurveillance or by a more general immunosup-
pression. Indeed it has been shown in rodent EAE that an
anti-a4 antibody which does not inhibit lymphocyte hom-
ing in vivo still ameliorates EAE [56]. This argues in favor
of an additional role for a4b1 apart from mediating extra-
vasation. In this context the recent data suggesting a role
for a4b1 in T cell activation are of special interest.
Conclusions
Advances in the ﬁeld of intravital imaging make it now
possible to track the dynamic behavior of cells in most
tissues of living animals. In combination with genetic
models where integrins are speciﬁcally deleted on
deﬁned blood cell lineages, this approach will allow the
pinpointing of many of the cell biological roles of b1
integrins on hematopoietic cells. This knowledge will be
decisive to predict side effects when pharmacological
approaches are developed in which integrins are targeted
in a non-cell-type-speciﬁc manner. Investigating cyto-
plasmic players involved in the activation of the b1
integrins will further teach us to what extent the signaling
pathways are cell-type- and a-chain-speciﬁc and will
eventually reveal new drug targets to inhibit extravasation
in a more cell- and tissue-type-speciﬁc manner.
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Table 1
Model system Involved integrin dimer and
mode of inhibition
Effects of integrin inhibition Proposed mode of action References
EAE, multiple sclerosis
(Lewis rat, mouse,
human)
a4b1 Reduced clinical signs of disease,
reduced inﬂammatory inﬁltrate
Blockade of ﬁrm adhesion to
endothelium and thereby
extravasation
[16,54,56]
Anti-a4 mAb
Morbus Crohn
(human)
a4 integrins Reduced clinical signs and lowered
C-reactive protein levels
Not addressed, probably
extravasation blockade
[68]
Humanized anti-a4 mAb
Arthritis
(mouse)
a4b1 Reduced clinical signs, reduced
inﬂammatory inﬁltrate and mediators;
bacterial clearance not affected.
Interference with neutrophil
activation, cellular trafﬁcking
not severely affected
[69]
S18407: synthetic a4b1
inhibitor
Hepatitis
(mouse)
a1b1, a2b1 Reduced clinical signs, reduced
inﬂammatory inﬁltrate
Unclear; either migration in
tissue or activation of cells
[46]
Anti-a1/a2 mAb, a1
deﬁciency
a4b1 Reduced clinical signs of disease Interference with a4b- mediated
rolling, adhesion in sinusoids
[12]
Anti-a4 mAb, anti-VCAM-1
mAb
Peritonitis (mouse) a4 integrins Defective recruitment of lymphocytes
and monocytes to the peritoneum
Probably extravasation blockade [70]
Y991A mutation in a4,
blocks paxillin binding
Inﬂuenza
(mouse)
a1b1 No inhibition of the recruitment to the
lung during primary infection; reduced
number of memory CD8+ T cells in the
tissue and compromised secondary
immunity
Inhibition of long term retention
of CD8 memory T cells in the
lung
[50]
a1 deﬁciency; anti-a1 mAb
Colitis
(mouse)
a1b1 Reduced clinical symptoms, reduced i
nﬂammatory inﬁltrate, decreased IFN-g
and TNF-a production
Reduced extravasation, migration
or retention of monocytes;
reduced cytokine production
[48]
a1 deﬁciency; anti-a1 mAb
CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis; TNBS, 2, 4, 6-trinitrobenzene sulfonic acid.
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Paper II
HEMATOPOIESIS
Adult murine hematopoiesis can proceed without 1 and 7 integrins
Gerd Bungartz, Sebastian Stiller, Martina Bauer, Werner Mu¨ller, Angela Schippers, Norbert Wagner,
Reinhard Fa¨ssler, and Cord Brakebusch
The function of 41 and 47 integrins
in hematopoiesis is controversial. While
some experimental evidence suggests a
crucial role for these integrins in reten-
tion and expansion of progenitor cells
and lymphopoiesis, others report a less
important role in hematopoiesis. Using
mice with a deletion of the 1 and the 7
integrin genes restricted to the hemato-
poietic system we show here that 41
and 47 integrins are not essential for
differentiation of lymphocytes or myelo-
cytes. However, 17 mutant mice dis-
played a transient increase of colony-
forming unit (CFU-C) progenitors in the
bone marrow and, after phenylhydrazine-
induced anemia, a decreased number of
splenic erythroid colony-forming units in
culture (CFUe’s). Array gene expression
analysis of CD4CD8 double-positive
(DP) and CD4CD8 double-negative (DN)
thymocytes and CD19 and CD4 spleno-
cytes did not provide any evidence for a
compensatory mechanism explaining the
mild phenotype. These data show that
41 and 47 are not required for blood
cell differentiation, although in their ab-
sence alterations in numbers and distribu-
tion of progenitor cells were observed.
(Blood. 2006;108:1857-1864)
© 2006 by TheAmerican Society of Hematology
Introduction
The development and maintenance of hematopoietic stem cells
(HSCs), which can self-renew and differentiate into all hemato-
poietic blood cell lineages, is thought to depend on their
interactions with the microenvironment. Integrins expressed on
HSCs are capable of mediating several of those interactions as
they can bind extracellular matrix components such as ﬁbronec-
tin and laminin, but also cellular receptors like VCAM-1
expressed on bone marrow (BM) stroma cells. Integrins are a
family of heterodimeric cell-surface receptors consisting of an 
and a  subunit.1 Integrins provide mechanical support by
connecting the extracellular matrix (ECM) with the cytoskel-
eton, but are also capable of transducing chemical signals upon
ligand binding. This signaling results in cytoskeleton reorganiza-
tion and changes in gene expression affecting proliferation,
differentiation, and survival of cells.2 Molecules inside the cell,
on the other hand, can modulate the afﬁnity and avidity of
integrins, called inside-out signaling, which is, for example,
crucial for the extravasation of leukocytes.3
In vitro and in vivo experiments suggests an important role of
41 and 51 integrins for the adhesion of HSCs and hematopoi-
etic progenitor cells (HPCs) to ﬁbronectin in the bone marrow
matrix.4,5 Integrin 41 was additionally shown to mediate binding
to VCAM-1, which is expressed on BM stroma cells.6 Injection of
ﬁbronectin fragments and blocking antibodies against 41 and
VCAM-1 led to a release of HSCs/HPCs into the blood, supporting
the proposed importance of these interactions in vivo.5,7 Condi-
tional deletion of the VCAM-1 gene resulted in an early exit of
B-cell precursors into the blood.8 Finally, it was shown that
41–mediated attachment of HPCs to ﬁbronectin promotes
proliferation and survival,9,10 suggesting a crucial role for self-
renewal and survival of HSCs.
In vivo studies with 1 integrin–deﬁcient somatic chimeric
mice, which are generated by injecting 1-null embryonic stem
(ES) cells into wild-type host blastocysts, demonstrated that 1
integrin is not required for the formation of HSCs, but is essential
for their migration to the fetal liver.11 Additionally, 1 integrin–
deﬁcient HSCs failed to engraft lethally irradiated mice.12 Alto-
gether, these data pointed to a key role of 41 integrin in
hematopoiesis. This notion was corroborated by the analysis of
4-null somatic chimeric mice, which have almost no mature B
cells, T cells, or erythroblasts derived from 4-null ES cells.13,14 In
vitro experiments with cells derived from the 4-null chimeric
mice suggested that both erythroid and B-cell precursors are less
able to transmigrate through the stroma, which may result in
reduced cell proliferation.14 Also, the number of 4-deﬁcient
myeloid cells was reduced compared with control chimera. Since
7 integrin constitutive null mice displayed normal hematopoi-
esis,15 it was suggested that 41 integrin might be the pivotal
integrin during hematopoiesis, as 4 can dimerize only with 1 and
7 integrins. Therefore, it was unexpected when 1 mutant BM
chimeras showed no defects in blood cell development.16 The
simplest explanation at that time was that 41 and 47 integrin
might have redundant functions in blood cell development and that
only the absence of both receptors leads to the described hematopoi-
etic defects. However, further experiments showed that inducible
deletion of the 4 integrin gene has only subtle effects on
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hematopoiesis.17 These mutants showed only a partial reduction of
the B220 B-cell and CD4 T-cell populations in BM. Monocytes
(Mac-1) and erythroblasts (Ter119) were reported to occur in
normal amounts in the BM. In this study, however, the 4 integrin
gene was not only deleted in hematopoietic cells but also in many
nonhematopoietic cells such as hepatocytes, endothelial cells, and
so on, which could contribute to the phenotype. An alternative
explanation for these contrasting results could be that fetal
hematopoiesis is more dependent on 4 integrin than adult
hematopoiesis.
To better understand the role of 41 and 47 integrin in adult
hematopoiesis, we generated and analyzed mice with a blood
cell–restricted knockout of 1 and a constitutive knockout of 7
integrin. As a consequence 47, 41 and also other 1 integrins
expressed on blood cells are lost. In contrast to the 4-null somatic
chimeras13,14 or the 4 conditional knockout mice17 used previ-
ously, we can exclude any effects due to deletion of 4 on
nonhematopoietic cells, which might inﬂuence hematopoiesis
through altered production of cytokines and growths factors or
different cell-cell interactions. This model was used to study HSC
maintenance, HPC distribution and differentiation, and the migra-
tion of differentiated cells in the absence of 1 and 7 integrins in
adult mice. We demonstrate now that even in the absence of both
41 and 47 integrins, hematopoiesis is normal.
Materials and methods
Generation of mice with a deletion of the 1 and the 7 integrin
genes in the hematopoietic system
Mice carrying a 1 integrin gene ﬂanked by loxP sites (ﬂ/ﬂ)16 were mated
with mice with a neomycin-disrupted 1 integrin gene (/),18 mice
lacking a functional 7 integrin gene (7/),13 and with mice carrying the
Mx transgene (Mx).19 17 mutant BM chimeras were generated by BM
transplantation as described previously.20 Recipient Ly-5.1 mice were
lethally irradiated and received BM cells from Ly-5.2 1ﬂ/7/Mx or
1ﬂ/ﬂ7/ mice (7 mutant BM chimeras) or from 1ﬂ/ﬂ7/Mx mice
(17 mutant BM chimeras). Four weeks after the transfer, deletion of the
1 gene was induced by polyIC injections as described previously.20
Animal treatment
Mice were maintained and bred under pathogen-free conditions. All animal
experiments were approved by the local ethics committee. Blood samples
were obtained from the retro-orbital plexus under anesthesia. Acute
hemolysis was assessed after phenylhydrazine (PHZ; Sigma, Steinheim,
Germany) treatment as described.16
Tu¨rk staining
Whole blood of control and 17 mutant BM chimeras was isolated,
diluted 1:10 with Tu¨rk stain (0.01% gentian violet, 1.0% acetic acid), and
differentially counted for polymorphonuclear and mononuclear cells in a
hemocytometer.
Flow cytometry
Single-cell suspensions were prepared and analyzed as described.16 Erythro-
cytes in blood samples were lysed by incubation in ACK-lysis buffer for 5
minutes at room temperature prior to staining.21
Deletion of the 1 integrin gene on BM stroma cells was assessed by
measuring the activity of the -galactosidase reporter.16 Five days after a
single injection of 250 g polyIC, BM cells were plated on tissue-culture
plates as described.22 After 24 hours, nonadherent cells were removed and
adherent cells detached by trypsin/EDTA. Nonhematopoietic BM stroma
cells were characterized as Ly-5.2Ter119adherent cells, which consist of
mesenchymal stem cells, ﬁbroblasts, endothelial progenitor cells, and
endothelial cells.23 Hematopoietic cells, on the other hand, were identiﬁed
as Ly-5.2 or Ter119 nonadherent cells. Cells were stained for -galacto-
sidase activity as described,24 with minor changes. Brieﬂy, 4  106 cells
were suspended in 20 L phosphate-buffered saline (PBS) added to 20 L
of 2 mM ﬂuorescein-di-(beta-D-galactopyranoside) (FDG; Sigma). Cells
were incubated at 37°C for 75 seconds and subsequently 200 L ice-cold
PBS was added. Cells were incubated for 3 hours on ice and analyzed by
ﬂow cytometry as described.16
For the analysis of platelets, 5 L antibody solution containing
FITC-conjugated anti–1 integrin (Ha2/5; 1:10 diluted; BD Pharmingen,
San Diego, CA) and PE-conjugated anti–GPIb-IX (p0p1) (kindly donated
by Dr B. Nieswandt, University of Wu¨rzburg, Germany; 1:10 diluted) was
added to 1 L whole blood. After a 15-minute incubation at room
temperature in the dark, 100 L PBS was added and samples were analyzed
by ﬂuorescence-activated cell sorting (FACS).
Colony formation assay
Pre-B and CFU-C colony formation assays were performed as described
previously.16 CFUe assays were carried out following the instructions of the
manufacturer (Stem Cell Technologies, Vancouver, BC, Canada).
Separation of splenocytes by MACS
Leukocyte subpopulations were isolated from single-cell suspensions of
splenocytes by positive selection using FITC-conjugated antibodies against
B220 (B cells), CD4 (CD4 T cells), or CD8 (CD8 T cells) and anti-FITC
MACS beads according to the manufacturer’s instructions (Miltenyi
Biotec, Bergisch Gladbach, Germany). The purity of the sort was checked
by FACS analysis.
Southern blot analysis
Southern blot analysis was carried out as described.16 Membranes were
exposed to x-ray ﬁlms and the resulting bands quantiﬁed using
Bio-PROFIL Bio-1D V97.03 software (Vilber Lourmat, Marne-la-
Valle´e, France).
DNA microarray hybridization and analysis
Total RNAwas isolated from FACS-sorted populations of thymocytes (DN,
CD4CD8; DP, CD4, CD8) and splenocytes (CD19 B cells; CD4 T
cells). For biotin-labeled target synthesis reactions were performed using
standard protocols supplied by the manufacturer (Affymetrix, Santa Clara,
CA). Brieﬂy, 5 g total RNA was converted to double stranded (ds) DNA
using 100 pmol of a T7T23V primer (Eurogentec, Seraing, Belgium)
containing a T7 promotor. The cDNA was then used directly in an in vitro
transcription reaction in the presence of biotinylated nucleotides.
The concentration of biotin-labeled cRNA was determined by UV
absorbance. In all cases, 12.5 g of each biotinylated cRNA preparation
was fragmented and placed in a hybridization cocktail containing 4
biotinylated hybridization controls (BioB, BioC, BioD, and Cre) as
recommended by the manufacturer. Samples were hybridized to an identical
lot of Affymetrix MOE430A for 16 hours. After hybridization, the
GeneChips were washed, stained with SA-PE, and read using anAffymetrix
GeneChip ﬂuidic station and scanner. Gene expression levels were deter-
mined by means of Affymetrix’s Microarray Suite 5.0 (MAS 5.0).
Results
1 and 7 integrins are coexpressed in many hematopoietic
cells, including HSCs
In order to replace each other functionally, 41 and 47 must be
expressed in the same cells. While 1 integrin is expressed on all
hematopoietic cells besides erythrocytes,12,16 the expression of 7
integrin is more restricted (Figure S1, available on the Blood
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website; see the Supplemental Figure link at the top of the online
article). In BM, 7 integrin was found on linc-kitSca1 high cells
(ie, bona ﬁde stem cells), most mature B cells (B220 high), on
subpopulations of mature and immature granulocytes (Gr-1 high;
Gr-1 medium), and on few erythroid cells (Ter119) and immature
B cells (B220 low). 7 integrin was furthermore found on subsets
of DN, CD4SP, and CD8SP thymocytes, whereas it was virtually
absent on DP thymocytes. In spleen and lymph nodes, 7 integrin
was present on most B cells (B220), T cells (CD4, CD8), and
granulocytes (Gr-1). In lymph nodes, about 50% of the erythroid
cells (Ter119) expressed 7 integrin, whereas only a few percent
of the erythroid cells in the spleen had 7 on their surface.
Normal maintenance of HSCs in the combined absence of 1
and 7 integrins
To directly assess possible redundant functions of 41 and 47,
mice were generated lacking both receptors in the hematopoietic
system. Mice carrying a conditional knockout for 1 integrin, a
1-null allele, and a cre recombinase transgene under the control of
the polyIC-inducible Mx-promotor were intercrossed with mice
lacking a functional 7 integrin gene.15 Thus, mice that were
deﬁcient for 7 integrin and carried an inducible 1-null gene
(1ﬂ/7/Mx-cre or 1ﬂ/ﬂ7/Mx-cre) were obtained. Mice
lacking 7, but constitutively expressing 1 (1ﬂ/7/Mx-cre
or 1ﬂ/ﬂ7/) were used as controls. To restrict the deletion to the
hematopoietic system, BM from these mice was transplanted into
lethally irradiated recipient mice (Figure 1A). The ablation of the
conditional 1 gene was induced by 3 intraperitoneal injections of
polyIC after reconstitution of the hematopoietic system (4 weeks
after irradiation). Mice were analyzed 2, 6, and 10 to 12 months
after the polyIC treatment.
At all time points analyzed, no expression of 7 integrin was
detectable in any tissue by FACS (data not shown). To analyze the
time course of the 1 integrin gene ablation, we monitored the loss
of 1 integrin expression on short-lived platelets. Two days after
the ﬁrst polyIC injection, 1-deﬁcient platelets were already
detectable in the blood of 17 mutant BM chimeras (Figure 1B).
The relative amount of 1-deﬁcient platelets increased continu-
ously to reach 93% after 14 days and 97% after 21 days and later. In
control BM chimeras, on the other hand, virtually all platelets
expressed 1 integrin at all time points analyzed. These data show
that the deletion of the 1 integrin gene can be induced within a
few days in a 7 mutant background. Furthermore, they conﬁrm
that the development of megakaryocytes and platelets is not
crucially dependent on 1 and 7 integrins. Southern blot analysis
of BM, spleen, and thymus of 2- and 10-month-old 17 mutant
and control BM chimeras conﬁrmed the efﬁcient 1 gene deletion
in all these tissues (Figure 1C and data not shown). Since only
HSCs can sustain hematopoiesis for more than 3 months, these data
indicate that 17-deﬁcient HSCs are maintained in vivo.
To investigate the development of different hematopoietic
lineages that derive from HSCs, we ﬁrst checked the cellularity of
Figure 1. Efﬁcient deletion of 1 integrin in the hematopoietic system does not affect cellularity of lymphoid organs. (A) Bone marrow of mice with a conditional
knockout of 1 integrin, an Mx-cre transgene, and a constitutive knockout of 7 integrin (1ﬂ/7/Mx cre) was transplanted into lethally irradiated wild-type host mice. In bone
marrow chimeras, donor and host cells could be distinguished by expression of Ly-5.1/Ly-5.2 surface marker. After repopulation of the hematopoietic system (4 weeks), polyIC
was injected to induce expression of the cre recombinase in the donor cells and deletion of the 1 integrin gene. (B) Percentages of 1 integrin–negative platelets isolated from
control and 17 mutant BM chimeric mice are shown at indicated time points after the ﬁrst of 3 polyIC injections (day 0). Error bars show the standard deviation (n [control BM
chimera]/[17 mutant BM chimera]: 9/6). (C) DNA was isolated from single-cell suspensions from BM, thymus, and spleen from 17 mutant BM chimeras 10 months after
polyIC treatment. Southern blot analysis detecting the conditional and the null allele was performed (a representative result is shown on the right panel). Band intensities were
quantiﬁed and visualized in a bar graph. Error bars show the standard deviation. (n [control BM chimera]/[17 mutant BM chimera]: 3/3). (D) Left panel: Single-cell
suspensions were made from BM (2 femurs), thymus, spleen, and lymph nodes (2 inguinal, 2 axial, 1 para-aortic) of control and 17 mutant BM chimeric mice 2 months after
the gene deletion. Cells were counted using a hemacytometer. The bar graph shows the absolute cell number in the respective tissues. Error bars show the standard deviation
(n [control BM chimera]/[17 mutant BM chimera]: 4/4). Right panel: Whole blood was collected retro-orbitally from control and 17 mutant BM chimeric mice 6 months after
the gene deletion. The blood was diluted 1:10 with Tu¨rk stain and differentially counted in a hemacytometer. The bar graph shows the concentration of mononuclear (M) and
polymorphonuclear (PMN) cells in the blood. Error bars show the standard deviation (n [control BM chimera]/[17 mutant BM chimera]: 4/4).
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different lymphoid organs. At 2 months (Figure 1D, left) and 10 to
12 months (data not shown) after induction of the gene deletion
there were no differences observed in the cellularity of BM,
thymus, or spleen of control and 17 mutant BM chimeras,
providing no evidence for defective hematopoiesis in the absence
of 1 and 7 integrins. Differential blood counts revealed similar
numbers of mononuclear and polymorphonuclear cells in the
peripheral blood (PB) of control and 17 mutant BM chimeras 6
months after polyIC treatment (Figure 1D, right).
Normal B-cell development in the absence of 1
and 7 integrins
Since previous studies suggested that normal B-cell development
was dependent on 4 integrin,13,14,17 but not on 4116 or 4715
alone, we investigated whether 1 and 7 integrins have a
redundant function in B-cell development. In pre-B colony assays,
control and 17 mutant BM gave rise to colonies that were
derived each from a single pre-B-cell pecursor. FACS analysis of
randomly picked colonies conﬁrmed that 36 of 39 colonies (92.3%)
of 17 mutant BM did not express 1 integrins, whereas all tested
colonies derived from control BM expressed 1 integrins. No
host-derived colonies expressing Ly-5.1 were detected. To further
monitor B-cell development, single-cell suspensions from BM,
spleen, and lymph nodes (LNs) were analyzed using B-cell–speciﬁc
markers: B220 (pre-proB and later), CD19 (proB and later), IgM
(immature B), and IgD (all mature B). The relative amount of cells
positive for the respective markers was unaltered in 17 mutant
BM chimeras compared with control BM chimeras 2 and 12
months after the knockout induction (Table 1 and data not shown).
FACS analysis of immature B cells (B220 medium) proved the
loss of 1 integrin (Figure 2A). Mature B cells (B220 high) express
only low amounts of 1 integrin, which makes it difﬁcult to
distinguish normal from 1-deﬁcient mature B cells by FACS
(Figure 2A). Therefore, the knockout efﬁciency in B220 B cells
puriﬁed from spleen was determined by Southern blot analysis
(Figure 2B). B220 B cells were enriched by MACS beads to a
purity of more than 95% (Figure 2B, left). Southern blot of
genomic DNA isolated from these cells revealed a deletion
efﬁciency of the 1 integrin gene of 93.5% 8.3% (n 5). These
data indicate that in the absence of 1 and 7 integrins, B cells can
fully mature. Furthermore, since spleen, LN, and BM contained
normal numbers of B cells, migration of immature B cells to spleen
and of mature B cells to LN and BM is apparently not impaired by
the combined loss of 1 and 7 integrins.
T-cell development in the absence of 1 and 7 integrins
Since in 4-null somatic chimeric mice 4-null T-cell precursors
were described to be unable to migrate to the thymus for further
differentiation, thymocyte development was analyzed in 17
mutant BM chimeric mice using the T-cell markers CD4 and CD8.
No signiﬁcant difference was found in the population sizes of
CD4CD8 (DN) thymocytes, which contain the early thymic
immigrants indicating that thymic colonisation was not altered in
17 mutant BM chimeric mice which lack both 41 and 47
integrins. Furthermore, the relative amounts of CD4CD8 (DP),
CD4 (CD4SP), and CD8 (CD8SP) cells in the thymus were
normal in 17 mutant BM chimeric mice (Figure 3A and Table
2). Staining of thymocytes for 1 integrin and subsequent FACS
analysis proved the absence of 1 integrin from DP T cells (Figure
3B). Normal numbers of CD4 and CD8 T cells in spleen, LN, and
BM of 17 mutant BM chimeras 2 and 12 months after induction
of the 1 gene deletion suggested normal migration of these cells to
secondary lymphoid organs and to the BM (data not shown). Since
mature CD4 and CD8 T cells express only low levels of 1
integrin, the deletion efﬁciency in these populations was tested on
the genomic level. Southern blot from CD4 and CD8 T cells,
enriched from the spleen, revealed that 78.5% 5% (n 3) of
CD4 T cells and 83.4% 10.8% (n 4) of CD8 T cells lacked
a functional 1 integrin gene (Figure 3C). These data show that 1
and 7 integrins are neither essential for the migration of T-cell
precursors to the thymus nor for T-cell maturation within the thymus.
Figure 2. Normal B-cell population sizes in the absence of 1 and 7 integrins.
(A) Representative histogram overlays show the 1 integrin expression on immature
(B220med) and mature (B220hi) B cells of BM and spleen, respectively, of control
(ﬁlled) and 17 mutant BM chimeras (line). (B) Single-cell suspensions from spleen
of control and 17 mutant BM chimeras 6 months after polyIC treatment were
prepared, stained with B220-FITC antibody, and subsequently sorted using anti-FITC
MACS beads. Left panel: FACS analysis of the B220-enriched fraction indicated
higher than 95% purity (representative histogram is shown). Right panel: DNA was
prepared from MACS-enriched B220 splenocytes, analyzed by Southern blot, and
densitometrically evaluated. The bar graph shows the relative amount of B220 cells
deﬁcient for a functional 1 integrin gene. Error bar shows the standard deviation (n
[control BM chimera]/[17 mutant BM chimera]: 5/5).
Table 1. B-cell population sizes
Population size
Control 17 mutant
BM
B220med 5.2  1.6 5.5  1.2
B220hi 5.7  1.8 4.7  1.1
CD19 12.9  6.2 10.5  2.5
IgM 6.0  1.1 5.1  1.4
IgD 8.5  6.5 4.7  1.1
Spleen
B220hi 40.5  12.0 37.7  12.8
CD19 38.9  13.9 36.9  10.5
IgM 34.6  3.5 32.8  9.3
IgD 39.7  1.6 45.5  15.7
LN
B220hi 19.8  4.0 18.3  4.5
CD19 17.4  4.3 16.1  5.5
IgM 8.4  3.7 9.0  3.5
IgD 15.0  1.7 16.7  7.0
For all populations, n  4. Single-cell suspensions from BM, spleen, and LN of
control and 17 mutant BM chimeras 2 months after polyIC treatment were
prepared; stained with antibodies against B220, CD19, IgM, IgD (med indicates
medium; hi, high); and 1 integrin and analyzed by FACS. The averages of the
population sizes in the respective tissues are shown with standard deviations.
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Myeloid and erythroid development in the absence of 1
and 7 integrins
To analyze myeloid development, we ﬁrst studied the capacity of
myeloid progenitors in control and 17 mutant BM chimeras
lacking 41 and 47 integrins to form colonies in vitro
(CFU-C). All CFU-C colonies analyzed from BM (n 37), spleen
(n  38), and PB (n 36) from control mice were positive for 1
integrin. From 17 mutant BM chimeras only 2 of 36 colonies
from the BM, 1 of 37 of the spleen, and 3 of 37 colonies derived
from PB were positive for 1 integrin. These results show ﬁrst, that
in the absence of 1 and 7 integrin granulocyte/monocyte
precursors have the potential to form colonies in vitro and second,
that the efﬁciency of the 1 integrin gene deletion is very high in
the myeloid lineage. Both control and mutant BM cells also formed
erythroid colonies (CFUe’s) in vitro. Of 42 colonies tested from
mutant BM, none showed a functional 1 integrin gene as tested by
genomic PCR, whereas in 24 of 24 colonies from control BM a
functional 1 gene was detected.
Monitoring the development of monocytes, granulocytes, and
erythroblasts in 17 mutant BM chimeric mice 2 and 12 months
after the 1 integrin gene deletion in vivo revealed no signiﬁcant
differences in the numbers of granulocytes, monocytes, and
erythroblasts, indicating no developmental defects in the absence
of both 41 and 47 integrins (Table 3 and data not shown). The
1 gene deletion on these cells was conﬁrmed by staining for 1
integrin and subsequent FACS analysis (Figure 4). These data
strongly suggest that HSCs and HPCs continuously provide myeloid
and erythroid cells in the absence of41 and47 integrins.
Emigration of granulocyte/monocyte progenitors from the BM
to the blood and spleen
Induced deletion of 4 integrin in hematopoietic and many
nonhematopoietic cells resulted in a slow increase of CFU-Cs in
the BM, an overproportional release into the PB, and an accumula-
tion of CFU-Cs in spleen, suggesting a role for 4 in the retention
of progenitor cells in the BM.17 To test this in 17 mutant BM
chimeras, we determined the frequency of CFU-C progenitors in
BM, PB, and spleen 2 and 10 months after the 1 integrin gene
deletion (Figure 5A). At 2 months, the number of precursor cells
was signiﬁcantly elevated in the BM of 17 mutant mice as
compared with controls. We also observed an increase of progeni-
tors in PB roughly proportional to the progenitor increase in the
BM, but signiﬁcantly less than reported for 4 conditional
knockout mice 8 weeks after induced gene deletion, thus not
indicating a severe defect in progenitor retention in the BM.
Furthermore, these alterations were transient, since they were
observed 2 months but not 10 months after knockout induction,
when 17 mutant and control mice had similar CFU-Cs, both in
BM and PB (Figure 5A). Unlike the conditional 4 integrin
knockout mice 2 weeks and 6 months after gene deletion,17 17
mutant BM chimeras did not accumulate precursor cells over time
in the spleen, as tested 2 and 10 months after the knockout
induction (Figure 5A). To the contrary, CFU-Cs were signiﬁcantly
decreased in 10-month-old mutant chimera.
FACS analysis of BM cells of nonchimeric (1ﬂ/ﬂMx-cre)
mice 3 days after a single polyIC injection revealed that the 1
integrin gene is not only deleted on most hematopoietic cells
Figure 3. 1 and 7 integrins are not essential for normal T-cell development.
Single-cell suspensions from thymus of control and 17 mutant BM chimeras 2
months after polyIC injection were prepared, stained with antibodies against CD4,
CD8, and 1 integrin, and analyzed by FACS. (A) The dot blots show a representative
staining of DN, DP, CD4SP, and CD8SP thymocytes for both control and 17mutant
BM chimeras. (B)A representative histogram displays 1 integrin expression on DPT
cells of control (ﬁlled) and 17 mutant (line) mice. (C) Single-cell suspensions from
spleen of control and 17 mutant BM chimeras 6 months after polyIC treatment
were prepared, stained with CD4-FITC or CD8-FITC antibody, and subsequently
sorted using anti-FITC MACS beads. FACS analysis of the CD4- or CD8-enriched
fraction indicated higher than 95% purity (representative histogram is shown). DNA
was prepared from MACS-enriched CD4 or CD8 splenocytes and analyzed by
Southern blot and densitometrically evaluated. The bar graphs show the relative
amount of CD4 or CD8 cells deﬁcient for a functional 1 integrin gene. Error bar
shows the standard deviation (n [control BM chimera]/[17 mutant BM chimera]:
CD4, 3/3; CD8, 4/4).
Figure 4. 1 and 7 integrins are not essential for myeloid and erythroid
development. The 1 integrin expression of immature granulocytes (Gr-1med) and
erythroblasts (Ter119) of control (ﬁlled) and 17 mutant BM chimeras (line) is
shown in representative histogram overlays.
Table 2. Thymic T-cell population sizes
Thymus subpopulation
Population size
Control 17 mutant
DN 3.0  1.2 2.0  0.4
DP 70.2  2.9 76.5  4.3
CD4SP 20.0  3.4 17.3  3.0
CD8SP 6.7  1.0 4.2  2.0
For both populations, n  4. The averages and standard deviation of the
population sizes are shown in the table for the respective subpopulations.
Table 3. Myeloid and erythroid cell populations in the BM
BM subpopulation
Population size
Control 17 mutant
Gr-1 50.7  4.9 63.5  11.0
Mac-1 64.4  10.6 73.5  14.2
Ter119 19.3  3.5 14.1  8.6
For both populations, n  4. Single-cell suspensions from BM of control and
17 mutant BM chimeras 2 months after polyIC treatment were prepared; stained
with antibodies against Gr-1, Mac-1, and Ter119 in combination with antibodies
against 1 integrin; and analyzed in FACS. The table shows the relative size of
granulocyte (Gr-1), granulocyte/monocyte (Mac-1), and erythroblast (Ter119) subpopu-
lations and standard deviation.
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(Figure 5B, Ly-5.2, Ter119), but also on many nonhematopoietic
BM stroma cells, deﬁned as (Ly-5.2, Ter119) plastic adherent
cells (Figure 5B). To assess whether loss of 1 and 7 integrin on
nonhematopoietic cells might contribute to the progenitor release,
the frequency of progenitor cells was determined in the PB of
nonchimeric 17 mutant mice 4 weeks after the knockout
induction. We found that the progenitor content in PB increased
approximately 8-fold in 17 mutant mice (data not shown),
comparable to the more than 10-fold increase of the CFU-Cs in 4
conditional knockout mice 4 weeks after gene deletion,17 indicating
that loss of 4 integrin on nonhematopoietic cells might contribute
to the release of CFU-C progenitors from BM to PB.
Expansion of erythrocyte precursors after hemolytic anemia
After phenylhydrazine (PHZ) induced lysis of erythrocytes in vivo,
erythroid precursor cells expand in order to compensate for the loss
of erythrocytes. In addition, hemolytic anemia promotes extramed-
ullary erythropoiesis leading to proliferation of progenitors in the
spleen.25 Since in 4 conditional knockout mice the ability of
erythroblasts to expand in response to a PHZ-induced hemolytic
anemia was reduced,17 we investigated whether combined loss of
1 and 7 integrins shows a similar effect. For better comparison
with the nonchimeric 4 conditional knockout mice we used
nonchimeric 17 mutant mice.
Two days after PHZ treatment the amount of erythrocytes
dropped in both control and 17 mutant mice by more than 55%
in BM (n  3) and was not signiﬁcantly different between both
groups. Similarly, also the number of erythroblasts in the BM as
assessed by Ter119 staining was reduced after the PHZ treatment
but comparable between 17 mutant mice and controls (Figure
6A). Since 4 conditional knockout mice were reported to have
fewer erythroid progenitor cells in the BM after hemolytic stress,
we tested at the same time point (ie, 2 days after PHZ treatment) the
relative amounts of cells of different erythroid developmental
stages by Ter119-CD71 staining and subsequent FACS analysis
separating different maturation stages of BM erythroblasts18 (Fig-
ure 6B). Neither in BM nor in spleen was a signiﬁcant difference
detected between 17 mutant and control mice at any of these
stages, providing no evidence for an impaired recovery from
hemolytic anemia in the absence of 1 and 7 integrin (Figure 6C
and data not shown). Analysis of CFUe’s conﬁrmed a normal
frequency of erythroid progenitors in BM, but surprisingly revealed
a signiﬁcant reduction of CFUe’s in the spleen of 17 mutant
mice compared with controls. Since the spleen is the most
prominent place for hematopoiesis after PHZ treatment these data
support a role for 41 and 47 integrin in the recovery of the
erythropoietic system after hemolytic anaemia.
Figure 5. No overproportional release of CFU-Cs from the BM into the PB. (A)
Single-cell suspensions were made from BM and spleen, and erythrocyte-depleted
blood cells (PB) from control and 17 mutant BM chimeras were prepared at
indicated times after the gene deletion. BM cells (180 000), splenocytes (3 600 000),
and PB (250 L) were seeded into MethoCult GFM3534medium and counted 7 days
later. Total numbers of colonies per femur, spleen, and mL PB are shown. Error bars
show the standard deviation, star indicates signiﬁcant difference (P 	 .05) (n (control
BM chimera)/(17 mutant BM chimera): 2 months 5/5, 10 months 3/3). (B)
Single-cell suspensions from BM of nonchimeric control (1ﬂ/ﬂMx-cre) and 1ﬂ/
ﬂMx-cre mutant mice were plated on tissue-culture plastic dishes. After 24 hours,
nonadherent cells were removed and adherent cells detached. Adherent and
nonadherent cells were then stained for Ly-5.2 and Ter119 and tested for -galactosi-
dase activity by an FDG assay as described in “Materials and methods.” Since loss of
1 integrin results in expression of the -galactosidase reporter,12 high -galactosi-
dase activity indicates deletion of the 1 gene. Representative histogram overlays
show the -galactosidase activity on hematopoietic (Ly-5.2 or Ter119) and
nonhematopoietic (Ly-5.2, Ter119) cells of control (ﬁlled line) and mutant mice
(line). The marked region on the overlay indicates cells with high -galactosidase
activity. PolyIC injection induced an efﬁcient deletion of the 1 integrin gene on
hematopoietic cells; about 86% of the (Ly-5.2 or Ter119) cells of the mutant mice
showed high green ﬂuorescence, compared with only 6% of the corresponding cells
of the control mice. Also, among the nonhematopoietic BM cells (Ly-5.2, Ter119)
the percentage of cells with high -galactosidase activity increased from less than 5%
in control to more than 42% in mutant, clearly indicating the presence of 1
integrin–deﬁcient nonhematopoietic cells in the BM of mutant mice.
Figure 6. Reduced number of splenic CFUe’s after hemolytic stress. (A) Single-cell suspensions from BM of control and 17 mutant mice (no BM transplantation)
untreated and treated at day 1 and 2 with PHZ were prepared at day 4, stained with Ter119 antibody, and subsequently analyzed by FACS. The total amount of Ter119
erythroblasts per femur is shown. Error bars show the standard deviation (n (controls)/(17 mutants): 4/4). (B) BM single-cell suspensions from PHZ treated 17 mutant BM
chimeras were prepared, stained with antibodies against 4, 1 integrin, CD71, and Ter119 and subsequently analyzed by FACS. (Ter119-CD71 staining distinguishes 5
different developmental stages.) (C) The amount of erythroid BM cells of PHZ-treated 17 mutant mice for each of the 5 developmental stages as distinguished by Ter119 and
CD71 is shown. Error bars show the standard error (n (controls)/(17 mutants): 4/4). (D) Single-cell suspensions from BM of control and 17 mutant mice (no BM
transplantation) treated at day 1 and 2 with PHZ were prepared at day 4 and tested for CFUe’s. Total numbers of colonies per femur and spleen are shown. Error bar shows the
standard error (n (controls)/(17 mutants): 3/3).
1862 BUNGARTZ et al BLOOD, 15 SEPTEMBER 2006  VOLUME 108, NUMBER 6
No apparent compensatory change in gene expression in the
combined absence of 1 and 7 integrin in different
leukocyte subsets
To investigate whether hematopoietic subpopulations of 17
mutant mice show major alterations in gene expression, we tested
mRNA levels of different hematopoietic subsets (DN, DP, B cells,
CD4 T cells) by array analysis. RNA was prepared from DP and
DN cells from the thymus, and CD19 (B cells) and CD4 cells
from the spleen, obtained from 5 pooled mutant and control mice,
respectively, and tested on affymetrix chips. All mutant mice had
an efﬁcient knockout of 1 integrin indicated by a loss of surface
1 integrin on more than 97% of the platelets.
We then analyzed the data by searching for genes that are up- or
down-regulated in mutant mice in all 4 different populations
investigated, which would suggest a crucial compensatory re-
sponse. However, only 3 genes encoding heat shock proteins (heat
shock protein 1, heat shock protein 1, heat shock protein 105)
were found with increased expression in the absence of 1 and 7
integrin. No genes were found with reduced expression in all
subpopulations derived from mutant mice.
We then screened the genes up- or down-regulated in the individual
hematopoietic subpopulations (thymus:DN,DP; spleen: B cells, CD4
T cells) for integrins (3-6, 2-10, X, D, M, L, E),
selectins (P-, L-, E-), CD44, and for the 41 and 47 integrin
ligands VCAM-1 and MAdCAM-1.All these genes showed normal
expression in 17 mutant cells compared with control cells.
Discussion
It has been reported that several classes of integrins play an
important role to attach hematopoietic stem cells and progenitor
cells as well as their differentiated lineages to the extracellular
matrix and to other cells.1 4 integrins, for example, have been
suggested to be crucial for the retention of hematopoietic stem cells
in the bone marrow, for the homing of lymphocytes to Peyer
patches and for the migration of T cells during inﬂammation.13,15,26
In addition, development of the hematopoietic system, character-
ized by the formation of the different blood cell lineages and their
distribution within hematopoietic organs, was reported to be 4
integrin–dependent, although the gradual contribution of 4 inte-
grins differed signiﬁcantly depending on the experimental ap-
proach.7,17 To study the role of 4 integrins in hematopoiesis,
mouse models were applied in which the 4 integrin gene was
deleted on hematopoietic as well as on nonhematopoietic cells.
Loss of the 4 integrins on the latter cell population might affect
hematopoietic development. To overcome this problem and to
assess by an alternative approach the function of 4 integrins in
hematopoiesis, we decided to generate and analyze mice, which
lack 1 and 7 integrins, and hence both 41 and 47 integrins,
exclusively in the hematopoietic system. Unexpectedly, we could
not ﬁnd an essential function for 41 and 47 integrins in blood
cell development or in progenitor retention in the bone marrow.
Detailed analysis of lymphoid and myeloid development by testing
the size of different blood cell subsets in lymphoid organs at
different time points and investigating the formation of pre-B and
CFU-C colonies did not reveal any impairment in the hematopoi-
esis of 17 mutant mice.
The only abnormality we observed in untreated mutant BM
chimeras was an increase in the amount of CFU-C precursors in the
bone marrow coupled with a proportional increase in the number of
CFU-C progenitor cells in the peripheral blood. This impairment
indicates a role of 4 integrins in the maintenance of HPCs.
Whether the increase in BM CFU-Cs is due to elevated prolifera-
tion, decreased cell death, or changed migratory behavior of
progenitor cells is currently unclear. The increase, however, was
only transient, since it was detected 2 months after knockout
induction, but not 8 months later, pointing to compensatory
mechanisms that kick off in the 17 mutant mice leading to a
reduction of progenitor numbers in BM and PB back to normal
levels. Alternatively, it is possible that transplantation-dependent
effects affect 17 mutant and control mice with different efﬁcien-
cies, thus contributing to the reduction of CFU-Cs. While in 4
integrin conditional knockout mice HPCs accumulate in spleen,17
this was not the case in 17 mutant BM chimeras. To the contrary,
relative to PB the number of HPCs in spleen was decreased in
young and old 17 mutant BM chimeras, which might indicate a
migration defect of 17 mutant HPCs to the spleen. Interestingly,
no increased CFU-Cs were observed in 1-null BM chimera.
Induction of hemolytic anemia revealed a reduced number of
splenic CFUe’s in 17 BM chimera, indicating a role for 41
and 47 integrin in erythroid recovery after stress. Also, 4
mutant mice showed an impaired recovery after PHZ-induced
hemolysis, although in that case the frequency of CFUe’s was
reduced in BM and not in spleen.17
Different explanations might be possible to reconcile the
published data with the ﬁndings of our investigations. First, in
4-null somatic chimera 4 integrin is lost already before the
development of hematopoietic stem cells, whereas in our system
41 and 47 are lost in adult animals 1 month after bone
marrow transplantation. It is possible, therefore, that the absence of
these integrins during the entire embryogenesis impairs develop-
ment of the hematopoietic system and causes defects that persist to
adulthood, whereas the loss of 4 in adult animals has no severe
consequences for hematopoiesis. However, recent data by Gribi et
al27 showed that transplantation of fetal 4-null hematopoietic stem
cells derived from the aorta-gonad-mesonephros (AGM) region of
4-deﬁcient embryos into adult microenvironment results in long-
term generation of mature B and T lymphocytes and myeloid cells.
These data indicate that neither fetal nor adult HSCs require 4
integrins for hematopoietic development.
Second, the defects observed in 4 integrin conditional knock-
out mice might be related to the fact that in this model 41 and
47 integrin are lost also on nonhematopoietic cells, whereas
deletion of the 1 and 7 integrin in our BM chimeras was
restricted to the hematopoietic system. Interference with the
functions of 4 integrins in nonhematopoietic tissues such as BM
stroma cells or endothelial cells might result in the production of
cytokines, which inhibit lymphopoiesis or favor the mobiliza-
tion of HPCs. We tested this possibility and found that
nonchimeric 17 mutant mice, which lack 41 and 47
integrin with a similar tissue distribution as the 4 conditional
knockout mice, do show an overproportional release of HPCs
into the peripheral blood. Furthermore, we could demonstrate
that induction of Cre in these mice disrupts the 1 integrin gene
in BM stromal cells. Altogether, these data underline the
importance of a strict tissue-restricted gene deletion in order to
avoid unwanted cross-talk between different tissues.
In summary, we demonstrate that 41 and 47 integrins are
not crucial for the differentiation of lymphoid and myeloid cells in
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adult mice. In fact, even the additional loss of all other 1 integrin
receptors besides 41, as occurring in our 17 mutant mice, did
not prevent hematopoietic development. 1 and 7 integrins affect
maintenance and distribution of CFU-C progenitors, though differ-
ently than previously suggested for 4 integrins.17 Our results do
not exclude effects of 41 and 47 integrins on fetal hematopoi-
esis, during immune response or in inﬂammation.
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RhoH is a small GTPase expressed only
in the hematopoietic system.With the use
of mice with targeted disruption of the
RhoH gene, we demonstrated that RhoH
is crucial for thymocyte maturation dur-
ing DN3 to DN4 transition and during
positive selection. Furthermore, the differ-
entiation and expansion of DN3 and DN4
thymocytes in vitro were severely im-
paired. These defects corresponded to
defective TCR signaling. Although RhoH
is not required for TCR-induced activa-
tion of ZAP70 and ZAP70-mediated activa-
tion of p38, it is crucial for the tyrosine
phosphorylation of LAT, PLC1, and Vav1
and for the activation of Erk and calcium
inﬂux. These data suggest that RhoH is
important for pre–TCR and TCR signaling
because it allows the efﬁcient interaction
of ZAP70 with the LAT signalosome, thus
regulating thymocyte development.
(Blood. 2007;109:2346-2355)
© 2007 by TheAmerican Society of Hematology
Introduction
RhoH is a member of the Rho GTPase family, expressed only in the
hematopoietic system. Rho GTPases are small GTPases that regulate
cytoskeletal organization, proliferation, survival, and cell polarization.1
They are present in an active, GTP-bound form and an inactive,
GDP-bound form. Only in the GTP-bound conformation can they
interact with a wide range of effector molecules, including serine-
threonine kinases, lipid kinases, and cytoskeletal proteins.
RhoH was shown to be expressed in hematopoietic progenitor
cells (HPCs), lymphocytes, and neutrophils.2,3 Because RhoH has
no functional intrinsic GTPase activity, it is thought to be constitu-
tively active and controlled only at the transcriptional level. Indeed,
RhoH expression is regulated in lymphocytes.2 In T cells, activa-
tion of the T-cell receptor reduced the RhoH message within a few
hours, whereas PMA treatment decreased RhoH mRNA levels in
Jurkat cells within 60 minutes.2 In diffuse large B-cell lymphoma,
RhoH is frequently mutated in the noncoding region, which might
affect mRNA stability or translation efﬁciency.4,5 Functionally,
RhoH was proposed to be a negative regulator of Rho GTPases and
integrins. RhoH inhibits Rac1-mediated activation of p38 MAPK
and NFB in Jurkat cells but has no effect on JNK or Erk or on the
activation of Rac1 in these cells.2 In hematopoietic stem cell
(HSC)/HPC preparations, RhoH negatively regulates the prolifera-
tion, survival, and migration and reduces the SCF-induced activa-
tion of Rac1.3 Finally, RhoH expression maintains lymphocytes in
a nonadhesive state by decreasing integrin-mediated attachment.6
These observations suggested an important role of RhoH in the
maintenance of HSCs, in leukocyte migration, and possibly in the
development of B-cell lymphoma. To test these hypotheses in vivo, we
generated mice that lacked a functional RhoH gene and analyzed the
development of different hematopoietic lineages. RhoH-null mice did
not develop lymphoma and had no obvious defects in HSC mainte-
nance, but they showed impaired T-cell differentiation attributed to
defective T-cell receptor (TCR) signaling.
Materials and methods
Mice
RhoH-deﬁcient mice were generated using procedures described previ-
ously.7 As a targeting vector, a 6.9-kb EcoRI-EcoRI genomic DNA
fragment was used in which a 0.9-kb HindIII-AatII fragment encoding the
ﬁrst 42 amino acids of the RhoH protein was replaced by a neomycin
resistance expression cassette. Wild-type and heterozygous knockout mice
were used as controls, with indistinguishable results in all assays. If not
stated otherwise, mice were kept as 129Sv/C57BL6 outbreds. 2-integrin8–
deﬁcient mice and RhoH-null mice were intercrossed to obtain RhoH-2-
null double-knockouts. RhoH mutant mice backcrossed for 6 generations to
C57BL6 were mated with OT-II transgenic mice9 to obtain RhoH-null/
OT-II mice. All mice were kept in a barrier facility in accordance with the
German policies on animal welfare.
Flow cytometry
Single-cell suspensions were prepared by gentle disaggregation of the
dissected organs through 70-m cell strainers. Cells were stained with
antibodies (all BD PharMingen [San Diego, CA] unless otherwise speci-
ﬁed) conjugated to FITC, PE, APC, or biotin in 1% bovine serum albumin
(BSA) in phosphate-buffered saline (PBS) and analyzed on a FACSCalibur
with CellQuest software. Biotinylated antibodies were detected by strepta-
vidin-Cy-5 (Jackson ImmunoResearch,West Grove, PA) or streptavidin-Cy-
Chrom. Dead cells were excluded by forward-scatter and side-scatter
proﬁles and by 1 g/mL propidium iodide counterstaining. The following
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antibodies were used: anti-B220 (RA3-6B2), anti-IgM (R6-60.2), anti-IgD
(11-26c.2a), anti–Gr-1 (RB6-8C5), anti-Mac1 (M1-70), anti-Ter119, anti–
NK1.1 (PK136), anti-CD4 (H129.19) (GK1.5; eBioscience, San Diego,
CA), anti-CD8 (53-6.7), anti-CD5 (53-7.3), anti-TCR (H57-597), anti-
CD69 (H1.2F3), anti-V2 (B20.1), anti-TCR (GL3), and anti-CD62L
(MEL-14; eBioscience). For the characterization of double-negative (DN;
Lin CD4CD8) thymocytes, cells were gated for lineage-negative
(Lin) (B220, CD4, CD8, NK1.1, Mac1, Gr-1, Ter119) cells and analyzed
for the expression of CD25 (7D4) and CD44 (IM7).
For proliferation assays, mice were given intraperitoneal injections
of 1 mg BrdU and were killed 2 hours later. BrdU incorporation of
thymocytes was determined using the BrdU Flow kit. AnnexinV staining
was carried out in binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl,
2.5 mM CaCl2) using Annexin V–Alexa 488 (kindly provided by Dr E.
Po¨schl, Erlangen, Germany).
T-cell development in vitro
In vitro T-cell development on OP9-DL1 stromal cells was carried out as
described previously.10 OP9-DL1 cells were maintained in -MEM me-
dium (Invitrogen, Carlsbad, CA) containing 20% FCS and penicillin/
streptomycin. Control and RhoH/ DN thymocytes enriched through
MACS (Miltenyi Biotec, Bergisch Gladbach, Germany) were sorted for
DN3 and DN4 populations with FACSAria. DN3 (5 104) and DN4
(2.5  104) thymocytes were plated onto a subconﬂuent OP9-DL1 mono-
layer in a 24-well plate and cultured in the presence of 5 ng/mL Flt3 ligand
(Peprotech, Rocky Hill, NU) and 1 ng/mL IL-7 (Peprotech) for 8 days. The
medium with cytokines was replaced after 4 days. Developmental progres-
sion of cultured cells was assessed by ﬂow cytometry after 4 and 8 days.
Cells were harvested by forceful pipetting and ﬁltered through a 70-M cell
strainer to remove OP9-DL1 cells.
TCR signaling
Freshly isolated thymocytes (0.5  107 to 1  107) were incubated with 5
g/mL biotinylated anti-CD3	 (145-2C11) and anti-CD4 or anti-CD3	
alone for 20 minutes on ice and washed. Cross-linking of the bound
antibodies was carried out with the addition of prewarmed streptavidin
(5-10 g/mL; Sigma, St Louis, MO) and incubation of the samples for 5
minutes at 37°C. After stimulation, 5 106 cells were directly ﬁxed in an
equal volume of 4% paraformaldehyde in PBS for 10 minutes at 37°C,
washed with PBS, and permeabilized in ice-cold 90% methanol for 30
minutes on ice. Cells were then washed twice in PBS, incubated with
ﬂuorescence-labeled anti-CD4, anti-CD8, and anti–phospho-ZAP70 (Y319)/
Syk (Y352), anti–phospho-Lck (Y505), anti–phospho-Erk1/2 (T202/
Y204), or anti–phospho-p38 MAPK (T180/Y182) for 1 hour at room
temperature, and analyzed by FACS.
Double-positive (DP) thymocytes (0.5 107 to 1  107) sorted by
FACSVantage were stimulated as described, washed with cold PBS, and
lysed in 100 L 50 mM Tris pH 7.4, 100 mM NaCl, 1% Nonidet P-40, 10%
glycerol, 2 mM MgCl2, 1 mM Na3VO4, and 100 mM NaF containing a
protease inhibitor cocktail (Complete Mini, EDTA free; Roche, Basel,
Switzerland) for 20 minutes on ice. Lysates were cleared by centrifugation
at 20 800 g for 15 minutes at 4°C and immunoprecipitated with anti-LAT
(Upstate Biotechnology, Lake Placid, NY) or anti-Vav1 (C-14; Santa Cruz
Biotechnology, Santa Cruz, CA) antibodies bound to protein A agarose
(Sigma-Aldrich, St Louis, MO). Phosphorylation of the immunoprecipi-
tated proteins was detected by Western blotting using anti–phosphotyrosine
PY-7E1 (Zymed, San Francisco, CA) antibody. Total levels of the immuno-
precipitated proteins were determined by reprobing the blots with anti-LAT
(11B.12; Upstate Biotechnology) or anti-Vav1 (D-7; Santa Cruz Biotechnol-
ogy) antibodies. Aliquots (20 L) of cell lysates were analyzed by Western
blotting using the following antibodies: anti–phospho-ZAP70(T319) (Cell
Signaling, Beverly, MA), anti-ZAP70 (99F2; Cell Signaling), anti–phospho-
Vav2(T172) (Santa Cruz Biotechnology), anti-Vav2 (H-200; Santa Cruz),
anti–phospho-LAT(T191; Cell Signaling), anti-LAT (11B.12; Upstate Bio-
technology), anti–phospho-PLC1(T783) (Cell Signaling), anti-PLC1
(Cell Signaling), anti–phospho-p44/p42 MAPK (T202/Y204) (New En-
gland BioLabs, Ipswich, MA), anti–p44/p42 MAPK (New England Bio-
Labs). Pull-downs for active Rac1 and Rac2 were performed as previously
described11 with 0.5  107 to 1  107 DP sorted thymocytes stimulated as
indicated by cross-linking of biotinylated CD3 and CD4 antibodies with
streptavidin for 30 seconds or 1 minute and 5 minutes at 37°C. Total lysates
and precipitates were analyzed by Western blotting with the use of
antibodies against Rac1 (Transduction Laboratories, Lexington, KY) and
Rac2 (Upstate Biotechnology).
For the detection of phosphorylated Vav2 and active Rac2, DP
thymocytes were sorted by positive selection using anti-CD8-FITC and
MACS anti-FITC microbeads (Miltenyi). The purity of obtained DP
thymocytes was 93% to 97%, as determined by ﬂow cytometry.
For measurement of calcium inﬂux, 2  106 thymocytes were loaded
with 2.5 M Fluo-4 (Molecular Probes, Eugene, OR) for 25 minutes at
37°C and washed twice with RPMI 1640, 25 mM Hepes, without phenol
red (Gibco, Grand Island, NY). Cells were stained on ice with 5 g/mL
anti–CD8-APC (53-6.7; eBioscience), anti–CD4-PE-Cy5.5 (RM4-5;
Caltag, Burlingame, CA), and biotinylated anti-CD3	. Cells were warmed
to 37°C and analyzed for 20 seconds to establish baseline calcium levels.
Then CD3	 was cross-linked by the addition of 10 g/mL streptavidin.
Flow cytometric analysis was performed with FACSCalibur using FlowJo
software (TreeStar, Ashland, OR).
Adhesion assays
Adhesion assays to ICAM-1, VCAM-1, and the endothelioma cell lines
bEnd5 and bEndI1.112 (kindly provided by Dr Britta Engelhardt, University
of Bern, Switzerland) were carried out as described previously12,13; 2  104
endothelioma cells were used per well.
Statistical analysis
All mean values are shown with standard deviation. Student t test was
performed to assess the signiﬁcance of observed differences.
Results
Generation of RhoH-deﬁcient mice
To generate mice with targeted disruption of the RhoH gene, we
replaced the genomic sequence encoding the translation start and
the switch1 region, which is crucial for the interaction with GEFs
or GAPs14 effectors, by a neomycin expression cassette using
homologous recombination (Figure S1A, available on the Blood
website; see the Supplemental Materials link at the top of the online
article). Mutation of the RhoH gene was conﬁrmed by Southern
blot analysis and genomic PCR (Figure S1B-D). Northern blot
analysis indicated the expression of a long transcript in RhoH
mutant mice that contained the sequence of the inverted neomycin
resistance gene, with at least 6 Kozak box ATGs followed by an
in-frame stop codon and the truncated RhoH coding region (Figure
S1E). These open-reading frames should prevent any expression of
a truncated RhoH molecule. RhoH mRNA levels in heterozygous
mutant mice were approximately 50% those of homozygous
wild-type mice.
Because of the lack of functional antibodies, conﬁrmation of
the loss of RhoH on protein level was not possible. Homozygous
mutant mice were born at Mendelian ratio (
/
, 23.2%; 
/,
50.8%; /, 26.0%; n  214), indicating no embryonic lethal-
ity. RhoH-null mice were fertile and were of normal weight and
life span.
Hematopoiesis
RhoH is expressed in HPCs, lymphoid cells, and myeloid cells.2,3
We analyzed the development of different blood lineages in mutant
and control mice. In 2-month-old mice, BM cellularity was not
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signiﬁcantly different between RhoH-null and control mice, but
splenocyte counts were lower in RhoH-deﬁcient mice (Figure S2).
Lymph node cellularity varied but tended to be lower in mutant
mice (Figure S2). Population sizes of granulocytes (Mac1
 Gr-1
),
monocytes (Mac1
 Gr-1), erythroblasts (Ter119
), and different
stages of B cells (proB 
 preB [B220
IgM], immature
[B220
IgM
], mature [B220
IgM
IgD
]) in BM were similar in
mutant and control mice (Table 1), indicating that RhoH is not
essential for the differentiation of myeloid, erythroid, or B cells.
Splenic granulocyte counts were unperturbed, whereas splenic
monocyte counts were slightly increased in RhoH-deﬁcient mice.
B-cell counts (IgD
) in spleen and lymph nodes were similar in
mutant and control mice (Table 1). In contrast, T-cell counts were
strongly decreased in BM, spleen, and lymph nodes. CD8
 T-cell
counts were reduced by approximately 75%, and CD4
 T-cell
counts were reduced by 50% (Table 1). Heterozygous mice showed
a normal phenotype and were included in the control group. These
data suggest a defect in the production, survival, or migration of T
cells in the absence of RhoH.
NK1.1
 cell counts, including those of NK and NKT cells, were
elevated in BM and spleen (Table 1). Six-month-old mutant mice
still had normal numbers of myeloid, erythroid, and B cells in the
BM, indicating that RhoH is not crucial for the maintenance of
HSCs (Table S1). Splenic granulocyte, monocyte, and B-cell
populations were similar in 6-month-old control and RhoH-
deﬁcient mice, whereas the number of splenic Ter119
 erythro-
blasts was greater in mutant mice. CD4
 and CD8
 T cells were
reduced in BM, spleen, and lymph nodes. In contrast to counts in
2-month-old mutant mice, NK1.1
 cell counts were not signiﬁ-
cantly changed in BM and spleen (Table S1).
Defective T-cell development in vivo
To test whether the production of T cells is impaired in the absence
of RhoH, we analyzed thymocytes of 2-month-old mice. Thymus
cellularity of RhoH-null mice was approximately 60% lower than
in control animals (Figure S2). In mutant mice, the absolute
number of DN (CD4CD8) thymocytes was increased more than
twofold, whereas the number of DP (CD4
CD8
) thymocytes was
reduced by 60%, indicating an incomplete developmental block
between the DN and the DP stages (Figure 1A, lower panel).
Absolute amounts of CD4SP and CD8SP thymocytes were reduced
by 80% and 85%, respectively, in RhoH-deﬁcient mice, implying
an additional defect during the development from DP to SP cells,
where positive selection takes place (Figure 1A).
To deﬁne the block during DN to DP development in more
detail, the population of DN cells was further divided into DN1
(CD25CD44
), DN2 (CD25
CD44
), DN3 (CD25
CD44),
and DN4 (CD25CD44) cells. The number of DN1 cells was not
signiﬁcantly different between control and mutant mice, suggesting
normal migration of T-cell precursors from the BM to the thymus
(Figure 1B). The very small population of DN2 cells was slightly,
but not signiﬁcantly, increased in the absence of RhoH. The total
number of DN3 cells, however, was elevated nearly 3-fold in the
absence of RhoH. DN4 cell counts were not signiﬁcantly
different between control and mutant mice, whereas DP cell
counts were reduced in the absence of RhoH. In addition,
6-month-old mutant mice showed a decrease in CD4SP and
CD8SP cells and an increase in DN3 thymocytes (Figure
S3A-B). These differences, however, were less pronounced than
Table 1. Absolute sizes of myeloid, erythroid, and lymphoid
populations in hematopoietic organs
Hematopoietic
organ
Control, 106
cells
RhoH/, 106
cells
PMean SD Mean SD
Bone marrow
Mac1
 Gr-1
 14.849 2.357 14.889 1.501 —
Mac1
 Gr-1 1.679 0.594 1.360 0.466 —
Ter119
 7.131 4.622 6.733 4.560 —
NK1.1
 0.151 0.100 0.355 0.092  .01
CD4
 0.218 0.123 0.101 0.021  .05
CD8
 0.225 0.159 0.054 0.007  .05
B220
IgM 2.377 1.110 2.620 0.745 —
B220
IgM
 1.602 0.645 2.084 0.591 —
B220
IgM
IgD
 0.740 0.183 0.971 0.422 —
Spleen
Mac1
 Gr-1
 10.192 3.666 9.721 4.169 —
Mac1
 Gr-1 5.879 1.351 8.971 2.366  .05
Ter119
 24.934 5.423 26.361 8.124 —
NK1.1
 2.791 1.337 7.816 2.617  .01
CD4
 64.082 7.282 23.741 5.426  .001
CD8
 27.418 3.342 7.500 0.743  .001
IgD
 97.934 12.041 89.384 7.611 —
Lymph nodes
CD4
 4.163 3.649 1.855 1.105 —
CD8
 1.603 1.506 0.281 0.226 —
IgM
IgD
 1.077 0.646 0.959 0.434 —
Data shown are the averages (means and SD) of the absolute sizes of the cell
populations carrying indicated surface markers in single-cell suspensions of bone
marrow, spleen, and lymph nodes of 2-month-old control and RhoH-null mice.
n [control]/[RhoH/]: 5/5.
— indicates not signiﬁcant (P .05).
Figure 1. Impaired thymocyte development in the absence of
RhoH. (A) Thymocytes of 2-month-old mice were analyzed for the
expression of CD4 and CD8 by FACS. Bar graph presents the
absolute cell number of each population. **P  .01; ***:P  .001.
Error bars show the standard deviation (n [control]/[RhoH/]:
11/11). (B) Thymocytes of 2-month-old mice were gated for
lineage-negative (B220, CD4, CD8, NK1.1, Mac1, Gr-1, Ter119)
cells and analyzed for the expression of CD25 and CD44. DN1,
CD25CD44
; DN2, CD25
CD44
; DN3, CD25
CD44; DN4,
CD25CD44. Bar graph presents the absolute cell number of
each population. *P  .05. Error bars show the standard devia-
tion (n [control]/[RhoH/]: 4/4).
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in 2-month-old mice. DP cell numbers were only slightly
decreased in mutant mice (Figure 3A-B).
This T-cell phenotype was indistinguishable in 129Sv/C57BL6
outbred and backcrossed C57BL6 mice (data not shown). Total
amounts of thymocytes with TCR were normal in the absence of
RhoH (Figure S4A), but the very small population of DN3 cells
expressing TCRwas increased (Figure S4B). These data indicate
that RhoH is only required for the development of T cells carrying
 TCR.  T-cell counts were slightly increased in spleen and
signiﬁcantly increased in lymph nodes (Figure S4A).
Heterozygous mice showed a normal T-cell phenotype and were
included in the control group. Quantitative RT-PCR revealed that
RhoH is expressed at all stages of thymocyte development, with
relative peaks at the DN3 and DP stages (Figure S5). These data
indicate defects in the DN3 to DN4 transition and in the differentia-
tion of DN4 to DP cells in RhoH-deﬁcient mice.
Aberrant thymocyte proliferation and survival
To characterize whether impaired thymocyte development was
caused by defective proliferation or increased apoptosis, we
assessed cell proliferation by measuring the incorporation of BrdU
and apoptosis by determining the percentage of AnnexinV binding
to thymocyte subpopulations.
The percentage of BrdU-incorporating, proliferating DN1 and
DN2 thymocytes was not signiﬁcantly different between control
and mutant mice (Figure 2A). However, DN3 and DN4 cells
showed signiﬁcantly decreased proliferation in the absence of
RhoH (Figure 2A). Proliferation of DP cells was unchanged,
whereas CD4SP and CD8SP cells showed increased proliferation
(Figure 2A).
In DN1, DN2, and DN3 cells, apoptosis was not signiﬁcantly
different between RhoH-null and control mice (Figure 2B). In
contrast, RhoH-deﬁcient DN4 cells displayed increased apoptosis
(Figure 2B). In addition, DP, CD4SP, and CD8SP thymocytes
showed a higher percentage ofAnnexinV
 apoptotic cells, possibly
indicating that fewer cells were positively selected (Figure 2B).
Defective TCR signaling suggested by altered expression of
maturation markers
During thymocyte development, the expression of CD5, TCR,
and CD69 is tightly regulated by pre–TCR and TCR signaling. At
the DN stage, pre–TCR signaling induces the expression of CD5.15
On DP cells, CD5 expression is maintained because of low-afﬁnity
TCR–major histocompatibility complex interactions. Finally, CD5
is up-regulated during DP to SP transition in response to TCR
signaling by positive- or negative-selecting ligands.
In all thymocyte populations tested (DN, DP, CD4SP, CD8SP,
and  T cells), the percentage of cells with low CD5 expression
was signiﬁcantly increased in RhoH-deﬁcient mice (Figures 2C,
S4C). In addition, RhoH-null DP cells expressed signiﬁcantly
lower levels of CD5 than control cells. In spleen, the percentage of
CD5low T cells was increased in the absence of RhoH (Figure S6A).
Among the CD4
 splenocytes, the amount of CD5low cells
increased from 1.5% to 24.6%, and among CD8
 cells it increased
from 3.7% to 18.5%. These data suggest defects in pre–TCR and
TCR signaling.
The expression of TCR and CD69 becomes up-regulated
during positive selection in response to TCR signaling.16,17 In
RhoH-null mice, the number of more mature, TCRhigh, and
CD69high thymocytes was signiﬁcantly decreased among DP,
CD4SP, and CD8SP cells, suggesting impaired positive selec-
tion and decreased TCR signaling (Figure 2D-E). No difference
was found in the number of CD69high CD4
 and CD8
 cells in
the spleen (Figure S6B). Interestingly, peripheral RhoH-null T
cells in the spleen and lymph nodes showed a signiﬁcantly
increased amount of cells with cell surface characteristics of
activated effector (CD62LlowCD44high) T cells, and more CD8

T cells demonstrated the memory (CD62LhighCD44high) pheno-
type (Figure S7A-B).
Defective thymocyte development in vitro
To directly assess the differentiation potential of DN3 and DN4
thymocytes in the absence of RhoH, thymocyte populations were
sorted and differentiated in vitro on OP9-DL1 cells. RhoH-
deﬁcient DN3 cells showed signiﬁcantly less ability than controls
to differentiate into DN4 and DP cells after 4 days and 8 days in
culture (Figures 3A, S8A). In addition, the total cell number was
severely lower in the absence of RhoH, indicating an impaired
expansion potential (Figures 3A, S8A). In addition, RhoH-null
DN4 cells showed a strongly reduced ability to develop into DP
cells compared with controls and did not expand as well as the
controls (Figures 3B, S8B).
Figure 2. Impaired proliferation and survival and decreased expression of maturation markers in RhoH-null thymocytes. (A-B) Thymocytes of 2-month-old mice were
analyzed for proliferating BrdU-incorporating cells and apoptotic AnnexinV
 cells. Different thymocyte populations were distinguished (see Figure 1A-B). *P .05; **P .01;
***P .001;BrdU,DN1-DN4, n [control]/[RhoH/]: 6/10;DP,CD4SP,CD8SP,n [control]/[RhoH/]: 8/10;AnnexinV,DN1 toDN4, n [control]/[RhoH/]: 10/10;DP,CD4SP,CD8SP,n
[control]/[RhoH/]: 8/9. (C-E) Thymocytes of 2-month-old mice were analyzed for the expression of CD4, CD8, and CD5 (C; n [control]/[RhoH/]: 9/9) or TCR (D; n
[control]/[RhoH/]: 4/4) or CD69 (E; n [control]/[RhoH/]: 6/6) by FACS. Percentages of cells marked in histograms are shown in graph. **P .01; ***P.001. Error bars show
standard deviation.
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These data demonstrate that in the absence of RhoH, the
differentiation and expansion potential of DN3 and DN4 are
decreased, conﬁrming the in vivo data. Furthermore, they prove
that this is a cell-autonomous defect of RhoH-null thymocytes.
Defect in positive selection
To test the positive selection of thymocytes into the CD4 lineage,
we intercrossed RhoH-deﬁcient mice backcrossed to C57BL6 with
OT-II transgenic mice, which express an ovalbumin-speciﬁc TCR
restricted to MHC class I-Ab as present in the RhoH-null mice.
FACS analysis for the transgenic TCR chain V2 indicated that
nearly all DP and CD4SP thymocytes expressed the ovalbumin-
speciﬁc TCR in control and mutant mice, though within the
RhoH-deﬁcient CD4SP cells a population expressing lower V2
levels could be detected (Figure 4C). Among the DN cells, which
up-regulate V2 expression during -selection, RhoH-null mice
showed a reduced amount of Va2
 cells compared with controls
(Figure 4C).
Expression of ovalbumin TCR in control mice led to a reduced
DP thymocyte count and an increased CD4SP cell count (Figures
1A, 4A). Furthermore, the percentage of DN3 cells was decreased,
and the DN4 population was increased (Figures 1B, 4B). In
contrast, RhoH deﬁciency severely impaired the generation of
CD4SP cells in mice expressing the ovalbumin TCR (Figures 1A,
4A). No increase in DN4 population was observed (Figures 1B,
4B). In addition, in the presence of the ovalbumin TCR, the
percentage of CD5low cells was higher in RhoH-null mice than in
controls (Figure 4D), and the relative amount of CD69high cells was
lower (Figure 4E).
These data indicate an impaired positive selection of DP cells
into the CD4 lineage in the absence of RhoH and conceivably a
defective -selection, which controls the DN3 to DN4 transition.
Defect in TCR signaling
In the absence ofRhoH, the defects observed in thymocyte development
and positive selection were consistent with impaired TCR signaling. To
test this possibility directly, we analyzed TCR signaling in vitro. We
induced TCR signaling in FACS-enriched preparations of DP cells by
cross-linking biotinylated antibodies against CD3 or CD3 andCD4with
streptavidin and investigated the activation of different steps of the TCR
signaling cascade. In addition, we measured the phosphorylation of
different signaling molecules by intracellular FACS staining of stimu-
lated thymocyte preparations.
TCR cross-linking triggers the activation of the tyrosine kinases
lck and ZAP70. ZAP70-mediated phosphorylation of the scaffold
protein LAT and associated molecules such as SLP-76 and PLC1,
which together form the LAT signalosome, is then crucial to initiate
downstream events such as calcium inﬂux or Erk activation.
In the absence of RhoH, TCR-induced autophosphorylation of
ZAP70 in DP cells was not altered (Figures 5A, S9A). Also, in
CD4SP cells, TCR-dependent activation of ZAP70 did not require
RhoH (Figure 6A). Furthermore, the phosphorylation of lck at
Y505 was not altered in the absence of RhoH in DP and CD4SP
cells (Figure 6B). Lck is negatively regulated by the phosphory-
lation of Y505, though this inhibition is overruled by the
activating autophosphorylation of Y394.18 These data indicate
that early events in TCR signaling are not strongly affected by
the loss of RhoH. In CD4
 T cells, ZAP70 activates p38 MAPK
independently of LAT.19 In RhoH-null CD4SP thymocytes, p38
was weakly, but signiﬁcantly, activated as in controls (Figure
6D), suggesting that this downstream pathway of ZAP70 is
normally intact in the absence of RhoH.
However, ZAP70-mediated total tyrosine phosphorylation of
LAT and tyrosine phosphorylation of LAT at Y195, which is
Figure 3. Impaired differentiation of RhoH-null DN3 and DN4 cells in vitro. (A) Sorted DN3 cells were cultured for 4 days on OP9-DL1 cells in the presence of IL-7 and Flt3
ligand. Differentiation from DN3 to DN4 was tested by FACS analysis of lineage-negative cells for the expression of CD44 and CD25. RhoH-null cells showed a signiﬁcantly
higher percentage of DN3 and a lower percentage of DN4. FACS staining for CD4 and CD8 revealed signiﬁcantly increased levels of DN and reduced levels of DP in the
absence of RhoH. Furthermore, cellularity of the RhoH-null cultures was approximately 5-fold decreased, indicating defective expansion in the absence of RhoH. **P  .01;
***P  .001. Error bars show the standard deviation (n [control]/[RhoH/]: 2/3). (B) Sorted DN4 cells were cultured for 4 days on OP9-DL1 cells in the presence of IL-7 and Flt3
ligand. FACS staining for CD4 and CD8 revealed signiﬁcantly increased levels of DN and reduced levels of DP in the absence of RhoH. Furthermore, cellularity of the RhoH-null
cultures was approximately15-fold decreased, indicating defective expansion in the absence of RhoH. **P .01. Error bars show the standard deviation (n [control]/RhoH/]: 3/4.
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important for the interaction of LAT with Gads and SLP-76 and
which indirectly supports the interaction of LAT with PLC1,20,21
were reduced in RhoH-null DP cells (Figures 5B-C, S9B-C).
Phosphorylation of PLC1 at Y783, which is important for the
activation of PLC1,22 was reduced in DP cells of RhoH-null mice
(Figures 5D, S9D). In addition, the TCR-dependent phosphoryla-
tion of Vav1, which is required for the GEF activity of Vav1,23 was
decreased in DP thymocytes in the absence of RhoH (Figures 5E,
S9E). Interestingly, the phosphorylation of Vav2 after TCR ligation
was similar in RhoH-null and control mice (Figures 5F, S9F).
Despite the decreased TCR-induced activation of Vav1, Rac1
and Rac2 activity after TCR activation were normal in RhoH-
deﬁcient DP cells (Figures 5G-H, S9G-H). However, the basal
level of Rac1 activity appeared to be higher in RhoH-null DP cells
than in controls, suggesting compensatory up-regulation of Rac1
activity in the absence of RhoH or inhibition of basal Rac1 activity
by RhoH (Figures 5G, S9G). Basal levels of active Rac2 were not
signiﬁcantly different between RhoH-null and control mice (Fig-
ures 5H, S9H).
We then tested TCR-dependent activation of Erk and calcium
inﬂux, each of which requires PLC1 activation. In the absence of
RhoH, TCR-induced Erk phosphorylation was severely reduced in
DP, CD4SP, and CD8SP cells (Figures 5I, 6C, S9I). To assess
TCR-induced calcium inﬂux, thymocytes and splenocytes were
loaded with the calcium-sensitive dye Fluo-4 and were incubated
with biotinylated antibodies against CD3. After the induction of
TCR signaling with streptavidin, the level of intracellular calcium
was determined by FACS. Costaining for CD4 and CD8 allowed us
to distinguish DN, DP, CD4SP, and CD8SP cells. No strong
calcium inﬂux was detected in DN control and mutant cells (Figure
6E). In DP, CD4SP, and CD8SP cells, however, RhoH-deﬁcient
cells exhibited a signiﬁcantly decreased percentage of cells respond-
ing to stimulation and a decreased mean ﬂuorescence of all cells,
indicating a partially impaired TCR-dependent calcium inﬂux
(Figure 6E). In addition, RhoH-deﬁcient CD4
 and CD8
 spleno-
cytes showed a reduced stimulation of calcium inﬂux after CD3
cross-linking, suggesting that RhoH is also important for TCR
signaling in peripheral T cells (Figure 6F).
These data show that RhoH is required for TCR signaling
downstream of ZAP70 in a cell-autonomous manner in thymocytes
and in mature T cells.
RhoH is not crucial for the regulation of 2 integrin–mediated
adhesion on thymocytes
Previously, it was suggested that RhoH is required to maintain
integrin LFA-1 (L2) in a nonadhesive state on lymphocytes.6 To
test whether this function could contribute to the defect observed in
Figure 4. Defective positive selection in the absence of RhoH. (A) Thymocytes of 4- to 7-week-old OT-II mice transgenic for an ovalbumin-speciﬁc TCR, either expressing
or not expressing RhoH, were analyzed for the expression of CD4 and CD8 by FACS (upper panel). Quantiﬁcation of absolute numbers of thymocyte subpopulations (lower
panel). *P  .05; **P  .01; ***P  .001. Error bars indicate the standard deviation (n [control]/RhoH/]: 3/4). (B) Thymocytes of 4- to 7-week-old OT-II mice transgenic for an
ovalbumin-speciﬁc TCR, either expressing or not expressing RhoH, were gated for lineage-negative (B220, CD4, CD8, NK1.1, Mac1, Gr-1, Ter119) cells and analyzed for the
expression of CD25 and CD44. DN1, CD25CD44
; DN2, CD25
CD44
; DN3, CD25
CD44; DN4, CD25CD44; upper panel). Quantiﬁcation of absolute numbers of
thymocyte subpopulations (lower panel; *P  .05. Error bars indicate the standard deviation (n [control]/RhoH/]: 3/4). (C) Decreased amount of V2
 DN thymocytes in 4- to
7-week-old OT-II mice transgenic for an ovalbumin-speciﬁc TCR in the absence of RhoH. *P  .05; **P  .01. Error bars indicate the standard deviation (n [control]/RhoH/]:
4/4). (D) Increased amount of CD5low thymocytes in 4- to 7-week-old OT-II mice transgenic for an ovalbumin-speciﬁc TCR in the absence of RhoH. **P  .01; ***P  .001; Error
bars indicate the standard deviation (n [control]/RhoH/]: 4/4). (E) Decreased amount of CD69high thymocytes in 4- to 7-week-old OT-II mice transgenic for an
ovalbumin-speciﬁc TCR in the absence of RhoH. *P  .05; **P  .01. Error bars indicate the standard deviation (n [control]/RhoH/]: 4/4).
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thymocyte development, we measured the adhesion of RhoH-null
thymocytes to the immobilized LFA-1 ligand ICAM-1. Manganese
(Mn2
; 2 mM) or PMA (100 ng/mL) activated RhoH-null thymo-
cytes bound to ICAM-1 with an efﬁciency equal to that of control
cells (Figure 7A). At lower concentrations of Mn2
 (1 mM) or
PMA (20 ng/mL), the combination of Mn2
 and PMA or, in the
presence of Mg2
, the binding to ICAM-1 was similar in RhoH-
null and control thymocytes (Figure S10). This demonstrated that
LFA-1–mediated adhesion of thymocytes is normally regulatable
in the absence of RhoH, at least under the conditions tested.
Adhesion to the 41 integrin substrate VCAM-1, carried out as an
additional control, was indistinguishable between control and
mutant thymocytes, even when stimulated with Mg2
, Mn2
, or
PMA (Figures 7A, S10).
In a more physiological setting, we investigated the adhesion of
T-cell blasts to the endothelial cell line bEnd5, which up-regulates
the expression of ICAM-1 and VCAM-1 on treatment with TNF.
Both RhoH-null and control T cells showed TNF-stimulated
binding to these endothelial cells, which was partially inhibited by
antibodies against LFA-1 and 4-integrin, respectively (Figure
7B). TNF-induced binding to the ICAM-1–deﬁcient cell line
bEndI1.1 was low for control and RhoH-null T cells and was
completely inhibited by antibodies against 4-integrin but was
insensitive to LFA-1 antibody inhibition (Figure 7B).
To investigate, by an alternative approach, whether RhoH-
dependent modulation of 2-integrin function was involved in the
defective thymocyte development in RhoH-null mice, we crossed
RhoH-deﬁcient mice with mice lacking 2-integrin and analyzed
T-cell development in the absence of both RhoH and 2-integrin. If
loss of RhoH indeed constitutively up-regulated L2 activity and
this contributed to the thymocyte phenotype, ablation of the
2-integrin gene would logically have rescued the defect. How-
ever, we found that population sizes of DN, DP, CD4SP, and
CD8SP thymocytes were identical in RhoH-null and RhoH-2-
integrin double-knockout mice (Figure 7C). Furthermore, the
increase of CD5low cells in different RhoH-null thymocyte popula-
tions was unaffected by the additional loss of 2-integrin (Figure
7D). These data indicate that the impaired thymocyte development
of the RhoH-null mice is independent of 2-integrin function.
Discussion
Previous work has shown that RhoH is a negative regulator of
Rac1-dependent signaling, HPC proliferation and survival, and
LFA-1–mediated adhesion.2,3,6 We demonstrated that during thymo-
cyte development, RhoH is a positive regulator of thymocyte
differentiation and TCR signaling and that it is crucial for
-selection and positive selection. Furthermore, we report that
RhoH also contributes to the TCR signaling of mature T cells.
In the absence of RhoH, thymocyte development was partially
blocked at the DN3 to DN4 transition. -Selection takes place at
this transition, which ensures that only thymocytes that have
generated a functional TCR chain can differentiate to DP cells. A
second partial block occurred at the transition from DP to CD4SP
and CD8SP cells, where positive selection allows only MHC-
restricted, self-tolerant thymocytes to develop further. In line with
defects in -selection and positive selection, the proliferation of
RhoH-null DN3 and DN4 cells was decreased, whereas apoptosis
of DN4, DP, CD4SP, and CD8SP cells was signiﬁcantly increased.
Furthermore, RhoH-null DN3 and DN4 cells showed a clearly
reduced ability to differentiate and expand in vitro. Previously, it
was documented that decreased RhoH expression increased the
proliferation and survival of HPCs.3,24 Our data suggest that RhoH
regulates proliferation and cell survival independently and in a cell
type– and differentiation stage–speciﬁc manner.
While -selection is dependent on pre–TCR signaling, positive
selection is thought to require weak TCR signaling.25 CD5
expression correlates with pre–TCR and TCR signaling strength.15
Reduced expression of CD5 on DP cells and an increased number
of CD5low cells among DN, CD4SP, and CD8SP thymocytes of
RhoH-null mice suggests defective pre–TCR signaling in DN and
impaired TCR signaling in DP, CD4SP, and CD8SP cells. Further-
more, reduced numbers of TCRhigh and CD69high cells among DP,
CD4SP, and CD8SP thymocytes indicated defective positive selec-
tion. Analysis of RhoH-null mice expressing an ovalbumin-
speciﬁc, MHC class II–restricted TCR conﬁrmed that RhoH is
important for positive selection because no signiﬁcant increase in
positively selected CD4SP thymocytes was observed, in contrast to
controls. Among DN cells, RhoH-null/OT-II mice did not display
Figure 5. Impaired TCR signaling in RhoH-null DP thymocytes. DP thymocytes of
4- to 8-week-old mutant mice were sorted by FACS or MACS microbeads. TCR
signaling was induced as indicated by cross-linking of biotinylated CD3 and CD4
antibodies with streptavidin for 5 minutes (A-E, I), 30 seconds (G), or indicated times
(F, H) at 37°C. Total lysates were analyzed by Western blot for ZAP70-P319 (A),
LAT-P195 (C), PLC1-P783 (D), Vav2-P (F), and Erk-P (I). Immunoprecipitations
(IPs) of LAT (B) and Vav1 (E) were blotted with antiphosphotyrosine antibodies and
reprobed with LAT (B) or Vav1 (E). Amounts of active Rac1 and Rac2 were
determined by pull-down assays (G-H). Bar graphs represent quantiﬁcations of 5 (A),
3 (B-D,I), 4 (E), 5 (F), 10 (G), or 4 (H) independent experiments. *P  .05; **P  .01.
All values are normalized to equal total amounts of the corresponding protein
determined by Western blot. Representative examples of the Western blots are
shown in Figure S9. Error bars show the standard deviation.
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the obvious reduction of DN3 or the increase of DN4 thymocytes
observed in controls, suggesting impaired -selection. Interest-
ingly, an increased proportion of peripheral T cells displayed
surface characteristics of activated and memory cells in the absence
of RhoH. We will test in the future whether this activation might be
attributed to an increased amount of autoreactive T cells escaping
negative selection that are activated in the periphery by high
amounts of self-antigen. Such a phenotype has been observed in
mice with a mutation in the ZAP70 gene; these mice also have
partially impaired TCR signaling.26
Our data indicated that RhoH is important for pre–TCR and
TCR signaling by facilitating the phosphorylation of the LAT
signalosome by ZAP70. TCR activation by cross-linking of CD3
leads to activation of the lck tyrosine kinase, which phosphorylates
the CD3 complex. Docking of ZAP70 to the phosphorylated
ITAMs of the TCR and phosphorylation by lck stimulates its
tyrosine kinase activity and results in ZAP70-dependent phosphor-
ylation of the membrane-anchored LAT protein and of LAT-
associated molecules, forming together the “LAT signalosome.”
Normal autophosphorylation of ZAP70 at Y319 in RhoH-null
thymocytes after cross-linking of CD3 suggests that TCR signaling
is not impaired at the level of ZAP70 activation. This notion is
strengthened by the normal TCR-dependent activation of p38 in
CD4SP cells because in T cells this activation is mediated by
ZAP70 independently of LAT.19 However, the phosphorylation of
LAT and the LAT-associated proteins PLC1 and Vav1 and the
activation of Erk and calcium inﬂux, which are downstream of
PLC1, were dramatically reduced in RhoH-deﬁcient thymocytes.
RhoH, therefore, seems to speciﬁcally interfere with the LAT
branch of ZAP70 signaling. The impaired TCR-dependent calcium
inﬂux in peripheral CD4
 or CD8
 T cells indicates that RhoH is
also important for TCR signaling in mature T cells and that loss of
RhoH is not compensated during development.
When comparing the RhoH-null phenotype with other mouse
mutants with defects in thymocyte development, striking similari-
ties with Vav1-deﬁcient mice become obvious27-29 and make it
Figure 6. Defective TCR signaling and calcium inﬂux in
RhoH-null thymocytes. Thymocytes of 2-month-old mice were
stimulated with biotinylated antibodies CD3 (C) or CD3 and CD4
(A-B, D) and streptavidin for 5 minutes at 37°C. Phosphorylation
of ZAP70(Y319)/Syk(Y352) (A), lck(Y505) (B), Erk1/2(T202/
Y204) (C), and p38 MAPK (T180/Y182) (D) was measured by
FACS. Different thymocyte populations were distinguished (ﬁlled,
nonstimulated; line, stimulated). Differences between the mean of
stimulated and nonstimulated (speciﬁc mean) cells are shown.
*P  .05; **P  .01. n [control]/RhoH/]: 5/5 (A-B, D). n [control]/
RhoH/]: 4/5 (C). Thymocytes (E) or splenocytes (F) of 2-month-
old mice were loaded with Fluo-4 and stained on ice for CD4,
CD8, and CD3. After warming to 37°C, baseline Fluo-4 ﬂuores-
cence was determined, and TCR signaling was induced by
cross-linking CD3 with streptavidin. Presented is the percentage
of cells above a threshold ﬂuorescence (responding cells; left
panel) and the mean ﬂuorescence of all cells (right). Shown are
representative results of 5 (E) or 2 (F) independent experiments.
Error bars indicate the standard deviation.
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tempting to speculate that RhoH function is closely linked to Vav1.
Given that Vav1 is a GEF binding to Rho GTPases, the simplest
link would be a direct interaction of Vav1 with RhoH. This could
lead to the recruitment of a constitutively active RhoH to the TCR
complex, enabling further protein–protein interactions through
RhoH. As a second possibility, Vav1 might activate RhoH by
catalyzing the exchange of GDP to GTP. This would imply that, in
thymocytes, RhoH activity is regulated by GEFs and GAPs and
that RhoH is not constitutively active, as presently assumed.2 Like
RhoH, the small GTPase Rap1 does not have detectable intrinsic
GTPase activity because of the mutation of a catalytic glutamine.30
However, Rap1 can hydrolyze GTP with the help of Rap1GAP,
which provides a catalytic asparagine.31 It remains to be tested
whether such a GAP exists for RhoH. Interestingly, we did not
observe any defect in hematopoiesis in heterozygous RhoH-mutant
mice, though mRNA levels of RhoH were reduced by half.
Our data indicate that RhoH is upstream of Vav1 because
TCR-dependent activation of Vav1, as determined by tyrosine
phosphorylation, is reduced in RhoH-null mice, whereas total
levels of Vav1 are unchanged. A conceivable scenario might be
that though RhoH is weakly associated in the resting state with
Vav1 or other members of the LAT signalosome, this interaction
becomes strengthened on TCR stimulation, resulting in the
stabilization of the entire LAT signalosome complex. Thus,
RhoH can be involved in a positive feedback loop downstream
of Vav1, which increases the tyrosine phosphorylation of LAT,
PLC1, and Vav1 itself. However, thus far we have been
unsuccessful in coimmunoprecipitation of recombinant RhoH
with Vav1, ZAP70, or LAT from lysates of resting and stimulated
thymocytes or Jurkat cells transfected with tagged RhoH,
suggesting that such interactions, if existent, are weak or
transient (data not shown).
Several functions have previously been assigned to RhoH. First,
RhoH was described as a negative regulator of p38 MAPK in
Jurkat and 293 cells.2 In thymocytes lacking RhoH, we did not
detect increased activation of p38 MAPK, suggesting a cell
type–speciﬁc function of RhoH in this respect.
Second, RhoH was reported to decrease LFA-1–mediated
adhesion in Jurkat cells and human peripheral blood lymphocytes.6
We showed here that LFA-1–mediated adhesion of thymocytes and
T cells to ICAM-1 is not affected by the absence of RhoH. Our
results do not rule out a more subtle role for RhoH in cell adhesion
and cell–cell contact in vivo.
Finally, RhoH inhibited SCF-induced Rac1 activation in HPCs.3
Indeed, basal Rac1 activity was increased in RhoH-null DP
thymocytes, suggesting that RhoH is a negative regulator of Rac1
activity in the resting state. Increased Rac1 activity could be a
compensatory change in response to the loss of RhoH. Other
compensatory changes might not yet have been found, and future
studies will address this search. It is unlikely that the increased
basal activity of Rac1 in RhoH-null DP thymocytes is the reason
for the impaired thymocyte development. Constitutive activation of
Rac1 should rather result in “augmented” TCR signaling because
constitutively active Rac1 can rescue the defective DN3 to DN4
transition in Vav1-null thymocytes and can increase the expression
of TCR, CD5, and CD69 on DP and CD4SP cells, in contrast to
Figure 7. RhoH does not affect thymocyte development through regulation of L2 integrin-mediated adhesion. (A) Relative adhesion of thymocytes to the
immobilized L2 ligand ICAM-1 and to the 41 ligand VCAM-1. Integrins were activated by treatment with 2 mM Mn2
 or 100 ng/mLPMAas indicated. Adhesion of wild-type
(RhoH 
/
), heterozygous (RhoH
/), and homozygous RhoH-null thymocytes (RhoH /) was indistinguishable at all conditions tested. Error bars show the standard deviation
(n [RhoH
/
]/[RhoH
/]/[RhoH/]: 1/2/3. (B) Relative adhesion of T-cell blasts to the endothelial cell line bEnd5 and the ICAM-1–deﬁcient endothelial cell line bEndI1.1
(ICAM1/ ). Adhesion was stimulated by treating the endothelial cells with TNF. Antibodies against 4-integrin and LFA-1 were used to determine the speciﬁc contribution of
these adhesion receptors to the attachment. An unrelated antibody was added as a control for nonspeciﬁc effects. Wild-type (RhoH
/
), heterozygous (RhoH
/), and
homozygous (RhoH/ ) RhoH-null T cells showed indistinguishable adhesion at all conditions tested. Error bars show the standard deviation (n [RhoH
/
]/[RhoH
/]/[RhoH/]: 2/2/4.
(C)Thymocytes of 6- to 10-week-old 2-integrin-null, RhoH-null, and 2-integrin-RhoH double-knockout mice were analyzed for the expression of CD4 and CD8 by FACS. Bar
graph presents the absolute cell numbers of each population. Error bars indicate the standard deviation (n [2/]/[RhoH/]/[2/RhoH/]: 3/3/3. (D) Expression of CD5 and
amount of CD5low thymocytes in 6- to 10-week-old 2-integrin-null, RhoH-null, and 2-integrin-RhoH double-knockout mice. Error bars indicate the standard deviation (n
[2/]/[RhoH/]/[2/RhoH/]: 3/3/3.
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the phenotype of RhoH-deﬁcient cells.32,33 Conceivably, the differ-
ent phenotypes are explained by the fact that the level of active
Rac1 is lower in RhoH-deﬁcient thymocytes than in thymocytes
overexpressing the constitutively active mutant form (L61Rac1).32,33
In conclusion, our data suggest that RhoH is required for
efﬁcient -selection and positive selection because it promotes the
ZAP70-dependent phosphorylation of the LAT signalosome during
pre–TCR and TCR signaling.
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Inhibition of the α4 subunit of the integrin heterodimers α4β1 and α4β7 with the 
monoclonal antibody natalizumab is an effective treatment of multiple sclerosis 
(MS)1. Since α4 integrins control multiple functions on almost all hematopoietic 
cells it is not clear where and how the antibody executes its beneficial effect. 
One assumption is that the interaction of α4 integrins on autoreactive T cells 
with VCAM-1 on the activated blood brain barrier endothelium is blocked, 
preventing their extravasation into the central nervous system (CNS). However, 
there are conflicting data regarding which integrin heterodimer is responsible for 
the clinical effect2,3, and whether more fundamental processes such as T cell 
activation and polarization are affected. Finally, it is unknown whether inhibition 
of cell types other than T cells contributes to the beneficial effect of α4 blockade. 
To address these questions, we studied MS-like experimental autoimmune 
encephalomyelitis (EAE) in mice with a β1 integrin gene deletion in either all 
hematopoietic cells or selectively in T cells. We found that β1 integrin-deficient 
autoreactive T cells were unable to firmly adhere to CNS endothelium in vivo 
while priming and expansion of T cells and CNS infiltration of myeloid cells 
remained unaffected. Our data suggest that α4β1 integrin is essential for T cell 
entry into the CNS. 
Multiple sclerosis is considered an autoimmune disease where activated CD4+ T cells 
reactive against myelin components enter the central nervous system, recruit additional 
inflammatory cells like macrophages and cause inflammation, edema and 
demyelination which set the stage for the clinical picture of this chronic disabling 
disease4. Thus, T cell trafficking into the CNS is a major hallmark of the 
immunopathogenesis of MS. Natalizumab (marketed as Tysabri), a humanized 
monoclonal antibody against the α4 integrin subunit has been approved for the 
treatment of relapsing-remitting MS under the assumption that it prevents extravasation 
of activated T cells into the CNS5. However, there is accumulating evidence that α4 
integrins are also involved in immunological processes other than T cell extravasation 
including activation of myeloid cells6, activation of naïve T and B lymphocytes7, 
polarization of effector T cells into the TH1 or TH2 lineage8, retention of memory T cells 
in their niches9 and localization of hematopoietic stem cells10. While these findings 
largely stem from studies in rodents, the very rare but fatal side effects such as the 
development of progressive multifocal leukoencephalopathy (PML) in natalizumab-
treated patients also pointed to the possibility that the antibody has a broader systemic 
immunosuppressive or immunmodulatory effect11,12. 
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To investigate these issues we chose a genetic approach where we selectively deleted 
the gene encoding the β1 integrin subunit, thus restricting our findings to the α4β1 
integrin heterodimer and excluding potential effects of α4β7 blockade. In order to 
directly compare the fate and the functional properties of wild type (wt) and β1 integrin-
deficient T cells within the same animal we established an animal model in which Cre-
mediated deletion of the β1 integrin gene occurred in approximately half of the T cells. 
This was achieved by generating bone marrow (BM) chimeric mice carrying floxed β1 
integrin alleles and an inducible Mx1-Cre transgene13 (β1fl/fl/MxCre+) in the 
hematopoietic compartment. This genetic set-up restricts the ablation of the conditional 
β1 integrin gene exclusively to hematopoietic cells, which occurs in T cells to a rate of 
approximately 60% and in other hematopoietic cells to a rate of 95-98% (Fig. 1a). The 
presence of β1 integrin-positive T cells is thought to be due to absent Mx1-Cre 
transgene expression in thymic and peripheral T cells14. Active immunization of 
β1fl/fl/MxCre+ bone marrow chimeras (called β1-/- BM chimeras) with the myelin 
oligodendrocyte glycoprotein (MOG)-peptide MOG35-55 led to the development of EAE 
with a similar devastating impact on weight and clinical scores as for control 
(β1fl/fl/MxCre-) BM chimeras (Fig. 1b). Moreover, histology of diseased animals 
revealed no qualitative difference in leukocyte infiltration in the CNS (Fig. 1c). These 
findings suggest that (i) loss of β1 integrin expression on the myeloid and B cell lineage 
did not influence the development of the disease, and that (ii) a bisected pool of naïve 
T cells was sufficient to trigger disease induction. 
To assess the contribution of β1 integrin-deficient inflammatory cells within the 
diseased tissue we isolated the infiltrating leukocytes from the CNS of animals at the 
peak of their disease and determined the cellular composition of the infiltrates. In line 
with the severity of the clinical course the total number of isolated leukocytes was 
similar between control and β1-/- BM chimeras (Fig. 2a). Furthermore, the population 
sizes of isolated CD4+ and CD8+ T cells, macrophages and granulocytes were 
comparable in control and β1-/- BM chimeras (Fig. 2b). We next took advantage of our 
internally controlled system and determined the contribution of β1-deficient cells to the 
inflammatory infiltrates. In β1-/- BM chimeric mice CD45.1negGr-1medMac-1+ infiltrating 
macrophages and CD45.1negGr-1highMac-1+ granulocytes were uniformly β1-deficient 
(Fig. 2c) indicating that inflammatory bystander cells are recruited into the CNS in a β1 
integrin-independent manner. In contrary, CD4+ and CD8+ T cells isolated from the 
CNS of β1-/- BM chimeric mice were almost entirely β1 integrin-positive (Fig. 2c). Thus, 
a 60:40 ratio of β1 integrin-negative to β1 integrin-positive peripheral T cells in the 
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peripheral circulation shifted towards an almost pure population of β1-positive cells 
within the inflamed CNS. These data impressively demonstrate that T cells but not 
myeloid cells require β1 integrins to infiltrate the CNS. 
To further corroborate our findings we employed the CD4-Cre transgene15 to 
specifically ablate the β1 integrin gene on T cells. Mice carrying floxed β1 integrin 
alleles and the CD4-Cre transgene (named β1fl/fl/CD4Cre+) displayed a 90% deletion 
efficiency on T lymphocytes (Fig. 3a). Upon active immunization these mice exhibited a 
significant delay in the onset of clinical EAE symptoms (Fig. 3b+c). Interestingly, these 
animals eventually developed clinical symptoms, which were accompanied by an influx 
of β1 integrin expressing T cells into the CNS that escaped CD4-Cre-mediated deletion 
(Supplementary Fig. 1). Taken together, these findings indicate that loss of β1 integrin 
expression on 90% of the peripheral T lymphocyte population delays the development 
of EAE, while the presence of only 10% of β1 integrin expressing T cells is sufficient to 
eventually trigger the disease.  
In order to further clarify this issue, we next investigated whether lack of β1 integrin on 
T cells leads to their insufficient activation, to their impaired extravasation into the CNS, 
or both. To test T cell activation we intercrossed β1fl/fl/MxCre+ mice with transgenic 
animals expressing MHC II-restricted T cell receptors (TCR) specific for the ovalbumin 
(Ova)-peptide Ova323-339 (OT-II.2)16. Two to three months after polyIC injection CD4+ T 
cells were purified and injected intravenously into wild-type recipients. LPS matured 
Ova323-339-loaded bone marrow-derived dendritic cells were intravenously co-injected 
and the proliferative response was tracked by carboxyfluorescein diacetate 
succinimidyl ester (CFSE) dilution. β1 integrin-deficient T cells showed comparable 
proliferation and division indices to control T cells (Fig. 3d+e). This indicates that β1 
integrins were not required to induce T cell priming. Similarly, intracellular flow 
cytometry revealed similar cytokine responses between β1fl/fl/MxCre+ and control cells 
(Supplementary Fig. 2).  Together, these findings indicate that the lack of β1 integrin-
deficient T cells in the EAE lesions is not due to impaired activation.  
To investigate whether β1 integrins are required for T cell infiltration into the CNS we 
employed an in vitro as well as an in vivo approach that allowed assessing the 
interaction of β1 integrin-deficient T cells with inflamed CNS endothelium. We isolated 
T cells from polyIC-induced OT-II.2 transgenic β1fl/fl/MxCre+ BM chimeras and 
triggered their proliferation by co-culturing them with Ova323-339 loaded dendritic cells. 
For further analysis T cell blasts were sorted into β1 integrin-positive and -negative 
populations. Flow cytometry of the surface integrins showed a high expression of the 
α4, β1 and β7 subunit on control cells. On the knockout cells expression of the entire 
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β1 integrin subfamily was lost, while the αLβ2 integrin and the β7 subunit was slightly 
increased (Fig. 4a). First, we tested their static adhesion to the TNF-α stimulated brain 
endothelioma cell line bEnd5 and observed no difference in binding between β1-
positive and -negative T cells at room temperature (Fig. 4 b). Since the adhesion was 
likely due to a predominant interaction between αLβ2 integrin and endothelial ICAM-1 
we also performed adhesion assays on the ICAM-1-/- endothelioma cell line bEndI1.1, 
which significantly impaired adhesion of β1 integrin-deficient T cells (Fig. 4 b). The 
reduced adhesion of β1-/- T cells was even further impaired when the assays were 
performed at 4°C (Supplementary Fig. 3), which diminishes the contribution of αLβ2-
mediated adhesion17. These findings suggest that T cells adhere to activated 
endothelial cells by binding VCAM-1 with α4β1 integrin and ICAM-1 likely with αLβ2 
integrin. To test whether the αLβ2 integrin binding to ICAM-1 plays a compensatory 
role for T cell adhesion to inflamed brain endothelium, we performed intravital 
fluorescence videomicroscopy (IVM) of the spinal cord white matter microvasculature. 
Interestingly, adoptive T cell transfers into diseased wild-type animals revealed that 
adhesion of β1-deficient Ova323-339-specific T cells to the endothelium was significantly 
diminished in comparison to control Ova323-339-specific T cells (Fig. 4c). Since the 
events during initial cell contact (i.e. rolling and immediate capture) are slightly but not 
significantly impaired (Fig. 4d) the dramatic reduction of T cell adhesion is probably due 
to their inability to maintain a firm contact without β1 integrins. Performing the same 
experiment with β1 deficient MOG35-55-specific T cells18 produced similar results 
(Supplementary Fig. 4). Together, these findings impressively demonstrate that the 
interaction of α4β1 integrin with endothelial VCAM-1 is the critical molecular interaction 
for the stable adhesion of activated T cells to the brain vasculature.  
Our results show that the genetic deletion of β1 integrin in the hematopoietic system 
does not impair the potency of antigen presenting cells, granulocytes and 
macrophages to contribute to the development of EAE. Furthermore we show that 
active EAE development is significantly delayed in mice lacking β1 specifically in the 
majority of their T lymphocytes. Taken together, these results suggest that the 
beneficial clinical effects of natalizumab are due to a direct effect on the T cell lineage. 
We further show that adhesion of T cells to inflamed endothelial cells is mediated by β1 
integrins, which suggests that the anti α4 antibody is interfering with α4β1 and not α4β7 
binding. Our data also demonstrate that β1 integrins play an essential role during 
extravasation but not during T cell priming or polarization. Hence it is likely, that the 
profound clinical efficacy of the antibody therapy is due to interference with the α4β1-
integrin mediated extravasation of effector T cells into the CNS. 
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Methods 
Animals. Mice carrying a floxed β1 integrin gene19 (referred to as β1fl/fl) were 
intercrossed with mice carrying a Mx1 promoter-driven Cre recombinase transgene13 
(referred to as MxCre+). To obtain T cell receptor (TCR) transgenic β1-deficient T cells 
β1fl/fl/Mx1Cre+ mice were intercrossed with ovalbumin-specific TCR transgenic mice16 
(referred to as OT-II.2). To obtain mice with a deletion of the β1 integrin subunit 
restricted to the hematopoietic system of β1fl/fl/MxCre+ irradiation bone marrow 
chimeras were made as described20. Mice with a Cre-mediated deletion of the T 
lymphocyte compartment were obtained by crossing β1fl/fl mice with mice carrying a 
CD4 promoter-driven Cre recombinase (referred to as β1fl/fl/CD4Cre+)15. Mice were 
kept on a mixed 129Sv/C57BL/6 genetic background and bred in the animal facilities of 
the Max Planck Institute of Biochemistry. All animal studies were performed with the 
license of the government of Oberbayern. Female C57BL/6 mice (8-10 weeks) for IVM 
were purchased from Harlan (Netherlands). All IVM experiments were performed in 
accordance with the requirements of the local government in Bern, Switzerland 
(permission number 55/04 for EAE experiments and 104/04 for IVM). 
Induction and evaluation of active EAE. Active EAE was induced by subcutaneous 
injection at the tail base of an emulsion of complete Freund´s adjuvant (CFA) and 200 
µg MOG35–55 peptide (Biotrend) in PBS (1:1 volume ratio). CFA was prepared by 
supplementation of incomplete Freund´s adjuvant (Sigma-Aldrich) with 5 mg/ml 
inactivated Mycobacterium tuberculosis (H37Ra; Difco). 400 ng Pertussis toxin (List 
Biological Laboratories) in PBS was injected intraperitoneal on days 0 and 2 after 
immunization. Clinical disease and weight were checked daily and scored as 
described21. Mice scored 1 (limp tail) to 2 (hind leg weakness) were used as recipients 
for IVM experiments. 
Southern Blot analysis. Southern blotting to detect the Cre-mediated knockout 
efficiency was carried out as described14,22. 
Histological analysis. The spinal cord was rapidly dissected and in part frozen unfixed 
in optimal cutting temperature compound. Cryosections of 10 µm thickness were cut 
and used for immunofluorescence staining according to standard protocols. The 
following biotinylated monoclonal antibodies were used: Ly5.1 (A20) and Mac-1 
(M1/70) (both from BD Pharmingen). After blocking unspecific binding with a 
Streptavidin/Biotin blocking kit (Vector Laboratories), Cy3-conjugated Streptavidin was 
used to detect the primary antibodies. A pan-laminin antibody (L9393, Sigma) was 
used to stain blood vessels. Images were taken with a DMIRE2 confocal microscope 
(Leica). 
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Flow cytometry. Mononuclear cells were isolated from the central nervous system 
(CNS) by Percoll density gradient centrifugation23 of the dissected brain and spinal 
cord. Single-cell suspensions from hematopoietic organs and staining for FACS 
analysis were prepared as described23. The following fluorochrome or biotin-labelled 
monoclonal antibodies were used: CD4 fluorescein isothiocyanate (FITC), 
phycoerythrin (PE) and biotin (H129.19), CD8 biotin (53-6.7), Gr-1 PE  (RB6-8C5), 
integrin α4 biotin (9C10), integrin α5 biotin (5H10-27), integrin α6 PE (GoH3), integrin 
αE PE (M290), integrin αV PE (RMV-7), integrin β1 FITC (Ha2/5), integrin β2 biotin 
(C71/16), integrin β7 PE (M293) and Mac-1 biotin (M1/70) (all from BD Pharmingen), 
integrin β1 PE (HMbeta1-1) (BioLegend), integrin αL biotin (M17/4) and Vα 2 TCR 
biotin (B20.1) (both from eBioscience). As controls the following isotype-matched 
antibodys were used: hamster IgM FITC (G235-1),  rat IgG1 (R3-34) and rat IgG2a,κ 
PE (R35-95) (all from BD Pharmingen), hamster IgG PE (HTK888) (BioLegend) and rat 
IgG2a, κ biotin (eBiosciences). All biotinylated antibodies were detected with Cy5-
conjugated streptavidin (Jackson ImmunoResearch). Dead cells were excluded from 
the analysis by staining with propidium-iodide (2.5 µg/ml, Sigma), residual host cells in 
the bone marrow chimeras were excluded by staining with CD45.1 CyChrome. 
Measurements were performed on a FACSCalibur (BD Biosciences) and analyzed 
using the FlowJo software (version 6.1.1, TreeStar).  
Cell culture. Dendritic cells (DC) were generated from murine bone marrow cells as 
described24. Activated T cells for adhesion assays and IVM experiments were 
generated from β1fl/fl/Cre+; OT-II.2 mice. Mice received a single intraperitoneal injection 
of 250 µg polyIC (Amersham Biosciences) in PBS to induce the knockout. Six to eight 
weeks after knockout induction the mice were sacrificed and single cell suspensions of 
splenocytes were obtained. After ACK-lysis of red blood cells according to standard 
protocols22 splenocytes from one mouse were cocultured with 4 x 106 DCs loaded for 2 
hours with 20 µg/ml Ova323-339 peptide (in-house peptide synthesis service). After four 
days of co-culture the cell suspensions were split 1:2 into fresh medium containing 5 
ng/ml IL-2 (R&D Systems). After another two days of co-culture dead cells were 
removed by Nycoprep 1.077 A (Axis-Shield) density gradient centrifugation. For 
depletion of β1 positive T cells the cell suspension was subsequently incubated with a 
biotinylated integrin β1 antibody (Ha2/5) (BD Pharmingen) followed by streptavidin-
microbead separation according to the manufacturers protocol (Miltenyi Biotech). The 
efficiency of sorting was monitored by staining with fluorochrome-labelled CD4 and β1 
antibodies and subsequent FACS analysis. On average 90,4% of the cells were CD4+ 
and 92,2% of the β1-depleted cells were β1 negative. For unspecific stimulation single 
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cell suspensions of splenocytes were stimulated after ACK-lysis for 2 days with 50 
ng/ml Phorbol-12-Myristate-13-Acetate (PMA; Calbiochem) and 500 ng/ml Ionomycin 
(Calbiochem).  
Proliferation assays. Sorting of T cells, in vivo proliferation assays and FACS analysis 
of the proliferated cells were performed as described23. Proliferation parameters were 
analyzed using the proliferation platform of the FlowJo software (version 6.1.1, 
TreeStar). The division index indicates the average number of division that a dividing 
cell underwent, whereas the proliferation index indicates the average number of 
divisions all cells underwent. The percentage of initially present cells which divided is 
shown by the percent of dividing cells. For intracellular cytokine stainings splenocytes 
were stimulated after isolation for 4 hours with 50 ng/ml PMA, 500 ng/ml Ionomycin and 
10 µg/ml Brefeldin A (Sigma). Intracellular cytokine staining was performed according 
to the manufacturers guidelines using the Leucoperm kit (AbD Serotec) and the 
following PE-labelled monoclonal antibodies: IL-2 (JES6-5H4), IL-4 (11B11), IL-17 
(TC11-18H10.1), IFN-γ (XMG1.2) and TNF-α (MP6-XT22) (all from BD Pharmingen). 
As controls the following isotype-matched antibodys were used: rat IgG1 (R3-34) (BD 
Pharmingen) and rat IgG2b (eB149/10H5) (eBioscience). 
Adhesion assays. Adhesion assays to the endothelioma cell lines bEnd5 and 
bEndI1.1 were carried out as described previously25. 2 x 104 endothelioma cells per 
well were plated. 1 x 105 cultured, MACS-sorted OT-II.2 transgenic T cell blasts were 
allowed to adhere per well either at room temperature or at 4 °C. All conditions were 
performed in duplicates. After fixation two pictures were acquired from each well with 
an Axiovert 200M microscope (Zeiss) and the number of adherent T cells was 
quantified using the MetaMorph software (version 6.3r6, Molecular Devices).  
Intravital fluorescence videomicroscopy. Surgical preparation of the spinal cord 
window, intravital microscopy and quantitative analysis of the spinal cord white matter 
microcirculation were performed exactly as described26 using a custom made Mikron 
IVM500 fluorescence microscope connected to a SIT camera (Dage-MTI). Epi-
illumination techniques were used to visualize the spinal cord microvasculature after 
injection of 0.1 ml 1 % TRITC-conjugated dextran (MW = 155,000; Sigma-Aldrich). 
Real time observations were made using x4, x10 and x20 long-distance working 
objectives and microscopic images were recorded using a DSR-11 digital 
videocassette recorder (Sony) for later offline analysis, which was performed exactly as 
described before26,27. β1 integrin-deficient CD4+ T cells and control CD4+ T cells, 
isolated as described above, were fluorescently labelled with 125 nM Calcein-AM 
(Molecular Probes) prior to their infusion via the right carotid artery. For direct 
comparison of the interaction of β1 integrin-deficient and β1 integrin-positive T cells 
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within the same spinal cord white matter vascular bed, the injection of β1 integrin-
deficient CD4+ T cells (4 x 106 cells in 300 µl 0,9 % NaCl injected in aliquots of 100 µl) 
was followed by injection of control T cells (4 x 106 cells in 300 µl 0,9 % NaCl injected 
in aliquots of 100 µl) into the same mouse 1 hour later. This technique might produce 
artefacts due to the extended observation time necessary in this experimental setup. 
Thus, the interaction of β1 integrin-deficient and β1 integrin-positive CD4+ T cells was 
additionally compared in individual mice injected with one T cell population only. The 
same results were obtained using both experimental approaches. 
T cells passing through the spinal cord microvessels (∅ 20-60 µm) and T cells, which 
visibly initiated contact with the spinal cord microvascular endothelium and thus moved 
at a slower velocity than the main blood stream were counted during an observation 
period of 1 minute in frame by frame analysis of the videos using the CapImage 
software (version 8.3, Dr. Zeintl)26. The fraction of T cells initiating contact with the 
vascular wall was calculated for each microvessel as the percentage of interacting T 
cells among the total number of T cells passing through a given post-capillary venule 
during this 1 minute observation window. The rolling fractions and the capture fractions 
were counted accordingly. Permanently adherent T cells were identified as cells stuck 
to the vessel wall without moving or detaching from the endothelium within an 
observation period of ≥ 20 seconds and were counted 10 min, 30 and 60 minutes after 
T cell infusion (4 x 106 cells/mouse).  
Statistical analysis. All statistical analysis was performed using the GraphPad Prism 
software (version 5.00, GraphPad Software). Data are presented as medians with 
interquartile ranges. Mann-Whitney U statistics were used for comparisons between 
different data sets. Asterisks indicate significant differences (*P<0.05, **P<0.01 and 
***P<0.005). For analysis of adherent T cells in the IVM analysis mean values were 
calculated from the values in each animal and the two groups were compared using a 
Mann-Whitney U test. 
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Figure 1: The clinical course of EAE is not altered in β1-/- BM chimeras. (a) 
Knockout efficiency for the indicated total and MACS-sorted cell populations was 
determined by southern blotting. The number of samples for each population is given in 
each bar. Bars represent medians and interquartile ranges. (b) The relative weight 
normalized to day 0 and the clinical disease score of control and β1-/- BM chimeras with 
active EAE are shown. Data points indicate the means of 13 mice from 3 independent 
experiments. Around day 16, mice were sacrificed for histological and flow cytometric 
analysis. (c) Immunostaining of the spinal cord white matter of control and β1-/- BM 
chimeras with ongoing active EAE (clinical score 3). Infiltrating leukocytes were stained 
with Ly5.2, CD4 or Mac-1 antibodies (red), blood vessels with a laminin antibody 
(green) and nuclei with DAPI (blue) (scale bar, 100 µm). 
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Figure 2: T lymphocytes depend on β1 integrins to enter the CNS. (a) Shown is the 
total number of leukocytes and microglia cells isolated by density gradient 
centrifugation from the brain and spinal cord of control and β1-/- BM chimeras with 
ongoing active EAE (average clinical score = 3, n = 5). Shown is the median number of 
isolated cells per CNS of one animal and the interquartile range. (b + c) The isolated 
leukocytes were analyzed by flow cytometry. In (b) the relative numbers of CD4+ T cells 
(CD4+), CD8+ T cells (CD8+), Macrophages (Mac) and Granulocytes (Gr) are shown 
(controls, n = 8, β1-/- n = 9). (c) The β1 expression of the four leukocyte subsets was 
analyzed by flow cytometry. Macrophages and granulocytes were distinguished by their 
different expression levels of Gr-1 and Mac-1. Microglia cells are mainly host cell 
derived and were excluded based on their cell surface expression of CD45.1. Each bar 
represents at least 5 mice. (b + c) Bars in all panels represent medians and 
interquartile ranges. 
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Figure 3: β1 integrin is important for T cell extravasation but not proliferation. (a) 
Splenocytes from control, β1fl/fl/MxCre+ or β1fl/fl/CD4Cre+ mice were stimulated 
unspecifically in vitro. Subsequently, isotype control staining and β1 integrin expression 
of CD4+ T cells were analyzed by FACS. Graphs show the medians and interquartile 
ranges of at least 5 animals per group. (b) The median day of disease onset of control 
and β1fl/fl/CD4Cre+ mice with active EAE is shown. (c) The relative weight normalized 
to day 0 and the clinical disease score of control and β1fl/fl/CD4Cre+ mice with active 
EAE are shown. Data points indicate the means of 7 mice from 3 independent 
experiments. (d) Naïve CFSE-labelled CD4+ OT-II.2 T cells were cotransferred with 
Ova323-339 peptide loaded dendritic cells into wildtype mice. After three days cells were 
isolated from the spleen and analyzed for CFSE-dilution. The division and proliferation 
index and the percentage of dividing cells were calculated from the generation sizes (n 
= 6). (e) CFSE stainings from one representative control and β1-/- sample are shown. 
Light grey shaded histograms represent control animals that received dendritic cells 
without Ova323-339 peptide. 
 15 
 
Figure 4: In vivo firm adhesion of β1-/- T lymphocytes in the spinal cord 
microvasculature is dramatically reduced. Proliferating CD4+ OT-II.2 transgenic 
control and β1-/- T lymphocytes were analyzed for their adhesive behaviour in vivo and 
in vitro. (a) Integrin expression of proliferating control and β1-/- T lymphocytes was 
analyzed by FACS. Blue and red histograms represent control and β1-/- T cells, 
respectively. Isotype control stainings are shown in shaded grey histograms. 
Histograms are representative of 3 independent experiments. (b) Adhesion of T cell 
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blasts to the endothelioma cell lines bEnd5 (wildtype) and bEndI1.1 (ICAM-1-/-). 
Endothelioma cell lines were stimulated with TNF-α prior to the adhesion assay, which 
was performed at room temperature. Graphs show the medians and interquartile 
ranges (n = 4). (c) Firm adhesion of control and β1-/- T cell blasts to the spinal cord 
microvascular wall was analyzed by IVM of the spinal cord white matter 
microvasculature in wildtype mice with ongoing active EAE. Firm adhesion was 
analyzed 10 minutes, 30 minutes and 1 hour after infusion of T lymphocytes. Bars 
represent the medians and interquartile ranges (n = 6). (d) Initial contact events of T 
cell blasts with endothelial cells were analyzed by IVM. From 6 experiments with 
control and β1-/- T cells, 46 and 30 vessels were analyzed, respectively. Shown is the 
percentage of rolling or captured T cells among the total number of T cells passing 
through a given venule during a 1 minute observation period. Each dot represents one 
vessel, the red line indicates the median. 
 
 
Supplementary Figure 1: CD4+ T lymphocytes isolated from the CNS of 
β1fl/fl/CD4Cre+ mice with active EAE are β1 positive. (a) Leukocytes and microglia 
cells were isolated by density gradient centrifugation from the brain and spinal cord of 
control (n = 2) and β1fl/fl/CD4Cre+ (n = 3) mice with ongoing active EAE. The β1 
expression of CD4+ and CD8+ T cells was analyzed by flow cytometry. Bars represent 
medians and interquartile ranges. (b) Shown are representative histograms of 
unspecifically stimulated splenocytes and T lymphocytes isolated from the CNS of mice 
with active EAE gated for CD4 or CD8 expressing cells. Blue and red histograms 
represent control and β1-/- T cells, respectively. Isotype control stainings are shown in 
shaded grey histograms. 
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Supplementary Figure 2: The cytokine expression profile of β1 deficient T cells is 
not altered. The intracellular cytokine expression of control and β1-/- T lymphocytes 
was analyzed by FACS. Cells were isolated after 3 days of in vivo proliferation and 
additionally incubated for 4 hours with ionomycin, PMA and Brefeldin A. (a) Blue and 
red histograms represent control and β1-/- T cells, respectively. Isotype control stainings 
are shown in shaded grey histograms. Histograms are representative of 4 independent 
experiments. (b) Shown are the percentages of cytokine expressing T cells. Bars 
represent medians and interquartile ranges (n = 4). 
 
 
Supplementary Figure 3: Static adhesion of T cells to endothelioma cell lines is 
mainly integrin αLβ2 dependent. Adhesion of T cell blasts to the endothelioma cell 
lines bEnd5 (wildtype) and bEndI1.1 (ICAM-1-/-) were analyzed. Endothelioma cell lines 
were stimulated with TNF-α prior to the adhesion assay, which was performed at 4°C 
to reduce the contribution of the interaction between LFA-1 and ICAM-1. Graphs show 
the medians and interquartile ranges (n = 4). 
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Supplementary Figure 4: In vivo firm adhesion of β1-/- T lymphocytes to the 
spinal cord microvasculature is dramatically reduced. To obtain T cell blasts 
specific for the MOG35-55 peptide mice with β1-deficient T cells (β1fl/fl/Mx1-Cre) were 
intercrossed with MOG-specific TCR transgenic mice (referred to as 2D2)18. 
Proliferating CD4+ 2D2 transgenic control and β1-/- T lymphocytes were analyzed for 
their adhesive behaviour in vivo. Firm adhesion of control and β1-/- T cell blasts to the 
spinal cord microvascular wall was analyzed by intravital microscopy 10 minutes, 30 
minutes and 1 hour after infusion. Each dot represents the mean of one experiment, 
lines indicate the medians (n = 2). 
 
Supplementary Movie 1 (on the enclosed CD): In vivo adhesion of control T 
lymphocytes to the spinal cord microvasculature. Proliferating CD4+ OT-II.2 
transgenic control T lymphocytes were analyzed for their adhesive behaviour in vivo. 
The interaction of T cell blasts with endothelial cells was observed by IVM of the spinal 
cord white matter microvasculature in wildtype mice with ongoing active EAE. The 
movie shows first the injection of Calcein-AM labelled lymphocytes into the spinal cord 
white matter microvasculature of anesthetized mice. Afterwards scanning of the 
microvasculature for adherent T cells 10 minutes and 1 hour after infusion is shown. 
 
Supplementary Movie 2 (on the enclosed CD): In vivo adhesion of β1-/- T 
lymphocytes to the spinal cord microvasculature. Proliferating CD4+ OT-II.2 
transgenic β1-/- T lymphocytes were analyzed for their adhesive behaviour in vivo. The 
movie shows first the visualization of the microvasculature by injection of TRITC-
conjugated dextran and then injection of the Calcein-AM labelled lymphocytes. 
Afterwards scanning of the microvasculature for adherent T cells 10 minutes and 1 
hour after infusion is shown. Supplementary movies 1 and 2 show the vascular bed of 
the same mouse into which first β1-/- and then control T cells were injected. 
 
 
Paper V
3. Analysis of Integrin Functions in Blood
The leukocyte-specific b2 and b7 integrins as well as almost all members
of the b1 integrin subfamily play important roles in the hematopoietic system
(Sixt et al., 2006). The integrins are required for the homing of hematopoietic
stem cells to the fetal liver and bone marrow (Hirsch et al., 1996; Potocnik
et al., 2000), hematopoiesis (Bouvard et al., 2001), extravasation of leukocytes
at sites of inflammation (Mizgerd et al., 1997; Yednock et al., 1992), and the
formation of lymphatic organs such as Peyer’s patches, and so on. Conse-
quently, the analysis of integrin function in the hematopoietic system will
undoubtedly contribute to our understanding of how the various blood cells
move from one site to another, how the cells communicate with each other,
and how they exert their functional properties. A serious problem of genetic
studies of blood cells can be early embryonic lethality, or the loss of gene
expression in several non-hematopoietic cell types relevant for blood cells,
such as endothelial cells or stromal cells. This problem can be elegantly
circumvented with conditional and inducible gene deletions. Numerous,
well-characterized Cremouse lines are available that restrict the gene ablation
in a constitutive or temporal manner to specific cell types or compartments
of the hematopoietic system. This rich resource makes genetic studies of
hematopoiesis very attractive and doable (Table 12.2).
The Mx1-Cre mouse strain represents an excellent option to temporally
ablate genes in the hematopoietic system (Kuhn et al., 1995). The Mx1
promoter is activated by interferon-a or -b, whose expression in turn can
readily be induced by the intraperitoneal injection of the synthetic double-
stranded RNA polyinosinic-polycytidylic acid (pI-pC). Since the Mx1 pro-
moter is highly active in hematopoietic stem cells, pI-pC injections lead to a
rapid and efficient deletion of loxP-flanked (also-called floxed) genes in all
hematopoietic cells. Unfortunately, a large number of nonhematopoietic cells,
such as hepatocytes and endothelial cells, among others, also express the
interferon a/b receptors and hence also lose the floxed gene. To restrict the
deletion to the hematopoietic compartment, the loxP/Mx1-Cre system must
be combinedwith the generation of bonemarrow chimeras (Fig. 12.3), which
is a rather easy task. This task is usually done with C57BL/6 mice that express
the Ly-5.2 and B6SJL that express the Ly-5.1 surface antigen on all leukocytes.
The two mouse strains provide an elegant system to generate bone marrow
chimeras between C57BL/6 donors (floxed gene/Mx1-Cre bone marrow)
and lethally irradiated, wild-type B6SJL hosts, thereby providing a marker to
easily exclude remaining cells of the irradiated host from the analysis.
Bone marrow chimeras cannot be generated when a gene mutation leads
to embryonic lethality. In such a case, it may still be possible to isolate and
transfer hematopoietic stem cells from the fetal liver cells or the adreno-
gonadal-mesonephros region into lethally irradiated hosts (Gribi et al., 2006).
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3.1. Generation of bone marrow chimeras
3.1.1. Materials
Borgal: 7.5% antibiotic solution for small animals (commercially available
from Hoechst).
pI-pC: Poly(I)-poly(C) (Amersham Biosciences); the stock solution with
a final concentration of 2 mg/ml is prepared with PBS according to
manufacturer’s instructions and stored at –20.
Table 12.2 Cre lines for gene deletions in the hematopoietic system
Promoter Expressionpattern Special notes/reference
Lck T cells Onset of deletion during the DN1 stage of
thymocyte development (Lee et al., 2001)
CD4 T cells Onset of deletion during the double positive
stage of thymocyte development (Lee
et al., 2001)
mb1 B cells Onset of deletion in early pro-B cells, low
frequency of deletion in T cells (Hobeika
et al., 2006)
CD19 B cells Onset of deletion during the pre-B cell stage
(Rickert et al., 1997)
CD21 B cells Onset of deletion in mature B cells, high
deletion in the ovary (Kraus et al., 2004)
hCD2 T cells and B cells Onset of deletion before the DN4 stage of
thymocyte development and in early
pro-B cells, mosaic expression in testis
(de Boer et al., 2003)
Vav All cells of
hematopoietic
system
Expression in ovaries and testis (de Boer et al.,
2003), endothelial cells, and testis
(Georgiades et al., 2002)
CD11c Dendritic cells
(DC)
Cre expression is induced by tamoxifen, only
a few CD11cþ DCs are expressing Cre
(Probst et al., 2003)
GATA1 erythroid cells and
mast cells
Onset of deletion at the time of Ter119
expression, deletion also in
megakaryocytes and eosinophils ( Jasinski
et al., 2001)
LysM granulocytes Partial deletion in macrophages and splenic
CD11cþ DCs (Clausen et al., 1999)
CD11b peritoneal
macrophages,
mature
osteoclasts
Partial deletion in macrophages and
granulocytes, deletion in B and T cell
subsets (Ferron and Vacher, 2005)
Pf4 megakaryocytes Complete and speciﬁc deletion in the
megakaryocytic lineage (Tiedt et al., 2006)
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3.1.2. Procedure
1. The ideal recipients are 8- to 12-week-old B6SJL mice that are sex-
matched with the donor mice (to prevent an immune response against
donor cells). The recipient mice are g-irradiated at 1000 rad with an
X-ray machine.
2. Single-cell suspensions of bone marrow cells are prepared (see Section
3.2), resuspended in PBS, and adjusted to 5  106 cells/ml PBS.
3. The recipient mice are immobilized in custom-made conical metal
chambers (Fig. 12.4) and the tails of the recipient mice are warmed for
30 sec in a 50 water bath (to increase blood flow and vessel size). Around
200 ml of the bone marrow cell suspension (1  106 cells/mouse) are
injected with a 30G needle into the lateral tail vein.
4. The first 2 weeks after the transplantation, 1 ml of Borgal solution is
added to 500 ml of drinking water; this will prevent infections in the
irradiated, immunocompromised mice.
5. Four weeks after the bone marrow transplantation, the hematopoietic
system of the recipient mouse is fully reconstituted with donor cells (this
can be easily checked by determining the number of Ly-5.1–positive
Figure 12.3 Generation of bone marrow chimeras using the Mx1-Cre/loxP system.
Bone marrow from a Ly-5.2^positive donor mouse carrying the target gene flanked by
loxP sites, and the Mx1-Cre transgene is transferred into an irradiated, Ly-5.1^positive
wild-type recipient mouse. Four weeks after bone marrow transfer the hematopoietic
system of the recipient mouse is fully reconstituted and the knockout can be induced by
repeated pI-pC injections.
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cells in the peripheral blood using the flow cytometer). To induce the
Mx1-Cre–mediated gene ablation, the pI-pC stock solution is diluted to
0.5 mg/ml with PBS, and 500 ml is then injected intraperitoneally. The
pI-pC injection is repeated 2 and 4 days later.
6. It is necessary towait at least 4weeks before attempting in vivo analysis of the
hematopoietic system to exclude effects caused by the pI-pC–triggered
interferon production.
3.2. Standard flow cytometric analysis of cell
surface receptors
Analysis of the cellular composition of hematopoietic tissues/compartments
is done by determining the expression of cell surface receptors unique for
distinct subsets of blood cells with the fluorescence-activated cell sorter
(FACS).
3.2.1. Materials
Isoflurane: Isoba, a ready-to-use solution is commercially available (Essex
Tierarznei)
Heparin: 20 U/ml heparin (Sigma) in TBS (50 mM Tris, 10 mM NaCl,
pH 7.5).
ACK buffer: Ammonium chloride potassium phosphate buffer: 150 mM
NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH 7.3.
FACS-PBS: PBS supplemented with 1% BSA.
70-mm cell strainer: sterile 70-mm nylon cell strainer (BD Falcon).
Propidium-iodide: Propidium-iodide (Sigma) is prepared as a stock solution
of 50 mg/ml in PBS, which can be stored at 4 in the dark.
A B
Figure 12.4 Injection of bone marrow cells into a recipient mouse. (A) The mouse is
immobilized in a conical metal chamber. (B) Bone marrow is injected into the lateral
tail vein of the prewarmed tailwith a 30G needle.
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3.2.2. Isolation of peripheral blood leukocytes
Procedure
1. The mouse is anesthetized by putting it into a beaker that contains a tissue
drenched with 1 to 2 ml of isoflurane.When movements cease, the mouse
should be immediately removed from the beaker. Extended exposure to
isoflurane stops the heart beat and makes blood collection impossible.
Around 50 ml of blood are collected with a heparin-soaked glass capillary
from the retro-orbital venous plexus. The blood is resuspended in 500 ml
PBS and centrifuged for 5 min at 400g. The supernatant is carefully
removed and discarded.
2. The cell pellet is resuspended in 500-ml ACK buffer, incubated for 5 min at
RT, and centrifuged again. The supernatant, which should appear reddish
due to the lysis of the erythrocytes, should be carefully removed and
discarded. The cell pellet is resuspended in 100 ml of PBS. The amount
of cells should be sufficient for two to three flow cytometry stainings.
3.2.3. Isolation of bone marrow cells
Procedure
1. The femurs of a mouse are carefully dissected and the muscles are removed
by rubbing each femur with a Kleenex tissue. If cells should be sterile (e.g.,
for generation of dendritic cells), the femurs must stay intact during the
removal of the muscle tissue and are incubated after muscle removal for
2 min in 70% ethanol and then rinsed in PBS.
2. Both ends of the femur are abscised with a sharp scalpel and the bone is
subsequently flushed from both ends with 10-ml ice-cold PBS using a
10-ml syringe and a 23G needle. The isolated cell clumps are broken up
into a single cell suspension by vigorous pipetting and then transferred
through a 70-mm cell strainer into a 50-ml tube.
3.2.4. Isolation of cells from lymphatic tissues
Procedure
1. The organs of interests (such as thymus, spleen, lymph nodes, or Peyer’s
patches) are isolated, freed from surrounding connective tissue as much
as possible, rinsed with PBS to remove blood and put into a cell strainer,
which is placed in a Petri dish together with 10 ml of ice-cold PBS. To
keep the cell strainer at 4, the Petri dish is kept on ice.
2. Each organ is homogenized by gently squeezing it with the piston of a
plastic syringe through the cell strainer. The cell suspension is transferred
from the Petri dish into a 50-ml tube by filtering it again through the cell
strainer. Toobtain all remaining cells floating in the Petri dish, the Petri dish
is rinsed again with 10 ml of ice-cold PBS and the suspension is combined
with the other cells in the 50-ml tube.
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3.2.5. Immunofluorescence staining of suspended
hematopoietic cells
Procedure
1. The cells are pelleted by centrifugation at 300g, resuspended in an
appropriate volume (2 to 10 ml) of ice-cold PBS, and counted.
2. If a centrifuge capable of centrifuging 96-well plates is available, the
staining is most conveniently performed in 96-well round-bottom plates.
For each staining, 1  106 cells or 100 ml of peripheral blood suspension
are pipetted into each well. The plate is centrifuged for 5 min at 300g.
The supernatant is removed and the pellet resuspended in 50 ml of
FACS-PBS with the first antibody.
3. After a 30-min incubation at 4 in the dark, 200 ml FACS-PBS are added
to each well. Subsequently, the cells are pelleted by centrifugation
(300g). Upon removal of the supernatant, the cell pellet is resuspended
in 50-ml of FACS-PBS containing the secondary antibody.
4. The cell suspension is incubated for 15 min at 4 in the dark, and then
diluted by adding 200 ml of FACS-PBS and finally centrifuged again at
300g andRT.The supernatant is removed and the cell pellet resuspended
in 200 ml FACS-PBS. Immediately beforemeasuring, the fluorescent signal
with the flow cytometer 10 ml of propidium-iodide (50 mg/ml) is added to
each sample, which allows identification of dead cells. After brief vortexing,
the fluorescence is measured with a cytometer.
Table 12.3 lists a number of surface markers that are commonly used
singly or in combination to analyze the hematopoietic system. Please note
that many of the markers are also useful for immunostaining of tissue
sections of lymphatic organs, thereby also allowing assessment of the spatial
distribution of blood cell types.
3.3. Flow cytometric lacZ staining of hematopoietic cells
The bacterial lacZ gene is an elegant means to examine the expression of a
gene of interest. If knockout constructs are engineered to replace the dis-
rupted gene with a lacZ gene, Cre-driven excisions can easily be monitored
histochemically. Expression of the lacZ gene results in the production of
b-galactosidase (b-gal), which can be readily detected by a number of
chromogenic or fluorogenic b-gal substrates (Rotman et al., 1963). This
allows visualization of the gene deletion by histochemically staining tissue
sections (see Section 4.4) or whole-mount embryos. Importantly, lacZ-
positive cells can also be detected by flow cytometry. In the protocol
described here, the lacZ measurement can be combined with immuno-
fluorescent staining allowing to precisely determining the identity of the
lacZ-positive cells.
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Table 12.3 Surface antigens supporting analysis of the hematopoietic system
Surfacemarkers Cell type
Spleen
CD4þ T helper cells
CD8þ Cytotoxic T cells
IgDþ B cells
NK1.1þ NK and NKT cells
Ter-119 Erythroblasts
B220þ CD21high
CD23low
Marginal zone B cells
CD23high CD21low Follicular B cells
Bone marrow
B220þ IgM Pre–pro B cells and later developmental stages
CD19þ Pro B cells and later developmental stages
B220low IgMþ Immature B cells
B220high IgMþ IgDþ All mature B cells
Mac-1þ Gr-1þ Granulocytes
Mac-1þ Gr-1 Monocytes
Ter-119 Erythroblasts
NK1.1þ NK and NKT cells
CD4þ T helper cells
CD8þ Cytotoxic T cells
Lin c-kitþ Sca-1high Hematopoietic stem cells
Lymph nodes
B220þ CD19þ B cells
CD4þ T helper cells
CD8þ Cytotoxic T cells
Thymus
Lin– B220–, CD4–, CD8–, Mac1–, Gr-1–, Ter119–
Lin– CD25– CD44þ DN1
Lin– CD25þ CD44þ DN2
Lin– CD25þ CD44– DN3
Lin– CD25– CD44– DN4
CD4– CD8– Double-negative T cells
CD4þ CD8þ Double-positive T cells
CD4þ CD4 single-positive T cells
CD8þ CD8 single-positive T cells
Peyer’s patches
CD4þ T-helper cells
CD8þ Cytotoxic T cells
Analysis of Integrin Functions 255
3.3.1. Materials
FDG: Fluorescein Di-(B-D-galactopyranoside) (Sigma). Dissolve 5 mg of
FDG in a mixture of 304.8 ml of H2O, 38.1 ml of dimethyl sulfoxide
(DMSO) (Sigma), and 38.1 ml of ethanol (8:1:1) to obtain a 20-mM
solution. Add 3429 ml of H2O (10:1) as soon as the FDG is completely
dissolved to obtain a 2-mM working solution. Store aliquots of around
300 ml at –20 in the dark.
Procedure
1. If immunofluorescence staining is combined with lacZ staining, the cells
are stained as described (see Section 3.2.5). Use around 3  06 cells per
staining, since the described method can lead to cell mortality and hence
loss of cells. After staining, the cells are pelleted by centrifugation at
300g at RT and resuspended in 20 ml of FACS-PBS.
2. The cell suspension is admixed with 20 ml FDG to each sample, and
incubated for 75 sec in a 37 water bath to allow FDG uptake. The
uptake is then quickly terminated by the addition of 200 ml of ice-cold
FACS-PBS. Since exceeding the 75-sec incubation time with FDG
significantly increases cell death, avoid handling more than five samples
at the same time.
3. The cell suspensions are incubated for 2 h on ice in the dark and then
measured in the flow cytometer. Excluding dead cells by the addition of
propidium-iodide is recommended (see Section 3.2.5).
Flow cytometry and histology allow determination of the number, size,
distribution, and differentiation of distinct cell populations. Additional
assays further help to pinpoint potential functional defects of blood cell
lineages. Standard procedures include in vitro colony formation assays with
stem/progenitor cells, which permit evaluation of the formation of ery-
throid and myeloid cells; co-culture assays of bone marrow precursors with
stromal cells that permit determination of differentiation and proliferation of
B cells; and bone marrow precursor cell differentiation into dendritic cells,
which permits determination of T-cell proliferation and dendritic cell
analysis in vitro.
3.4. Generation of dendritic cells from bone marrow
Bone marrow–derived dendritic cells represent an elegant tool to study
antigen presentation and T-cell proliferation. Furthermore, dendritic cells
are also used to study cell migration, polarity, phagocytosis, adhesion, and
podosome formation (Calle et al., 2006), among other processes. Our
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protocol for generating dendritic cells is a slightly modified procedure
originally described by Lutz et al. (1999).
3.4.1. Materials
R10 medium: RPMI-1640 (Gibco) supplemented with 100 U/ml of peni-
cillin, 100 mg/ml of streptomycin, 2 mM of L-glutamin (all from PAA),
and 10% heat-inactivated FCS (Gibco).
GM-CSF: rmGM-CSF (Peprotech)—20 ng/ml correspond to 200 U/ml.
Alternatively, cell culture supernatant collected from Ag8653 myeloma
cells transfected with the murine GM-CSF cDNA can be used (Zal et al.,
1994).
Freezing medium: Heat-inactivated FCS is supplemented with 10%
DMSO. Freezing medium is always freshly prepared.
LPS: Lipopolysaccharides from Escherichia coli (Sigma). A stock solution of
1 mg/ml is prepared with PBS.
Procedure
1. At day 0, bone marrow cells are isolated as described in Section 3.2.3,
resuspended in 10 ml of R10 medium, and counted.
2. Around 2.5  106 cells in a total volume of 10 ml of R10 medium
containing 20 ng/ml GM-CSF or 10% GM-CSF supernatant are trans-
ferred to a 10-cm Petri dish. Dendritic cells should be cultured in
bacterial-grade Petri dishes, since they strongly adhere to the plastic
surface of cell culture dishes, which prevents their differentiation.
3. Ten milliliters of R10 containing 20 ng/ml GM-CSF or 20% GM-CSF
supernatant are added at day 3 to the bone marrow culture. At day 6,
10 ml of the medium are carefully removed by tilting the plate slightly
and slowly sucking off the medium. Stirring and shaking should be
avoided when taking the plates out of the incubator. The removed
medium is replaced with 10 ml of fresh R10 containing 20 ng/ml of
GM-CSF or 20% GM-CSF supernatant.
4. At day 8, one of the following two possibilities is selected. First, the
immature dendritic cells can be frozen for later usage: The cells from a
10-cm cell culture dish are collected by gentle pipetting, centrifugation
at 300g, and the cell pellet is resuspended in 1 ml of freezing medium.
The 1-ml suspension is transferred into a freezing tube and quickly
transferred to a –80 freezer. Second, the immature dendritic cells are
brought to maturation: The cells from a 10-cm culture dish are collected
as described above, resuspended in 10 ml of R10 containing 20 ng/ml
GM-CSF or 10% GM-CSF and 200 ng/ml LPS, and cultured overnight
in a 6-cm cell culture dish.
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3.5. In vitro T-cell proliferation assay
Several possibilities are available to trigger and determine T-cell proliferation.
First, T cells can be treated with ionophores and phorbol esters (e.g., iono-
mycin and phorbol-12-myristate-13-acetate [PMA]). Ionomycin increases
the intracellular calcium concentration by facilitating calcium transport
through the plasma membrane. Using this procedure, protein kinase C
(PKC) can be activated in a phospholipase C–independentmanner. Addition-
ally, phorbol esters such as PMA activate PKC by mimicking the action of
diacylglycerol (DAG). Second, T-cell proliferation can also be induced by
cross-linking T-cell receptors (TCR) with antibodies to the CD3 T-cell co-
receptor. This treatment mimics antigen-dependent TCR cross-linking,
and thereby evokes signaling from the TCR. Third, antigen-dependent
T-cell stimulation can be rather easily examined by crossing the integrin
knockouts with a mouse strain expressing a transgenic TCR. A transgenic
MHC class II–restricted TCR is expressed in the OT-II.2 mouse strain,
which generates CD4þ T cells specific for the OVA323–339 peptide from
chicken ovalbumin (Barnden et al., 1998). Upon intercrossing gene-
targeted mice with OT-II.2 transgenic mice, mutant CD4þ T cells can be
stimulated by co-culture with OVA323–339–loaded dendritic cells. A similar
system exists with the OT-I mice for CD8þ T cells (Clarke et al., 2000).
We usually monitor division of the stimulated T cells by determining the
dilution of the carboxy-fluorescein diacetate succinimidyl ester (CFSE).
CFSE diffuses freely into cells where it is converted by esterases into a
membrane-impermeant dye, which becomes covalently bound to cellular
proteins and is then capable to emit a fluorescence signal that can be assessed
with a flow cytometer equipped with 488-nm excitation and emission
filters. The CFSE fluorescence signal is halved during each cell division.
An alternative procedure to monitor cell division is measuring the incor-
poration of H3-thymidine (Krishnamoorthy et al., 2006), which is more
sensitive but does not permit the analysis of the proliferationon a single-cell basis.
3.5.1. Materials
Magnetic sorting of T cells: CD4þ TCell Isolation Kit, LSMACS columns,
and magnetic separation unit (all from Miltenyi).
ACK buffer: 150 mM NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH 7.3.
MACS buffer: PBS containing 0.5% bovine serum albumin and 2 mM
EDTA.TheMACS buffer is degassed by applying vacuumor sonification.
anti-CD3e: Purified hamster anti-mouse CD3e monoclonal antibody (BD
Biosciences, clone 145–2C11).
CFSE: Carboxyfluorescein diacetate succinimidyl ester (CFDA, SE) (Mole-
cular Probes). A 6-mM stock solution is prepared in DMSO and stored
at – 20 in the dark.
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OVA323–339 peptide: The sequence of the OVA323–339 peptide is
H-ISQAVH AHAEINEAGR-OH. A stock of 2 mg/ml is prepared in
PBS and 100 ml aliquots are stored at –20.
Dendritic cells: 1.5  106 bone marrow–derived dendritic cells matured
overnight with 200 ng/ml LPS (see Section 3.4) are resuspended in R10
medium to a final concentration of 0.4  106/ml.
PMA: Phorbol-12-myristate-13-acetate (Calbiochem). A 1-mg/ml stock is
prepared in DMSO, and 20-ml aliquots are stored at –20. A 1:300
dilution in R10 medium is the working dilution and is always freshly
prepared.
Ionomycin: Ionomycin calcium salt from Streptomyces conglobatus (Calbio-
chem). A 1-mg/ml stock is prepared in DMSO and 20-ml aliquots are
stored at 4 in the dark. A 1:50 dilution in R10 medium is the working
dilution and is always freshly prepared.
3.5.2. Magnetic sorting of T cells
For high sorting purities, it is critical to cool the cells and solutions on ice.
Procedure
1. The spleen is dissected and a single cell suspension prepared (see Section
3.2.4). The cell suspension is pelleted by centrifugation at 300g, and
then thoroughly resuspended in 5 ml of ACK buffer and incubated at
RT for 5 min. Afterward, 10 ml of PBS is added to the cell suspension
and centrifuged.
2. After centrifugation, the cell pellet is resuspended in 10 ml of MACS
buffer, counted, and 4  107 cells are centrifuged. The cells are labeled
and sorted using the CD4þ T Cell Isolation Kit according to the manu-
facturer’s instructions. With this kit, non-CD4þ T cells are labeled indi-
rectly magnetically with a cocktail of biotin-conjugated antibodies and
magnetic anti-biotin beads, and are subsequently depleted. Therefore, the
isolated CD4þ T cells remain untouched.
3.5.3. CFSE staining of T cells
Procedure
1. The sorted CD4þ T cells are resuspended in PBS in a concentration of 1
107/ml. TheCFSE stock solution is diluted 1:240with PBS and added 1:50
to the cell suspension to reach a final concentration of 0.5 mM. Themixture
is briefly vortexed to ensure even distribution. The T-cell suspension is
incubated for 10 min at RT in the dark.
2. The reaction is stopped by the addition of 5 ml of ice-cold R10 medium.
The cells are centrifuged at 300g, and then taken up in R10 medium to
obtain a final concentration of 1  106/ml.
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3.5.4. Proliferation assay
Procedure
1. Fifty microliters of 10 mg/ml of anti-CD3e in PBS is added to three of
the positive control wells (Fig. 12.5) of a 96-well, round-bottom plate,
and the plate is then incubated for 1 h at 37.
2. The dilutions of the OVA peptide are prepared according to Fig. 12.5 in
a 12-well plate. Each dilution step must be thoroughly mixed before
proceeding to the next dilution.
3. One hundredmicroliters of the peptide dilution are added to the respective
wells (Fig. 12.5). The wells in row 5, which lack OVA peptide, serve as
negative controls. Next, 50 ml of dendritic cells (DCs) (0.4  106/ml) and
50 ml of CFSE-labeled T cells (1  106/ml) are then added to each well.
4. The anti-CD3e–coated wells are washed carefully two times with 200 ml
of PBS. Then 100 ml ofR10medium are supplementedwith 2 ml of PMA
(1:300 dilution) and 100 ml of CFSE-labeled T cells (1  106/ml) are
added to each well. This will result in a final PMA concentration of
33 ng/ml. To the remaining ‘‘positive control wells,’’ 100 ml of R10
medium is supplemented with 2 ml of PMA (1:300 dilution) and 2 ml of
ionomycin (1:50) dilution, and 100 ml CFSE-labeled T cells (1 106/ml)
is added. This will result in a final ionomycin concentration of 200 ng/ml.
5. The plate is incubated for 72 h at 37 in a regular cell-culture incubator.
For each measurement, the cells from three wells are collected and
pooled by thorough pipetting. The CFSE signal is determined in the
fluorescein channel of a flow cytometer. It is often convenient to analyze
additional parameters such as activation markers, for example. In this
case, an immunofluorescence staining of the cells with antibodies against
markers such as CD25, CD44, and CD69 antibodies must be performed
as described in Section 3.2.5 before the flow cytometric analysis.
A
B
1485 m1 R10 + 15 m1 OVA stock
1350 m1 R10
150 m1 R10
150 m1 R10
150 m1 R10
1350 m1 R10
1350 m1 R10
1500 m1 R10
Control T-cells
10 mg/ml OVA peptide
1 mg/ml OVA peptide
0,1 mg/ml OVA peptide
0,01 mg/ml OVA peptide
0 mg/ml OVA peptide
Positive controls
Knockout T-cells
Figure 12.5 Pipetting scheme for peptide dilutions andT-cell proliferation assays.
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3.6. In vivo T-cell proliferation assay
The intravenous injection of T cells together with antigen-loaded dendritic
cells into mice is the most physiological way to examine antigen-dependent
proliferation of TCR transgenic T cells. The two injected cell types will
move to the spleen where they interact in a physiological environment and
trigger T-cell proliferation.
3.6.1. Materials
Magnetic sorting of T cells, ACK buffer, MACS buffer, CFSE, and
OVA323–339 peptide. See Section 3.5.
Dendritic cells: 2.5  106 bone marrow–derived dendritic cells/mouse,
matured overnight with 200 ng/ml of LPS. They are prepared as
described in Section 3.4.
3.6.2. Magnetic sorting of T cells
Magnetic sorting of the cells is performed as described in Section 3.5. Around
3 106 T cells are needed per mouse. Therefore, 5 107 splenocytes should
be sorted to obtain enough cells for three experiments.
3.6.3. CFSE staining of T cells
Procedure
1. The sorted CD4þ T cells are resuspended in PBS to obtain a concentra-
tion of 2  107/ml. The CFSE stock solution is diluted 1:600 with PBS
and added 1:1 to the cell suspension to obtain a final concentration of
5 mM. The mixture is vortexed briefly to ensure even distribution. The
T-cell suspension is incubated for 10 min at 37.
2. The reaction is stopped by the addition of 10 ml of ice-cold R10
medium. The cells are then centrifuged at 300g and taken up in PBS
to obtain a final concentration of 15  106/ml.
3.6.4. Proliferation assay
Procedure
1. Around 5 to 15  106 matured dendritic cells are resuspended in 3 ml of
R10 medium containing 20 ng/ml of GM-CSF or 10% GM-CSF
supernatant and 20 mg/ml of Ova peptide. They are transferred in a
50-ml tube and incubated for 4 h in a cell culture incubator. A control
batch of dendritic cells should be incubated without the peptide. After
the incubation, the dendritic cells are washed twice with 10 ml of PBS,
and are taken up in PBS after a subsequent centrifugation to obtain a
dendritic cell concentration of 12.5  106/ml.
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2. About 3  106 of CFSE-labeled OT-II T cells resuspended in 200 ml
PBS are injected into the tail vein of a mouse (see Section 3.1). Sex-
matched mice of 6 to 10 weeks of age are used as recipients. Around 4 h
later, 2.5  106 of Ova-loaded dendritic cells resuspended in 200 ml of
PBS are injected into the same recipients.
3. Three days later the spleens are dissected and a single cell suspension is
prepared as described in Section 3.2.4. To analyze T-cell proliferation by
flow cytometry, 5 106 splenocytes are stained with the desired markers
and measured in a flow cytometer. Care should be taken to adjust the
gains and compensations of the cytometer to avoid leakage of the CFSE
signal into other channels. Furthermore, it is important to include a
control with unloaded dendritic cells to determine the fluorescence
intensity of nondividing T cells.
3.7. Induction of experimental autoimmune
encephalomyelitis in C57/BL6 mice
Experimental autoimmune encephalomyelitis (EAE) is a very well-established
animal model representing the human disease multiple sclerosis (MS). Over
the years it has become increasingly clear that integrins play an important role
for the development of both EAE and MS (Yednock et al., 1992). Nonethe-
less, the exact function of integrins during the disease-relevant processes of
T-cell activation and proliferation and extravasation into the brain are still
not clear. Aspects like T-cell adhesion to endothelial cells can be analyzed
in vitro in adhesion assay (Reiss et al., 1998), as well as in vivo by intravital
microscopy (Vajkoczy et al., 2001). But to analyze the overall contribution of
genetically altered hematopoietic cells to the development of EAE, it is
necessary to induce EAE in knockout mice. This has been done in many
mutant mouse strains that are deficient in adhesion molecules with a potential
role in inflammatory conditions (Kanwar et al., 2000; Kerfoot et al., 2006).
3.7.1. Materials
Complete Freund’s Adjuvant (CFA): 50 mg of Mycobacterium tuberculosis
H37 Ra (Difco Laboratories) is first thoroughly ground with 1 ml of
Incomplete Freund’s Adjuvant (Sigma) using mortar and pestle, and then
suspended with an additional 9 ml of Incomplete Freund’s Adjuvant to
obtain a total volume of around 10 ml, and finally stored at 4. The
suspension must always be homogenized with a syringe prior to usage.
MOG35–55 peptide: The sequence isH-MEVGWYRSPFSRVVHLYRNGK-
OH. A stock of 2 mg/ml is prepared in PBS and 500-ml aliquots are
stored at –20.
Syringes, adaptor, and needles: 2 1-ml glass tuberculin syringes with Luer
lock tip and a female Luer lock to female Luer lock syringe adaptor
(Sigma), and disposable 23G and 26G needles.
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Pertussis toxin: Pertussis toxin (List Biological Laboratories). The vial contain-
ing pertussis toxin powder is reconstituted according to the manufacturer’s
instructions to a 100 ng/ml-stock solution and stored at 4.
3.7.2. Procedure
1. For every mouse, 100 ml MOG in PBS and 100 ml CFA are mixed using
two syringes that are connected with an adaptor. The two solutions are
mixed until a white emulsion forms,which is hard to push fromone syringe
to the other. Themixed emulsion is kept on ice. Themouse is anesthetized
with Isoflurane and 100 ml of the emulsion are injected with a 23G needle
subcutaneously into the tail base as well as the neck of the mouse.
2. To prepare 400 ng of pertussis toxin, add 4 ml of the stock solution to
200 ml PBS. The toxin is injected intraperitoneally using a 26G needle.
3. The mice are assessed daily for clinical EAE symptoms and weight loss.
Clinical scoring should be performed blinded if possible, and according to
the established classification as, for example, described by Krishnamoorthy
et al. (2006).
3.8. Mononuclear cell isolation from the central nervous
system
The first step to analyze the diseased mice is often histological analysis of the
central nervous system (CNS).With H&E and luxol fast blue staining of CNS
sections, infiltration of immune cells and demyelination of nerves can be
assessed (Krishnamoorthy et al., 2006). Additionally, mononuclear cells can
also be isolated from the CNS by a Percoll density-gradient centrifugation,
and subsequently be analyzed by flow cytometry.
3.8.1. Materials
Percoll: Medium for density centrifugation with a density of 1.130 g/ml
(Fluka).
10 PBS: 80 g NaCl, 2 g KCl, 2 g KH2PO4 and 14.4 g Na2HPO4 
2 H2O are dissolved in 1 liter of distilled water.
Medium: DMEM cell culture medium (Gibco), supplemented with 2%
FCS and 2.5% HEPES (1-M stock solution, pH 7.0).
Procedure
1. For each gradient, 9 ml of Percoll are mixed with 1 ml of 10 PBS to
obtain an isotonic Percoll stock solution (IPSS) with a density of
1.123 g/ml. The IPSS can be stored at 4 for about 2 weeks. For each
gradient, 4 ml of IPSS are mixed with 2.23 ml of PBS to obtain Percoll
with a density of 1.08 g/ml.
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2. All glass- and plasticware should be coated with serum-containing
medium by wetting them once. This prevents cells sticking to surfaces.
3. The brain is carefully dissected out from the skull. The spinal column is
transected in the cervical and lumbar part. The spinal cord is flushed out
with 10 ml of PBS by inserting the end of a truncated 18G needle
connected to a 10-ml syringe into the spinal column and applying gentle
pressure with the syringe. Both the brain and spinal cord are rinsed with
PBS to remove blood and put into a cell strainer, which is placed in a
Petri dish together with 5 ml of ice-cold medium. To maintain the tissue
at 4, the Petri dish is kept on ice.
4. The brain is homogenized by gently squeezing it with the piston of a
plastic syringe through the cell strainer. The piston should be only
pressed, not ground, since grinding will result in increased mortality of
T lymphocytes. The cell suspension is transferred from the Petri dish into
a 15-ml tube by filtering it again through the cell strainer. To obtain all
remaining cells floating in the Petri dish, the Petri dish is rinsed again
with 5 ml of ice-cold medium, and then the suspension is combined with
the other cells in the 15-ml tube. The volume is adjusted to 12.5 ml with
the medium, and the suspension is mixed with 5.4 ml of IPSS.
5. Five milliliters of Percoll with a density of 1.08 g/ml are carefully under-
layed by putting the tip of a 5-ml plastic pipette filled with 5.5 ml of the
latter to the very bottom of the tube and slowly releasing the liquid. The
last 0.5 ml should not be released from the pipette since this would often
result in disturbance of the layering.
6. The gradient is centrifuged at 1200g for 30 min at 20. Afterward, the
myelin debris, which is on top, is sucked away. The mononuclear cells
that accumulated at the interface of the two solutions are sucked away
with a medium-coated Pasteur pipette and transferred into a medium-
coated 50-ml Falcon tube. The recovered suspension is filled up to 50 ml
with medium and centrifuged at 300g for 10 min at 4. The pelleted
cells can now be resuspended—for instance in FACS-PBS—and
analyzed by flow cytometry as described in Section 3.2.5.
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